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Prevalence and risk factors  
Nonalcoholic fatty liver disease (NAFLD) is emerging as one of the most common chronic 
liver diseases during the last decades (1). In US, a dramatic increase in patients with 
NAFLD has been observed from 30% in 2008 to 46% in 2011 (2) and the prevalence of 
NAFLD in Asian countries is alarmingly high with 17% in China, 32% in India, 18% in Japan, 
32% in Malaysia and 55% in Indonesia (3, 4). Depending on the study population and the 
diagnosis approach used, the prevalence of NAFLD is estimated between 20% and 40% in 
the general population (1, 5, 6).  
    NAFLD is strongly associated with metabolic comorbidities, such as obesity, diabetes 
mellitus, and dyslipidemia (1). Most recent studies report that NASH has a prevalence of 
2-3% in the lean non-Asian population (7) and the prevalence markedly increases in obese 
(up to 20%) and morbidly obese subjects (up to 50%) (8, 9). However, Asian people with a 
low body mass index or BMI (~23.5) but higher proportion body fat already has an 
increased risk for NAFLD. Recent reports have shown that 15%-21% of Asian patients with 
NAFLD are non-obese (4), suggesting that the other risk factors or the distribution of body 
fat may be important for NAFLD development as well. Globally, there is a 60% to 76% 
prevalence of NAFLD in diabetic patients and 22% of those further develop NASH (2, 3). 
Histopathological evaluation showed that patients with diabetic NAFLD have more severe 
inflammation than non-diabetic NAFLD patients and are susceptible for rapid progression 
to fibrosis (8, 9). Furthermore, dyslipidemia is also associated with an increased 
prevalence to develop NAFLD, for instance in patients with the metabolic syndrome (10). 
In 2002, the National Institute of Health (NIH) reported that the presence of dyslipidemia 
(hypertriglyceridemia, hypercholesterolemia, or both), was associated with NAFLD in 20% 
to 80% of the cases (11). A South Korean study in nonobese, nondiabetic adults showed 




Most persons with NAFLD are asymptomatic and the disease is usually discovered when 
laboratory examination shows abnormal and persistently high levels of liver enzymes, that 
is alanine aminotransferase (ALT) and aspartate aminotransferase (AST), during screening. 
However, ALT and AST are also frequently elevated in obese subjects, and it is very 
difficult to define the upper limits of ‘normal’ for these routine liver enzymes tests (13). 
Alternatively, NAFLD with bland steatosis can be diagnosed by non-invasive imaging 
techniques, such as ultrasound, computed tomography (CT) and magnetic resonance 
imaging (MRI), however, imaging approaches are unable to detect inflammation, a 
required criteria for NASH diagnosis. Currently, liver biopsy is still the ‘golden standard’ for 
NASH diagnosis in the clinic and there is an urgent need for alternative diagnostic tools. 
The procedure of patient selection for biopsy-based diagnosis is illustrated in Figure 1. 
However, since liver biopsy is expensive and invasive and clearly cannot be employed for 
population screening, accurate noninvasive tests would be of tremendous benefit. The 
                                                                                                      
12 
 
apoptosis marker CK-18 has been reported recently to be a most promising noninvasive 
diagnostic test for NASH. In 2006, Wieckpwski et al (14) found that measurement of 
caspase-cleaved CK-18 levels showed a specificity of 99.9%, and a sensitivity of 85.7% for 
the diagnosis of NASH. Further validation studies are still needed to clarify the cut-off 
















Figure 1: Selection algorithm for 
assigning patient to biopsy-based 
diagnosis. Copyright 2009, 2010 The 




Histopathologic features  
The hallmarks of NASH are steatosis and inflammation (Figure 2). Steatosis is always a 
component of NAFLD and is characterized as an accumulation of intrahepatic lipids in the 
form of triglycerides and cholesterylesters within hepatocytes (15). Using hematoxylin and 
eosin (HE) staining or specific stainings for lipids identification such as Oil Red O, 
intrahepatic fat accumulation can be observed in different forms, namely: 1) 
macrovesicular steatosis: large fat droplets fill the cytoplasm of hepatocytes, displacing 
the remaining contents of the cell and the nucleus to the periphery, or 2) microvesicular 
steatosis: small fat droplets accumulate around the nucleus of the hepatocytes (16). 
Lobular inflammation is a defining characteristic of NASH livers and foci of inflammatory 
cell infiltrates, which consist of Kupffer cells, monocytes, and polymorphonuclear 
leukocytes, are typically detected. Hepatocellular injury is another important feature of 
NASH and is usually identified as cellular ballooning. Hepatocellular ballooning refers to 
enlarged hepatocytes, with rarefied and reticulated-like cytoplasm. The ballooned 

















Figure 2: characterization of steatosis and inflammation in human NASH. Macrovesicular steatosis (         ), 
microvesicular steatosis (             ), foci of inflammatory cell infiltrates indicates inflammation (             )  
 
 
Figure 3: zonation of the liver: schematic diagram (left) and histological (HE) cross- section (right). 
 
    The liver parenchyma can be functionally divided into three zones, Z1, Z2 and Z3 (Figure 
3), which differ with respect to oxygen supply. Z1 is the periportal area, where oxygen- 
and nutrient enriched blood enters the tissue via the hepatic artery and the portal vein. Z2 
is the midzonal area, and Z3 is the pericentral area. The incoming blood flows through 
sinuses to the central vein. Adult and pediatric patients (2-19 years old) show a different 
zonal steatosis pattern as shown in Table 1. 
 




Predominant pattern Zonal location Severity 
Adult mixed macro- and microvesicular steatosis pericentral, Z3 + 
Pediatric macrovesicular steatosis periportal, Z1 ++ 
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Scoring system for pathologic evaluation 
In 2005, the NASH Clinical Research Network (NASH-CRN) has developed and validated a 
system of histological evaluation for the full spectrum of NAFLD that could be useful in 
clinical trials (17). This scoring system of Kleiner et al. (17) separates the grading (activity) 
from staging (fibrosis) and is also called NAFLD activity score (NAS). The grading is feature-
based and encompasses steatosis, inflammation and hepatocellular ballooning (18). 
Notably, this scoring system of NASH not only relies on the presence of the different 
features mentioned above, but also on the zonal pattern that develops within the liver. 
The NAFLD activity score is however not applicable for diagnosis of NASH, but developed 
for monitoring the severity of the disease in order to assess putative changes in disease 
progression during the duration of a clinical trial.  
 
Regular intervention and treatment  
Lifestyle modification  
In clinical practice, the approach for NAFLD and NASH treatment begins with advices on 
lifestyle modification to induce weight loss. The goal of this primary treatment is to 
improve steatosis (which is often a reversible condition) and prevent the development of 
fibrosis, which can lead to cirrhosis and its complications. A Randomized controlled trial 
(RCT) with 31 obese NASH patients receiving intensive lifestyle changes for 48 weeks 
showed that subjects with ≥7% weight loss had significant improvement in steatosis, 
lobular inflammation and ballooning (19). It has been suggested that body weight loss 
between 5~10% is beneficial for improvement of hepatic steatosis and liver histology (19, 
20). Weight loss is commonly achievable by calorie restriction, especially the reduction of 
calories from dietary carbohydrates, combined with regular exercise. In 2012, the 
American Association for the Study of Liver Disease (AASLD) proposed a dietary guideline 
for patients with NAFLD, which recommends an approach of calorie restriction with a low-
carbohydrate (40%-45%) or low-fat (<30%) daily calorie intake, to reduce hepatic 
triglyceride content and to improve insulin resistance (21, 22). A mild and significant 
reduction in intrahepatic triglyceride content was reported in a recent randomized clinical 
trial (RTC) after 16 weeks of 150-300 min (per week) of moderate intensity exercise (23). 
Another RCT showed similar reduction in hepatic fat content, as well as an improvement 
of BMI and insulin resistance after following aerobic exercise and anaerobic resistance 
training for 4 months (24). In practice, the initiation of an exercise program is 
recommended based on the current activity level of the patient, however, it is hard to 
reach a consensus on the type, intensity and duration of exercise which are optimal for 
patients with NAFLD or NASH.  
 
Vitamin E 
Although the most safe treatment for NAFLD or NASH is lifestyle modification,  weight loss 
is still difficult to maintain in the long term (25). Therefore, additional supplementary 
therapy is often necessary. Vitamin E (α-tocopherol) is an antioxidant and vitamin E-800 
international units (IU)/day is currently considered as a first-line treatment for non-




tested 800 IU/day vitamin E in 84 subjects with NASH for 96 weeks, showed significant 
reductions in ALT (P<0.001), AST (P<0.001), hepatic steatosis (P<0.005), and lobular 
inflammation (P<0.02), but no significant improvement in fibrosis (P<0.24) (26). After 2 
years, the follow-up analysis showed that beneficial changes in ALT were more frequent 
among vitamin E treated subjects (48%) than placebo (16%) recipients (P<0.001). Among 
vitamin E recipients, ALT responses were associated with decreases in NAS (P<0.001), but 
not with fibrosis scores (P=0.34) (27). Although vitamin E has consistently shown to have 
an effect in improving serum ALT and AST as well as liver histology in patients with NASH, 
one concern is whether it increases all-cause mortality. Since there are conflicting data 
from different clinical trials, additional RCTs are needed to determine long-term efficacy 
and safety of vitamin E (28).  
 
Thiazolidinediones 
When vitamin E is not effective, administration of pharmacological agents (e.g. 
pioglitazone rosiglitazone) as adjunctive therapy is widely applied in the clinic. 
Pioglitazone and rosiglitazone belong to the class of thiazolidinediones (TZDs). TZDs can 
improve insulin sensitivity by activating the nuclear transcription factor peroxisome 
proliferator activated-receptor-gamma (PPAR-γ), thereby upregulating gene transcription 
for several proteins involved in glucose and lipid metabolism (29). A pilot study in 18 non-
diabetic NASH patients showed that 30 mg/day pioglitazone for 48 weeks led to a 
significant reduction in transaminases (ALT, AST), and a significant improvement in NAS 
(P<0.05) (30). A recent meta-analysis that included 5 RCTs showed that pioglitazone 
significantly improved steatosis (OR 4.05, 95% CI 2.58-6.35) and inflammation (OR 3.53, 95 
% CI 2.21-5.64), but not fibrosis (OR 1.40, 95% CI 0.87-2.24) (3). The long-term safety of 
TZDs has been debated regarding the risk of cardiovascular disease (31), congestive heart 
failure (32) and bladder cancer (33). In a recent meta-analysis (32) of 19 trials enrolling a 
total of 16.390 patients with T2DM, pioglitazone treatment was associated with a 
significant reduction (18%) in the primary outcome of death, myocardial infarction or 
stroke (P<0.005), however, there was also a higher rate of congestive heart failure with 
pioglitazone (2.3% vs.1.8% in the control group, P<0.002). Therefore, in September 2010, 
the European Medicines Agency (EMA) recommended that the drug should be suspended 
from the European market because the benefits of rosiglitazone no longer outweighed the 
risks. In US, rosiglitazone only could be sold with a prescription from a certified doctor and 
patients were required to be informed of the risks associated with its use through 
specified pharmacies. Until November 2013, the FDA lifted its earlier restrictions on 
rosiglitazone after reviewing the results of several other clinical trials, which did not 
provide evidence for an increased risk of heart infarct associated with the use of the drug. 
 
Agents in clinical trials 
Ezetimibe 
Ezetimibe, as a potent inhibitor of cholesterol absorption, inhibits Niemann–Pick C1-like 1 
(NPC1L1)-dependent cholesterol transport in liver (34). The beneficial effects of ezetimibe 
on improvement of liver steatosis and insulin resistance have been observed in mice fed a 
high fat diet (35) and Zucker obese fatty rats (36). An open-label study enrolled 45 
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patients with liver biopsy-proven NAFLD for treatment with ezetimibe (10 mg/day) for 24 
months. It was found that ezetimibe therapy significantly lowered serum ALT and CRP 
levels, whereas no significant changes were observed in adiponectin, leptin, and resistin 
levels. Histological features of steatosis score (P=0.0003), necro-inflammatory score 
(P=0.0456), ballooning score (P=0.0253) and NAS (P=0.0007) were significantly improved 
relative to baseline (the trial had no placebo control group). However, the fibrosis stage 
was not significantly (P=0.6547) changed (37). A recent RCT trail showed that ezetimibe 
(10 mg/day) treatment for 6 months significantly lowered the level of serum total 
cholesterol and also improved hepatic ballooning score and fibrosis stage, but significantly 
increased hepatic long-chain fatty acids and HbA1c compared to the control group (38). 




In February 2014, the US Food and Drug Administration (FDA) approved orphan drug 
MYALEPT™ (metreleptin for injection), which is indicated as an adjunct to diet as 
replacement therapy for the treatment of complications of leptin deficiency in patients 
with lipodystrophy. Metreleptin is recombinant human leptin. In a recent human study, 
NASH patients received subcutaneous administration of metreleptin daily for 2 years (39). 
Besides a significant improvement in metabolic profile, ALT and AST, patients treated with 
metreleptin also showed significant improvements in steatosis (reduction of mean score 
from 1.8 to 0.9) and ballooning injury scores (from 1.2 to 0.4), as well as a 44.2% reduction 
in NAS (p<0.0001) while fibrosis remained stable (39). Another ongoing RCT has been 
performed by the University of Michigan and is expected to complete in September 2015. 
The aim of this trail is to determine if the one-year treatment of metreleptin can improve 
NAFLD or NASH in patients with concurrent lipodystrophy, By taking pre-treatment and 
post-treatment liver biopsies and measuring various metabolic markers, this trial will 
evaluate the safety and effectiveness of metreleptin for the treatment of NAFLD/NASH.   
 
L-carnitine 
In mammals, L-carnitine is a conditionally essential nutrient that can be synthesized 
endogenously from lysine and methionine or obtained from the diet, primarily from red 
meat (40). L-carnitine is indispensable for energy metabolism and has been proposed as a 
supplement to treat a variety of health conditions including heart attack and heart failure 
(41, 42). In vitro and in vivo studies found that L-carnitine enhances both lipolysis and fatty 
acid oxidation (43) and that it reduces serum fatty acid levels by increasing beta-oxidation 
in hepatocytes (44, 45). Recently, dietary supplementation of L-carnitine (1000 mg/day) 
was investigated in 74 NASH patients, over a period of 6 months (46). Laboratory 
parameters in patients treated with L-carnitine showed significant improvements in 
plasma risk factors, among which a decrease of serum ALT/AST, TNF and CRP levels, and 
an improvement of insulin resistance. All patients (36) showed a significant reduction in 
steatosis, parenchymal inflammation, and hepatocellular injury, and 32 patients (86%) had 
improvement in fibrosis. Another recent RCT trail has been performed by Tehran 




treatment of L-carnitine (1000 mg/day), the level of ALT, AST and liver elasticity in NASH 
patients will be measured to evaluate the effect of L-carnitine on NASH (28).    
 
Polyphenols 
Polyphenols are often concentrated in leaf tissue and consist of 1-25% of the dry green 
leaf mass (47). A high amount of polyphenols has been found in green tea (about 35% of 
its total dry weight) (48). Studies from Park HJ et al. indicate that green tea extract 
attenuated hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic 
anti-oxidant defenses in ob/ob mice (49), as well as that it suppressed hepatic NFκB 
activation and inflammatory responses in diet-induced obese rats (50). Although several 
human studies have been conducted on the anti-obesity effects of dietary polyphenols (51, 
52), the effects of dietary polyphenols on NAFLD are missing. In a recent RCT study, 44 
participants (age 18–25 y, BMI ≥23.1 kg/m
2
) were given 250 mL of either bayberry juice or 
placebo twice daily for 4 weeks. Compared with placebo, the consumption of bayberry 
juice significantly decreased the plasma levels of TNF-α (P<0.001) and IL-8 (P=0.022), 
although no significant changes in plasma TGs, TC, LDL-C, fasting glucose level, insulin 
concentration, or HOMA-IR were found (53). Due to variation among subjects (age, gender, 
ethnicity), chemical forms of the dietary polyphenols used and confounding factors such 
as other weight-reducing agents, future RCT are warranted to evaluate the efficacy of 
dietary polyphenols on NAFLD/NASH.  
 
 
EXPERIMENTAL NASH  
 
Taken together, the major current challenges for the study of human NASH are: 1) lack of 
specific and efficient non-invasive methods that detect inflammation and fibrosis in the 
liver and 2) lack of effective and reliable therapeutic approaches that are based on 
understanding the pathogenesis of NASH. Furthermore, studies of NASH in humans have 
limitations or ethical issues regarding the collection of liver biopsies from patients and the 
administration of drugs to patients because of safety concerns. Animal models of NASH 
that mimic human disease can thus provide crucial mechanistic information, not only for 
elucidating the pathogenesis of NASH but also for examining therapeutic effects of various 
agents.  
 
Available diet-inducible animal NASH models 
Ideally, animal models should mimic both histopathology and pathophysiology of human 
NASH. Recently, several review articles on animal models of NAFLD/NASH have been 
published (54-56). An overview of the metabolic and hepatic characteristics of current 
diet-inducible NASH animal models is provided in Table 2. C57BL6 mice fed a HFD acquire 
a human NASH-like metabolic and histological phenotype, but a very long feeding period 
(>50 weeks) is required. MCD diet-induced NASH shows similar pathohistological features 
as human NASH, but does not develop the metabolic syndrome characteristics of human 
risk groups and therefore do not exhibit the metabolic context which is seen in most 
human NASH patients. Fructose with/without HFD or ALIOS diet feeding leads to elevated 
plasma insulin, resistin, and leptin levels, as well as increased plasma ALT levels, liver TNF-
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α and procollagen mRNA, indicating an inflammatory and profibrogenic response to injury. 
These diets also lead to hepatic steatosis and inflammation with a similar histological 
featuresas observed in patients with NASH. LDLR
-/-
 mice fed a HFD or HFC also develop a 
human-like NASH with respect to the metabolic context and histological phenotype, and 
this strain of mice is prone to develop fibrosis. Although the available animal models do 
not reflect the full spectrum of human NAFLD pathology, they are useful for verifying 
hypotheses on the pathogenesis of NASH and for testing pharmaceutical compounds in 
intervention studies.  
 
 
Table 2: Metabolic and pathological characteristics of animal NAFLD/NASH models. Important phenotypic and 
histological hallmarks are compared and the severity of a particular parameter is indicated as “+”, “++”, “+++”, 
absence of a particular feature is indicated as”-”. 
 














Predominate pattern Severity 
C57BL6, HFD* + + + microvesicular ++ + + (57) 
C57BL6, 
HFD+fructose** +++ ++ +++ macrovesicular +++ + not described (58) 
C57BL6, ALIOS diet +++ ++ ++ macrovesicular ++ + not described (59) 
C57BL6, 
MCD diet - - - macrovesicular +++ 
+++, 
lymphocytes 
& neutrophils ++ (60-62) 
Ob/ob, HFD +++ ++ ++ not described ++ - - (63, 64) 
ApoE2 knock-in, 





synthesis genes (65, 66) 
ApoE
-/-
, HFC + + ++ macrovesicular ++ 
++, 
macrophages not described (67, 68) 
LDLR
-/-
, HFD ++ ++ ++ not described ++ ++ + (69) 
LDLR
-/-
, HFC +++ ++ +++ macrovesicular +++ 
+++, 
macrophages ++ (66, 70) 
hCRP, HFD ++ ++ ++ macrovesicular ++ ++ + (71) 
IR: insulin resistance; HFD: high fat diet; HFC: high fat high cholesterol diet; MCD: methionine choline deficient 
diet 
*C57BL6 wild type mice hardly develop NASH, the features shown in the table were present only when they were 
fed for up to 50 weeks.  
**Alios diet: 45% kcal from fat (30% from partially hydrogenated vegetable oil (28% saturated fatty acids, 57% 
monounsaturated fatty acids, 13% polyunsaturated fatty acids) + high fructose corn syrup equivalent (55% 




Note: Since the severity of NASH largely depends on how long a study is performed, studies with 8-15 weeks 




Pathogenesis of NASH 
Intrahepatic effects of lipid imbalance on NASH 
Triglycerides (TGs) are utilized as metabolic fuel via fatty acids oxidation. In liver, TGs can 
either be stored in hepatocytes or can be exported as very low density lipoprotein (VLDL).  
An increase of TGs in hepatocytes, which ultimately leads to hepatic steatosis, can be due 
to 1) increased dietary intake of free fatty acids, 2) increased de novo lipogenesis, 3) 
increased recirculation of non-esterified fatty acids to the liver from the peripheral tissues 
(e.g. adipose tissue or skeletal muscle), or 4) failure of hepatic clearance of fatty acids due 
to either impaired esterification to TGs and export as VLDL, or impaired hepatic 
mitochondrial β-oxidation (16). In the next paragraphs, the dietary intake and the 
contribution of different dietary components (HFD, dietary cholesterol and dietary 
carbohydrate) on NASH development will be discussed.  
 
HFD 
Studies in humans (15) and animals (72) have shown that different types of fatty acids can 
lead to different outcomes with respect to liver injury. Nutritional surveys showed that 
the dietary intake of saturated fats (SF) was significantly higher in NAFLD and NASH 
patients than in healthy controls (73, 74). Consistent with this, a high fat diet (HFD), that 
consists of >24% of energy from fat, is commonly used to induce hepatic steatosis in 
animal NASH models. In a high fat diet rat model, Buettner et al. (72) compared different 
high fat diets: coconut oil (primarily SF), olive oil (primarily monounsaturated fatty acids, 
MUFA), lard (mixture of SF and MUFA), and fish oil (primarily polyunsaturated fatty acids, 
PUFA). After 12 weeks, the first three diets significantly worsened hepatic steatosis as well 
as elevated plasma TG, whereas the fish oil (PUFA)-based diet did not. 
    However, growing evidence suggests that HFD alone is not sufficient to induce NASH (75, 
76). A refined time course analysis (77) of HFD feeding in rodents showed that the 
inflammatory response of the liver is transient and that the liver can adapt its metabolic 
program to the HFD overload. Therefore experimental steatosis hardly progresses into the 
extensively inflamed conditions of NASH as they are observed in patients. This suggests 
that additional inflammatory triggers are important to experimentally induce an inflamed 
fatty liver.  
 
Dietary cholesterol 
The role of cholesterol on the development of NASH is recently getting more attention. In 
a large, nationally epidemiological study in the United States, dietary cholesterol 
consumption was independently associated with the development of cirrhosis (78). 
Another recent, pilot trial of ezetimibe, as an intestinal cholesterol absorption inhibitor, 
found improvements in hepatic steatosis and inflammation in humans with NASH (37, 79). 
Animal data are also emerging to support a role for dietary cholesterol in the progression 
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towards NASH. Hofker MH and colleagues (66) suggested that dietary cholesterol induced 
hepatic inflammation independently of hepatic steatosis in a hyperlipidemic mouse model 
with NASH. A study by Ioannou at al. (80) recently compared different diets (high fat, high 
cholesterol and high fat+high cholesterol) to examine their effects on NASH development. 
After 30 weeks of diet feeding using C57BL/6J mice, only high fat+high cholesterol diet led 
to significant levels of hepatic steatosis, hepatic inflammation, and perisinusoidal fibrosis 
with a similar profile of risk factors as seen in human NASH. These effects were associated 
with adipose tissue inflammation and a reduction in plasma adiponectin levels. 
Interestingly, an investigation of dietary records by Yasutake et al. (81) revealed that 
cholesterol intake was significantly greater in both obese and non-obese NAFLD patients 
than in healthy controls. Surprisingly, non-obese NAFLD patients even had higher 
cholesterol consumption than obese NAFLD patients, suggesting that cholesterol intake 
may cause NAFLD independent of obesity. Based on available human and animal data, it 
has been hypothesized that cholesterol-induced liver injury could be an important cause 
of NASH independent of obesity, insulin resistance or even steatosis as proposed recently 
(82). However, the exact molecular mechanism of the effects of dietary cholesterol on 
NASH pathogenesis is still unknown.  
 
Dietary carbohydrate 
Several human and animal studies suggest that carbohydrates, such as sucrose and 
fructose, are possibly causative to NAFLD development (83). Nutrition reports have shown 
that the mean daily consumption and mean frequency of soft drinks is at least two fold 
higher in NAFLD patients than in healthy subjects (84, 85). High amount of fructose 
consumption is thought to be one of the most important dietary contributors to the 
pathogenesis of NAFLD. In a large clinical study performed by the NASH Clinical Research 
Network, dietary fructose consumption was found to be associated with induction of 
histological features of NASH, including hepatic inflammation and hepatocyte ballooning 
and fibrosis stage (86). Animal studies have shown that excess intake of fructose is closely 
associated with obesity and steatosis, through the activation of sterol regulatory element-
binding protein-1c (SREBP-1c), a transcription factor that enhances the expression of 
enzymes associated with fatty acid synthesis (87, 88), and with increased visceral adiposity 
(89) and insulin resistance (58). Some animal studies have shown that high-fructose 
feeding is associated with upregulation of markers of inflammation, macrophage 
activation and oxidative stress. A recent study form Bhattacharjee demonstrated that 
fructose-induced NAFLD is associated with recruitment of T cells and NK cells in mice (90).  
 
Intrahepatic effects of inflammation leading to NASH 
Pro-inflammatory cytokines 
Pro-inflammatory cytokines are important contributors to the development of NASH (91). 
TNF-α secreted by adipocytes and hepatocytes, was the first cytokine known to be 
elevated in NAFLD patients (92). Human data has shown that TNF-α is elevated in NAFLD 
patients compared with both obese and non-obese controls (93). Crespo et al. (94) 
identified increased mRNA expression of TNF-α and TNF-α receptor, p55, and showed that 




leptin-deficient (ob/ob) mice fed a high-fat diet, dietary manipulations that favor 
pathways which quench TNF-α improved insulin sensitivity, hepatic steatosis, and 
inflammatory cells infiltration in the liver (95).   
    Data from human studies have shown that increased systemic IL-6 levels are associated 
with increased inflammation and fibrosis in NAFLD patients (96). Wieckowska et al. found 
that IL-6 expression was increased in both hepatocytes and Kupffer cells and these levels 
positively correlated with both the inflammatory activity and the stage of fibrosis in 
NAFLD patients (97). Evidence from human and animal studies indicate that pro-
inflammatory (TNF-α, IL-6)-induced insulin resistance and lipid overloading of liver cells 
both involve activation of stress-related protein kinases such as IKKβ, an activator of the 
proinflammatory transcription factor NFκB) and Jun N-terminal kinase (JNK), an activator 
of AP-1. These pathways subsequently increase inflammatory mediators like CRP, TNF-α, 
IL-6, and IL-1β, which further can contribute to liver injury (16, 98). IKKβ activation leads 
to NFκB translocation to the nucleus, resulting in a feed–forward loop that promotes 
increased expression of pro-inflammatory cytokines and other mediators of inflammation 
that augment hepatic inflammation and insulin resistance (99). Activation of NFκB has 
been observed in human NASH (100) and NASH mouse models (101). Animal studies have 
shown that pro-inflammatory cytokines (e.g. TNF-α, IL-1β) released from NFκB-activated 
Kupffer cells could also activate NFκB in adjacent hepatocytes (102). The involvement of 
hepatic NFκB in the progression of bland steatosis to NASH has recently been proposed in 
transgenic mice selectively expressing constitutively active IKKβ in hepatocytes (98). The 
JNKs (1 and 2) can be stimulated via activation of TNF superfamily death-signaling 
receptors (e.g. Fas, TNF-R1, TNF-related apoptosis-inducing ligand death receptors) and 
TLRs, or they can directly activated by lipotoxic molecules and oxidative stress (103). 
Videla et al. (100) showed that, in liver, NFκB and AP-1 DNA binding is significantly 
increased in NASH patients. In animal studies, removal of JNK1 or IKKβ suppressed pro-
inflammatory gene expression and cytokine release (104, 105). Farrell et al. (106). showed 
that both JNK1 and JNK2 are activated in a NASH mouse model and, conversely, italso 
been shown that abolishing JNK activation can attenuate macrophage accumulation, 
hepatocyte apoptosis and liver injury in the context of NAFLD (102). However, the exact 
nature of most of the inflammatory mediators that cause the transition from bland 
steatosis to NASH is still largely unknown. 
 
Oxidative stress  
Oxidative stress, refers to an imbalance in the production of reactive oxygen species (ROS) 
and protective antioxidants, and has been considered to be an important contributor to 
the development of NASH (16). Oxidative damage is significantly correlated with 
inflammation and increased in the livers of patients with NAFLD when compared with 
controls (107). Sanyal et al. (108) demonstrated that immunohistochemical staining for 3-
nitrotyrosine, a marker for oxidative stress, was elevated in NAFLD patients as compared 
to controls and was markedly higher in NASH patients than in patients with bland 
steatosis. Mitochondrial dysfunction leading to uncoupling of oxidative phosphorylation 
and resulting in ROS generation has been reported in NASH subjects (108, 109). 
Furthermore, in NASH patients increased activity of the mitochondrial cytochrome P450 
2E1 (CYP2E1) has been observed (110). Studies in rats using the methionine choline 
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deficient diet to induce NASH found increased CYP2E1 activity (111). Using CYP2E1 knock-
out mice, Abdelmegeed et al. recently showed that CYP2E1 plays a role in NASH 
development (112) and the authors suggest that the CYP2E1 enzyme may have a capacity 
of directly generating ROS. Moreover, upregulaton of cytokine receptors, especially TNF-α 
and antigens derived from gut flora via activation of NADPH oxidase system, also may play 
a role in the progression of NASH (16, 113).  
    In 1998, Day and James proposed the ‘two-hit theory’ (114) and described a possible 
pathogenic mechanism for the development of NASH: extensive lipid accumulation as a 
‘first hit’ is followed by inflammation (as ‘second hit’) causes the progression of the 
disease towards NASH. On the other hand, clinical researchers occasionally found patients 
with NASH without obvious steatosis. Furthermore, steatosis could be improved in ob/ob 
mice when treated with anti-tumor necrosis (TNF)-α antibody (95). After a series of 
debates on the proposed sequence of events, either sequentially or in parallel, the 
concept of ‘multiple parallel hits’ has recently been considered (115). More recently, Jou 
et al. (116) proposed hepatocyte death and lack of repair as a possible ‘third hit’. This 
theory proposes that combined oxidative/metabolic stress and in imbalanced cytokine 
production, may lead to an increase of hepatocytes death. These multiple hits can occur 
simultaneously and are intertwined; this may eventually lead to NASH (16, 117).  
 
 
OUTLINE OF THE THESIS  
 
Metabolic stress caused by excess dietary intake is considered to be an important 
contributor to NASH in humans, but the exact molecular mechanism of metabolic 
overload-induced NASH is largely unknown. Therefore, the aim of this thesis was to better 
understand the role of metabolic overload and metabolic inflammation in the 
development of NASH.  
    The NAFLD activity score (NAS) used in clinical studies has not been validated for animal 
models of NASH. In Chapter 2, we developed a generic scoring system for the assessment 
of NAFLD in mice. This new scoring system allows to grade the histological features 
present in the various NASH mouse models currently used in preclinic research. Our 
scoring system is based on the human NAS system, and the inter- and intra-observer 
reproducibility was analyzed and found to be reliable.  
    After this methodological optimization and in order to get insight into the nature of the 
chronic inflammatory component that drives the development of NASH, we examined in 
Chapter 3 the effect of non-metabolic triggers (LPS, IL-1β administered by slow-release 
minipumps) and metabolic dietary triggers (carbohydrate, cholesterol) of inflammation on 
the progression of bland steatosis to NASH. We showed that HFD feeding followed by 
metabolic triggers induced extensive steatosis and specific inflammatory components 
(neutrophils, AP-1) which results in a human-like NASH phenotype, while long-term LPS 
and IL-1β stimulation on top of HFD feeding did not. We next analyzed the distinct types 
of steatosis, microvesicular and macrovesicular steatosis, during NAFLD development over 
time, and investigated how steatosis is related to the onset of hepatic inflammation. More 
specifically, we performed in Chapter 4 a time-course study using a metabolic 




vesicular/micro-vesicular steatosis, inflammatory cell infiltrates, NFĸB activation and 
fibrosis were evaluated, and the correlations between the specific forms of steatosis, 
hepatic inflammation and activation of inflammatory transcription factors were 
established.  
    Next, we examined specific nutritional and pharmacological interventions that may 
attenuate diet-induced experimental NASH. In Chapter 5, the effect of Mirtoselect, a 
standardized anthocyanin-rich bilberry extract was evaluated on the progression of NASH. 
We showed that Mirtoselect has profound effects on intrahepatic inflammatory processes 
resulting in a significant attenuation of NASH and associated fibrosis. In Chapter 6, we 
studied the effect of an anti-inflammatory drug, salsalate, on diet-induced NASH in a 
short-term and a long-term study. Salsalate exhibited strong NASH-reducing properties 
and almost fully attenuated hepatic steatosis and inflammation. 
    Besides in liver, chronic metabolic overload may also develop in other organs which 
potentially contribute to NAFLD development. In Chapter 7, we analyzed the development 
of metabolic stress in white adipose tissue and liver over time and found that white 
adipose inflammation preceded liver inflammation and NAFLD. The nature of the 
metabolic adaptations in WAT and liver were remarkably similar. The same transcriptional 
regulators were found to be activated to orchestrate the complex responses to metabolic 
overload. Finally, we investigated how long-term HFD-induced metabolic overload (t=42 
weeks) would affect metabolic and inflammatory processes in the kidney in Chapter 8. 
Drugs with established anti-inflammatory properties (rosuvastatin and rosiglitazone) were 
tested regarding their potency to reduce metabolically-induced organ inflammation and 
to improve kidney function.  
    Finally, the findings from the above studies and their implications are discussed in 
Chapter 9. 
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Background and aims: The recently developed histological scoring system for non-
alcoholic fatty liver disease (NAFLD) by the NASH Clinical Research Network (NASH-CRN) 
has been widely used in clinical settings, but is increasingly employed in preclinical 
research as well. However, it has not been systematically analyzed whether the human 
scoring system can directly be converted to preclinical rodent models. To analyze this, we 
systematically compared human NAFLD liver pathology, using human liver biopsies, with 
liver pathology of several NAFLD mouse models. Based upon the features pertaining to 
mouse NAFLD, we aimed at establishing a modified generic scoring system that is 
applicable to broad spectrum of rodent models. 
Methods: The histopathology of NAFLD was analyzed in several different mouse models of 
NAFLD to define generic criteria for histological assessment (preclinical scoring system). 
For validation of this scoring system, 36 slides of mouse livers, covering the whole 
spectrum of NAFLD, were blindly analyzed by ten observers. Additionally, the livers were 
blindly scored by one observer during two separate assessments longer than 3 months 
apart. 
Results: The criteria macrovesicular steatosis, microvesicular steatosis, hepatocellular 
hypertrophy, inflammation and fibrosis were generally applicable to rodent NAFLD. The 
inter-observer reproducibility (evaluated using the Intraclass Correlation Coefficient) 
between the ten observers was high for the analysis of macrovesicular steatosis and 
microvesicular steatosis (ICC=0.784 and 0.776, all p<0.001, respectively) and moderate for 
the analysis of hypertrophy and inflammation (ICC=0.685 and 0.650, all p<0.001, 
respectively). The intra-observer reproducibility between the different observations of 
one observer was high for the analysis of macrovesicular steatosis, microvesicular 
steatosis and hypertrophy (ICC=0.871, 0.871 and 0.896, all p<0.001, respectively) and very 
high for the analysis of inflammation (ICC=0.931, p<0.001). 
Conclusions: We established a simple NAFLD scoring system with high reproducibility that 









Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver 
disease in developed countries, paralleling the increased prevalence of obesity during the 
last decades [1-3]. NAFLD encompasses a wide spectrum of liver pathology ranging from 
non-alcoholic hepatic steatosis to steatohepatitis (NASH), which can evolve into liver 
fibrosis, cirrhosis and its life threatening complications or hepatocellular cancer [4]. 
    Currently, liver biopsy is still the ‘golden standard’ for NASH diagnosis in clinical setting. 
Liver biopsies will however often be taken in subjects at high risk, leading to a bias in the 
samples towards the more severe forms of NAFLD. Histological scoring systems designed 
for human diagnostic purposes therefore usually concentrate on facets of the later stages 
of NAFLD, making them less applicable for scoring early stages of NAFLD. However, in 
2005, the NASH Clinical Research Network (NASH-CRN) established and validated a system 
of histological evaluation for the full spectrum of NAFLD that could be useful in clinical 
trials [5]. Importantly, this scoring system of Kleiner et al. was not developed for 
diagnosing NASH, but for monitoring histopathological changes during clinical trials. The 
semi-quantitative scoring system separates the grading (activity) from staging (fibrosis) [5]. 
The grading or NAFLD activity score (NAS) encompasses steatosis, lobular inflammation 
and ballooning [5, 6]. The methodology proposed for scoring the different features of 
NAFLD has now been widely utilized, as evidenced by its application in numerous studies. 
Among the studies that use the Kleiner scoring system are several preclinical animal 
studies. However, despite this widespread use of the scoring system in different mouse 
models of NAFLD, the original scoring system was intended for human samples and has 
never been validated for experimental rodent samples. 
    To this end, by comparing human liver biopsies with the liver samples of different 
NAFLD mouse models (HFD-fed C57BL6, MCD-diet fed C57BL6, HC-diet fed APOE*3Leiden, 





 mice), we first assessed whether specific features of human NAFLD 
pathology are present in NAFLD mouse models. Additionally, and based upon the features 
pertaining to mouse NAFLD, we defined a set of robust histological criteria to analyze 
NAFLD in rodents and propose a modified Kleiner scoring system that is applicable to all 
stages of NAFLD etiology and that could generally be used in preclinical rodent studies 
because of its low inter- and intra-observer variability.  
 
 
MATERIALS AND METHODS  
Human NAFLD samples 
Thirty human liver biopsies were obtained during autopsy for postmortem histological 
analysis (Department of Pathology; Leiden University Medical Center/LUMC, Leiden, The 
Netherlands). Sample collection and handling was performed in accordance with the 
guidelines of the Committee Medical Ethics (CME, Leiden, The Netherlands) and the code 
of conduct of the Dutch Federation of Biomedical Scientific Societies and after permission 
of the institutional review board. The LUMC review board does not require ethical consent 




material is collected in the context of patient care and is later made available for scientific 
use provided that the material is used anonymously, not required for clinical use, that the 
patient has not objected to the further use, and that tissue handling is performed in 
accordance with the local and national guidelines. Cardiovascular disease was the 
predominant cause of death. Cases with a known or suspected alcohol abuse were 
excluded. Forty percent of the subjects were female and sixty percent male. The average 
age was 63 years. Liver samples were fixed in formalin, paraffin embedded and sections 
were stained with hematoxylin and eosin (H&E) and Sirius Red. Samples were scored for 
NAFLD (using NAS) and fibrosis stage and subsequently diagnosed as no evidence of fatty 
liver disease, steatosis or steatohepatitis by a clinical pathologist (A.D). In Table 1 the 
most important histological characteristics for the human samples are listed per 
diagnosed category, additional histological features are listed in Supplemental Table 1.  
 
 
Table 1: Histological characteristics of human samples per diagnosed category. 
 
Histological feature Score/code Healthy (n=9) NAFLD (n=11) NASH (n=10) 
Steatosis grade 0 9 0 0 
 1 0 4 4 
 2 0 6 4 
 3 0 1 2 
Lobular inflammation 0 9 11 0 
 1 0 0 10 
 2 0 0 0 
 3 0 0 0 
Ballooning 0 8 11 0 
 1 1 0 8 
 2 0 0 2 
Fibrosis stage 0 6 6 2 
 1 1 0 0 
 1A 0 4 2 
 1B 1 0 4 
 1C 0 0 0 
 2 1 1 1 
 3 0 0 0 
 4 0 0 1 
Number of subjects per score/code are shown for the indicated histological features. 
 
 
Animals and induction of NAFLD 
Several animal models, covering the spectrum of NAFLD from simple steatosis to NASH 
without or with fibrosis, were used to define robust histological criteria for experimental 
disease and to validate the rodent scoring system. In Table 2 the metabolic and 





Table 2: Metabolic and histological characteristics of the used NAFLD mouse models. 
 
Model Obesity IR HTG Steatosis Hepatic 
inflammation 
Fibrosis 
C57BL6, HFD + + - + + - 
C57BL6, MCD - - - ++ ++ ++ 
E3L, HC - - - + ++ ++ 
E3L.CETP, HFD + + - ++ - - 
E3L.CETP, HFC + + + ++ ++ + 
LDLR
-/-
.Leiden, HFD ++ ++ + ++ ++ ++ 
LDLR
-/-
,Leiden, HFC + + ++ ++ ++ ++ 
KKA
y
, HFD ++ ++ + ++ - - 
Severity is indicated as + or ++, absence is indicated as -. IR: insulin resistance; HGT: hypertriglyceridemia; HFD: 




    Male C57BL/6J mice, 12 weeks of age, were obtained from Charles River and were fed a 
high fat diet (HFD: 45 energy% fat derived from lard, Research Diets, New Brunswick, NJ, 
USA) for 24 weeks (n=10).  
    Male C57BL/6J mice, 4-8 weeks of age, were obtained from Charles River and were fed 
a methionine choline deficient diet (MCD: cat#960439; MP Biomedicals, Eindhoven, The 
Netherlands) for 8 weeks (n=10).  
    Female APOE*3Leiden (E3L) mice [7], 17-20 weeks of age were obtained from the in-
house breeding colony (TNO Metabolic Health Research, Leiden, The Netherlands) and 
were fed a high cholesterol diet (HC: 35 energy% fat primarily as cocoa butter, 40 energy% 
sucrose and 1% cholesterol, modified semi-synthetic diet based on Nishina et al., [8]) for 
20 weeks (n=10). 
    Human CETP transgenic mice that express cholesteryl ester transfer protein (CETP) 
under control of its natural flanking regions (strain 5203) [9] were obtained from Jackson 
Laboratories (Bar Harbor, MC) and cross-bred with APOE*3Leiden mice in our local animal 
facility at TNO to obtain heterozygous E3L.CETP mice [10, 11]. Male E3L.CETP mice, 10-14 
weeks of age, were either fed a HFD for 16 weeks (n=10) to induce steatosis without 
steatohepatitis or were fed the HFD for 10 weeks, followed by 6 weeks of the HFD 
supplemented with 1% cholesterol (n=10), to induce steatohepatitis.  
    Male LDLR
-/-
 mice [12], 13-17 weeks of age, were obtained from the in-house breeding 
colony (LDLR
-/-
. Leiden strain; TNO Metabolic Health Research, Leiden, The Netherlands). 
This strain is more sensitive to diet-induced obesity and comorbidities than regular LDLR
-/-
 
mice. Mice were fed a HFD for 10 weeks, followed by 6 weeks of the HFD supplemented 
with 1% cholesterol (n=10), or in a separate experiment, fed a HFD for 21 weeks (n=10). 
Male KKA
y
 mice, 5-7 weeks of age, were obtained from Jackson Laboratories and were fed 
a HFD for 16 weeks (n=10).  
    All animals were housed in a temperature-controlled room on a 12 hour light-dark cycle 
and had free access to food and water. Mice were sacrificed using CO2 asphyxiation. Liver 




collected, fixed in formalin, paraffin embedded and sections were stained with 
hematoxylin and eosin (H&E) and Sirius Red. Animal experiments were approved by the 
Ethical Committee on Animal Care and Experimentation (Zeist, The Netherlands), and 
were in compliance with European Community specifications regarding the use of 
laboratory animals.  
 
Defining the overlapping features of NAFLD in humans and mice 
Using the histological scoring system of Kleiner et al., tissue samples from mouse NAFLD 
models were compared to liver biopsy samples obtained from NAFLD patients to examine 
whether recognized features of human NAFLD were present in any of the experimental 
NAFLD models (Table 3). Liver histology photomicrographs were taken to compare 
histological features from human and mouse (control vs. NASH) (Figure 1).  
 
 
Table 3: Histological features of NAFLD in humans and presence or absence in mice. 
   
Histological feature Human NAFLD Mouse NAFLD 
Steatosis   
 Steatosis √ √ 
     Microvesicular steatosis √ √ 
Inflammation   
 Lobular inflammation 
(overall assessment of all inflammatory foci) 
√ √ 
      Microgranulomas (small aggregates of  macrophages) √ √ 
      Large lipogranulomas √ √ 
      Portal inflammation √ √ 
Fibrosis √ √ 
Liver cell injury   
 Ballooning cells √ √* 
       Acidophil bodies (hepatic apoptosis) √ - 
       Pigmented macrophages √ - 
       Megamitochondria  √ - 
Other findings   
 Mallory-Denk bodies √ - 
      Nuclear glycogenation √ - 
The presence or absence of the main histological features of NAFLD as identified in humans was evaluated in 
several different mouse models for NAFLD (C57BL6  mice on a high fat diet or on methionine choline deficient 
(MCD) diet, E3L, E3L.CETP, LDLR-/-.Leiden, KKAy mice):  “√” presence; “-” absence of features.* Ballooning cells 
were occasionally observed in the models. 
 
 
Definition of histological NAFLD score  
Briefly, the two key features of NASH, steatosis and inflammation, were categorized as 
follows: steatosis was determined by analyzing hepatocellular vesicular steatosis, i.e.  




hypertrophy as defined below (Figure 2). Inflammation was scored by analyzing the 
amount of inflammatory cell aggregates (Figure 2).  The proposed rodent scoring system is 
shown in Table 4 and options for its use in diagnosis are shown in Supplemental Figure 1.  
 
Figure 1: Histological photomicrographs of human NASH and NASH in mice. Liver histological cross-sections 
from a healthy control subject (A) and a NASH patient (B). Liver histological cross-sections from a healthy control 













Figure 2: Hepatocellular steatosis, hypertrophy and inflammation. Liver cross-sections are from a NASH patient 
(A) or a E3L.CETP mouse fed a high fat diet supplemented with cholesterol to induce NASH (B). Macrovesicular 
steatosis (dotted line arrow): large lipid droplets are present in hepatocytes; microvesicular steatosis (bold 
arrow): small lipid droplets are present in hepatocytes. Hypertrophy (open arrow): the representative cell is 
much larger than the surrounding steatotic hepatocytes but has the same cytoplasmic characteristics. Clusters 
(aggregates) of inflammatory cells (within circles). All photomicrographs: Hematoxylin and eosin; magnification 


















Table 4: Grading system for rodent NAFLD. 
 
Histological feature Score 
0 1 2 3 
Steatosis:     
 Macrovesicular steatosis  <5% 5-33% 33-66% >66% 
 Microvesicular steatosis <5% 5-33% 33-66% >66% 
     Hypertrophy <5% 5-33% 33-66% >66% 
Inflammation:     
      Number of inflammatory foci/field <0.5 0.5-1.0 1.0-2.0 >2.0 
 
 
The purpose of this scoring system is however not to derive a single score, but to score 
the individual features. 
    Macrovesicular steatosis and microvesicular steatosis were both separately scored and 
the severity was graded, based on the percentage of the total area affected, into the 
following categories: 0 (<5%), 1 (5-33%), 2 (34-66%) and 3 (>66%). The difference between 
macrovesicular and microvesicular steatosis was defined by whether the vacuoles 
displaced the nucleus to the side (macrovesicular) or not (microvesicular). Similarly, the 
level of hepatocellular hypertrophy, defined as cellular enlargement more than 1.5 times 
the normal hepatocyte diameter, was scored, based on the percentage of the total area 
affected, into the following categories: 0 (<5%), 1 (5-33%), 2 (34-66%) and 3 (>66%). For 
hepatocellular hypertrophy the evaluation was merely based on abnormal enlargement of 
the cells, irrespective of rounding of the cells and/or changes in cytoplasm or the number 
of vacuoles, and is therefore not a substitute of ballooning. The unweight sum of the 
scores for steatosis (macrovesicular steatosis, microvesicular steatosis and hypertrophy) 
thus ranged from 0-9. Both steatosis and hypertrophy were evaluated at a 40 to 100 × 
magnification and only the sheets of hepatocytes were taken into account (terminal 
hepatic venules and portal tracts etc were excluded). 
    Inflammation was evaluated by counting the number of inflammatory foci per field 
using a 100 x magnification (view size of 3.1 mm
2
). A focus was defined a cluster, not a 
row, of ≥5 inflammatory cells. Five different fields were counted and the average was 
subsequently scored into the following categories: normal (<0.5 foci), slight (0.5-1.0 foci), 
moderate (1.0-2.0 foci), severe (>2.0 foci).   
    Hepatic fibrosis was identified using Sirius Red stained slides at 40 x magnification and 
evaluated by scoring whether pathologic collagen staining was absent (only in vessels) or 
collagen staining observed within the liver slide, the latter further defined as mild, 
moderate or massive. In addition, the percentage of the total area affected was evaluated 
using using image analysis of surface area on Sirius red stained slides.  
 
Validation of histological NAFLD scoring system in mice 
To validate the scoring system, 36 slides of mouse livers covering the whole spectrum of 
NAFLD, were blindly analyzed by a board-certified pathologist (A.L.M), a clinical 
pathologist (A.D.) and nine scientists with basic histological experience. For the validation, 




steatosis and hypertrophy (relative scale) and the number of inflammatory foci per field 
(absolute scale), instead of using the different categories for steatosis and inflammation 
(ordinal measure). Additionally, quantification of the steatosis and inflammation was 
determined by one observer during two separate assessments that were separated by an 
interval longer than 3 months. 
 
Statistical analysis 
The reproducibility of the scoring system was determined by calculating the Intraclass 
Correlation Coefficient (ICC) to determine inter-observer reliability among ten observers 
or the intra-observer reliability among two separate scoring assessments of one observer. 
Using two-way random model with absolute agreement and the 95% confidence interval 
(CI), ICCs were calculated for the agreement on NAFLD/NASH criteria of macrovesicular 
steatosis, microvesicular steatosis, hypertrophy and inflammation.  
    The ICC was interpreted as follows, according to the Munro classification system little or 
no correlation for values below 0.25, low correlation for values between 0.26–0.49, 
moderate correlation for values between 0.50–0.69 high correlation for values between 
0.70–0.89 and very good correlation for values between 0.90–1.00 [13]. The Bland-Altman 
plot [14] was used to analyze inter- and intra-observer reproducibility to permit a better 
visualization of the correlation between individual measures. Results were considered 
significant at P-value <0.05 and statistical analyses were performed using SPSS version 




Development of histological NAFLD scoring system in mice 
To define the overlapping NAFLD features in humans and mice, histological samples from 
several mouse NAFLD models were compared to human tissue biopsies of NAFLD patients. 
A summary of the main features of human NAFLD according to the Kleiner’s scoring 
system and their presence or absence in the mouse NAFLD models is shown in Table 1. 
Overall, the histological cross-sections of the mouse NAFLD looked similar to those of the 
human NAFLD patients (Figure 1), but not all main features of human NAFLD were present 
in the mouse NAFLD models. The most important features of steatosis and inflammation, 
as well as fibrosis, were all found to be present in mouse NAFLD models as well. However,  
the features for hepatocellular injury, like apoptosis, pigmented macrophages and 
megamitochondria, were not found in any of the mouse NAFLD models. Ballooning, 
defined as enlarged and rounded hepatocytes with clear cytoplasm, was only occasionally 
found in the experimental NAFLD models, and did not prominently exist. Although 
enlarged hepatocytes were retrieved in all mouse NAFLD models, a distinct rounding of 
these cells concomitant with clear reticular cytoplasm was rarely found in all models.  
    Based upon the most important overlapping features, we selected the following main 
criteria for establishing a rodent NAFLD scoring system: 1) steatosis by determining the 
severity of macrovesicular steatosis, microvesicular steatosis and hypertrophy (as 
percentage of total area affected) and 2) inflammation by counting the number of 




    In addition, the different staging of NAFLD was analyzed by identifying whether fibrosis 
was present and to which extent. In our present study, the most severe fibrosis was 
observed in the LDLR
-/-
.Leiden mice, followed by the E3L mice. In both models fibrosis was 
situated in both pericentral and perisinusoidal zone and sometimes bridging fibrosis was 
observed (Figure 3).  
 
Figure 3: Liver fibrosis. Photomicrograph of cells with collagen staining (Sirius red). Liver histological cross-
sections are from a healthy control subject (A) and a NASH patient (B) or a healthy control (C) and a LDLR
-/-
. 
Leiden mouse fed a high fat diet to induce NASH (D). All photomicrographs: Sirius red; magnification 100x. 
 
 
Validation of histological NAFLD scoring system in mice 
A total of 36 mouse liver samples were used as validation set. This set of histological 
specimen covered the whole spectrum of NAFLD, from healthy unaffected samples to 
severe NASH livers with fibrosis (and included livers from various strains of mice). To 
evaluate the agreement between different observers, ten different observers analyzed the 
study set blindly. The level of inter-observer variation was subsequently evaluated using 
the Intraclass Correlation Coefficient (ICC). The ICC indicated a high correlation for the 
analysis of macrovesicular steatosis and microvesicular steatosis (ICC=0.784 and 0.776, 
both p<0.001, respectively) and a moderate correlation for the analysis of hypertrophy 
and inflammation (ICC=0.685 and 0.650, both p<0.001) between the different observers 
(Table 5). In conjunction with ICC, the Bland-Altman plots for two observers were also 
reported to visualize the correlation (Figure 4). In addition, the agreement between two 
pathologists was examined. The ICC indicated a very good correlation for the analysis of 


















Table 5: Inter-observer reproducibility of NASH histological features according to the mouse NAFLD/NASH 
scoring system. 
 
Histological feature ICC CI P 
Macrovesicular steatosis 0.784 0.681–0.869 <0.001 
Microvesicular steatosis 0.776 0.679–0.860 <0.001 
Hypertrophy 0.685 0.565–0.796 <0.001 
Inflammation 0.650 0.517–0.779 <0.001 
ICC: intraclass correlation coefficient (two-way random effects model, with absolute agreement); CI: 95% 
























Figure 4: Bland-Altman plot for correlation analysis between two observers for measurement of 
macrovesicular steatosis, microvesicular steatosis, hypertrophy and inflammation. X-axis: average 
measurements of two observers. Y-axis: Difference between measurements of two observers. UL: Upper 95% 
limits of agreement. LL: Lower 95% limits of agreement. 
 
 
hypertrophy (ICC=0.814 and 0.784, both p<0.001, respectively) but low correlation for the 
analysis of inflammation (ICC=0.471, p<0.01) between the two pathologists 
(Supplemental Table 2). 
    The agreement between different observations of one observer was evaluated by 
analysis of the study set during two separate scoring assessments that were separated by 
an interval of more than 3 months. In the analysis of intra-observer reproducibility, the 




steatosis and hypertrophy (ICC=0.871, 0.871 and 0.896, all p<0.001, respectively) and a 
very high correlation for the analysis of inflammation (ICC=0.931, p<0.001) between the 
different time points of analysis (Table 6). The Bland-Altman plots confirmed that a 
correlation was observed between the first and second scoring assessments (Figure 5). 
 
 
Table 6: Intra-observer reproducibility of NASH histological features according to the mouse NAFLD/NASH 
scoring system. 
 
Histological feature ICC CI P 
Macrovesicular steatosis 0.871 0.729–0.937 <0.001 
Microvesicular steatosis 0.871 0.740–0.935 <0.001 
Hypertrophy 0.896 0.805–0.945 <0.001 
Inflammation 0.931 0.802–0.971 <0.001 
ICC: intraclass correlation coefficient (two-way random effects model, with absolute agreement); CI: 95% 
































Figure 5: Bland-Altman plot for correlation analysis between two observations of one observer for 
measurement of macrovesicular steatosis, microvesicular steatosis, hypertrophy and inflammation. X-axis: 
average measurements of two observations. Y-axis: Difference between measurements of two observations. UL: 







A uniform, well-defined grading system that accurately defines the severity of NAFLD is a 
prerequisite for diagnosis and treatment of NASH, but also for preclinical research and 
development of novel pharmaceutical treatments. This study systematically compared 
human NAFLD liver pathology with the experimental liver pathology of several NAFLD 
mouse models (with emphasis on diet-inducible NAFLD models with obese phenotype). 
We found that specific features of human NASH, like (macro- or microvesicular) steatosis, 
lobular and portal inflammation, microgranulomas, large lipogranulomas and fibrosis were 
present in the rodent models as well, but other features were absent (apoptosis, 
pigmented macrophages, megamitochondria, Mallory-Denk bodies and nuclear 
glycogenation) in the mouse NAFLD models or only occasionally retrieved (ballooning). In 
general, the NASH pathology of the mouse models was slightly less severe than the 
human NASH pathology, and many models mainly display early disease stages which make 
them particularly suitable for the development of novel treatments that target the early 
processes of NASH or try to prevent fibrosis. 
    Our proposed scoring system (Table 4) is based on the features pertaining to mouse 
NAFLD and differs from the NAS scoring method for humans in that we omitted the 
assessment of ballooning and added the measurement of hepatocellular hypertrophy. 
Clinically, hepatic ballooning is a structural manifestation of microtubular disruption and 
hepatocyte injury [15]. Hepatic ballooning can be histopathologically identified as cells, 
which have rounded contours, a central and (small) pyknotic nucleus and two to three 
times the size of adjacent normal hepatocytes and that are characterized by a clear or 
wispy cytoplasm on H&E stained sections [15-17]. The underlying source of the swelling 
cannot be determined on H&E staining and therefore consensus on the underlying 
mechanism has remained elusive. The grading of ballooning into different scores has been 
difficult to perform and the definition has remained largely descriptive for the less 
advanced ballooning cells (grade 1) [18, 19]. As a consequence, ballooning is subject to 
significant inter-observer variation: there is often disagreement even among experts 
about the presence or absence of cellular ballooning in NASH [5, 6]. Although enlarged 
hepatocytes were retrieved in all mouse NAFLD models, distinct ballooning was 
occasionally found in the models studied and under the conditions employed. The 
enlargement of the cells was primarily due to lipid accumulation, as confirmed via Oil-red-
O staining (data not shown). Since ballooning can be detected by the loss of K8/18 in the 
cytoplasm, we performed a CK-18 staining. In some hypertrophic cells a reduction, but not 
complete loss, in CK-18 staining in the cytoplasm could be observed (Supplemental Figure 
2). We cannot rule out that either in other animal models or in the models at a more 
advanced stage of NASH, ballooning can occur more prominently. In order to define 
quantitatively measures we decided to omit ballooning from the proposed non-human, 
rodent NAFLD scoring system and to add hepatocellular hypertrophy. Importantly, 
hepatocellular hypertrophy is not a substitute of ballooning because, in contrast to 
ballooning, hypertrophy is not a sign of cellular injury, and merely refers to an abnormal 
enlargement of the cells without acknowledging the source of this enlargement.  
    In order to enhance the reproducibility of the scoring system, between different 




system simple and did not take into account the zonal distribution pattern of the vesicular 
steatosis, hypertrophy and fibrosis nor with regards to inflammation, i.e. the type of 
inflammatory cells. Nevertheless, we do acknowledge the importance of this additional 
information and although not quantitatively embedded in our scoring system, we did 
evaluate the zonal patterns of the scored features and types of inflammatory cells in our 




 mice that the 
pericentral zone was most prominently affected thereby resembling the pathology in 
humans, whereas for C57BL6 on MCD diet predominantly macrovesicular steatosis around 
the periportal zone was observed. Furthermore, in all models with hepatic inflammation 
we found a mixture of inflammatory cells consisting of monocytes, Kupffer cells and 
polymorphic nuclear cells. Based on time course analyses in the models studied herein, 
MPO-positive immune cells (neutrophils) are typically found in the inflammatory cell 
aggregates, which resembles the situation in humans [20], and indicates that tissue 
damage has occurred. 
    The NASH CRN scoring system is not including fibrosis in the activity score, but is using a 
separate grading system for fibrosis, based on perisinusoidal, periportal and bridging 
fibrosis or cirrhosis. Although fibrosis is not a requirement for the diagnosis of NASH, 
fibrosis is often present in NASH patients. Until recently, NASH was the only pattern within 
NAFLD that was recognized to be associated with the development of advanced fibrosis 
[21]. Fibrosis however can be unequally distributed throughout the liver and therefore 
sampling variability plays an important role in the diagnosis of clinical samples [22]. As 
expected, small biopsies (<1.6 cm) present higher variability for NAFLD fibrosis stage than 
larger biopsies [23]. Fortunately with (rodent) animal studies the whole liver can be 
analyzed, facilitating a proper pathological classification.  
    In our analysis, the rodent scoring system appears to be reproducible since concordance 
in the inter-observer and intra-observer scoring of macrovesicular steatosis and 
microvesicular steatosis were both high and moderate for hepatocellular hypertrophy, 
with better intra-observer scores than inter-observer scores for all features. In rodents the 
best measure of steatosis is biochemical quantification of hepatic triglycerides. True 
validation of the scoring system of steatosis would therefore be a correlation with 
biochemical triglyceride analysis. In several experiments, using different mouse strain and 
diet combinations, we correlated the scores of macrovesicular steatosis, microvesicular 
steatosis and hypertrophy with the biochemically measured hepatic triglycerides. In all 
experiments, we found a correlation, although interestingly in some mouse strain-diet 
combinations the correlation was better with microvesicular steatosis and in other mouse 
strain-diet combinations the correlation was better with macrovesicular steatosis. As an 
example the correlation of the samples used in the validation set (consisting of different 
mouse strains and different diets) for biochemical triglyceride measurement and 
microvesicular steatotis is shown in Supplemental Figure 3). The inter-observer scoring of 
inflammation had the lowest concordance, while remarkably for the intra-observer 
scoring of inflammation the highest concordance was observed, suggesting that the 
scoring of this feature is the most subjective. These results corroborate the findings of 
several previous reproducibility studies that consistently report less agreement for scoring 
of inflammation [24-28]. The studies that also evaluated the inter-observer agreement all 




    One limitation of our study is that we based the rodent scoring system on the 
evaluation of five mouse strains and their comparison with the human features of 
steatosis and steatohepatitis. It remains to be seen whether the proposed rodent scoring 
system is applicable to other rodent models and whether the models used herein are 
representative for other models. However, since the basic features of NASH, namely 
steatosis and inflammation are displayed correctly in our scoring system, we expect the 
scoring system will be applicable for other animal models as well. 
    In conclusion, we established a simple, robust and generic NAFLD scoring system for 
rodents that is reliable and reproducible among observers. This study demonstrates its 
use in preclinical research using several rodent models which display different stages of 
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Score/code Healthy (n=9) NAFLD 
(n=11) 
NASH (n=10) 
Microgranulomas 0 9 11 10 
 1 0 0 0 
Large lipogranulomas 0 9 11 8 
 1 0 0 2 
Portal inflammation 0 9 11 9 
 1 0 0 1 
Acidophil bodies 0 9 11 10 
 1 0 0 0 
Pigmented macrophages 0 9 11 7 
 1 0 0 3 
Megamitochondria 0 9 11 8 
 1 0 0 2 
Mallory-Denk bodies 0 9 11 10 
 1 0 0 0 
Glycogenated nuclei 0 9 8 6 
 1 0 3 4 
Number of subjects per score/code are shown for the indicated histological features. 
 
 
Supplemental Table 2: Inter-pathologist reproducibility of NASH histological features according to the mouse 
NAFLD/NASH scoring system. 
Histological feature ICC CI P 
Macrovesicular steatosis 0.814 0.667–0.900 <0.001 
Microvesicular steatosis 0.919 0.848–0.957 <0.001 
Hypertrophy 0.784 0.619–0.883 <0.001 
Inflammation 0.471 0.145–0.704 0.003 
 
ICC: intraclass correlation coefficient (two-way random effects model, with absolute agreement); CI: 95% 





Steatosis (0-9):    Inflammation (0-3):   Diagnosis: 
Macrovesicular steatosis (0, 1, 2, 3)  (0, 1, 2, 3)     
Microvesicular steatosis (0, 1, 2, 3)      
Hypertrophy (0, 1, 2, 3)  
 
0     0, 1, 2, 3                                               No NAFLD 
 
1-9     0                                                  NAFLD 
 
     1, 2, 3                             NASH 
 








Supplemental Figure 2: CK-18 staining. Loss of CK18 staining in the cytoplasm could be observed in a few 
hypertrophic cells (arrow). 
Supplemental Figure 3: Correlation analysis. Correlation of the samples used in the validation set for 
biochemical triglyceride measurement and microvesicular steatotis.
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Background & aims: The nature of the chronic inflammatory component that drives the 
development of non-alcoholic hepatosteatitis (NASH) is unclear and potential 
inflammatory triggers have not been compared to date. We tested the influence/effect of 
non-metabolic triggers (LPS, IL-1β, administered by slow-release minipumps) and 
metabolic dietary triggers (carbohydrate, cholesterol) of inflammation on the progression 
of bland liver steatosis (BS) to NASH.  
Methods: ApoE3L.CETP mice fed a high-fat diet (HFD) developed BS after 10 weeks. Then, 
inflammatory triggers were superimposed or not (control) for 6 more weeks. Mouse livers 
were analyzed with particular emphasis on hallmarks of inflammation in human NASH. 
These hallmarks were defined in human liver biopsies with and without NASH.  
Results: Livers of HFD-treated control mice remained steatotic and did not progress to 
NASH. All 4 inflammatory triggers applied activated hepatic NFκB significantly and 
comparably (≥5-fold). However, HFD+LPS or HFD+IL1β did not induce a NASH-like 
phenotype and caused intrahepatic accumulation of almost exclusively mononuclear cells. 
By contrast, mice treated with metabolic triggers developed NASH, characterized by 
enhanced steatosis, hepatocellular hypertrophy and formation of mixed-type 
inflammatory foci containing MPO-positive granulocytes (neutrophils) as well as 
mononuclear cells, essentially as observed in human NASH. Specific for the metabolic 
inducers was an activation of the pro-inflammatory transcription factor AP-1, neutrophil 
infiltration, and induction of risk factors associated with human NASH, i.e. dyslipidemia 
(by cholesterol) and insulin resistance (by carbohydrate).  
Conclusion: HFD feeding followed by NFκB activation per se (LPS, IL-1β) does not promote 
the transition from BS to NASH. HFD feeding followed by metabolically-evoked 
inflammation induces additional inflammatory components (neutrophils, AP-1 pathway) 






Nonalcoholic fatty liver disease (NAFLD) is emerging as one of the most common liver 
disorders in modern societies (1). Its prevalence in the general population is strongly 
increasing together with obesity, dyslipidemia and the metabolic syndrome (2). NAFLD 
encompasses a range of conditions associated with accumulation of fat within liver cells. 
The most benign form of NAFLD is bland steatosis (BS), which is characterized by the 
accumulation of lipid droplets. BS can remain stable for many years and will never 
progress in many cases (1). In other cases BS does progress, leading to development of 
non-alcoholic steatohepatitis (NASH), which is characterized by fat accumulation and 
inflammation. This condition is not benign and can further progress to liver fibrosis and 
cirrhosis with high rates of morbidity and mortality (3, 4). The factors that trigger this 
transition from BS to NASH are unknown.  
    The pathogenesis of NASH is thought to be driven by a lipid component and an 
inflammatory component (2, 5). Excessive intrahepatic fat accumulation may sensitize the 
liver to subsequent inflammatory insults that promote the development of NASH. The 
exact nature of these inflammatory insults or ‘second hits’, viz. the mechanism inducing 
the inflammatory component of the disease, is largely unclear (6). The pro-inflammatory 
transcription factor NFκB may critically influence this process and chronic activation of 
NFκB is associated with many pathogenic liver conditions (7). A causal role for hepatic 
NFκB in the progression of BS to NASH has been proposed recently in transgenic mice 
selectively expressing constitutively active IKKβ in hepatocytes (8). Among the 
inflammatory triggers that may be responsible for chronic activation of NFκB in liver cells 
are circulating endotoxins (LPS) or pro-inflammatory cytokines such as interleukin-1beta 
(IL-1β) (9, 10). However, low-grade hepatic inflammation may also be evoked by other 
types of stimuli such as unhealthy diets or excess eating, which represent metabolic 
triggers of inflammation that may activate multiple pathways simultaneously (11, 12). For 
instance, diets with a high content of metabolizable energy from carbohydrate or diets 
rich in cholesterol can cause chronic activation of NFκB in the liver (6, 12-15). 
    In this study we tested the influence of different inflammatory triggers with NFκB-
activating properties on the transition of BS to NASH and analyzed whether disease 
progression depends on the type of trigger employed. More specifically, we compared the 
effects of non-dietary inflammatory stimuli (LPS, IL-1β) and diet-related metabolic 
inflammatory stimuli (carbohydrate, cholesterol) all of which were superimposed on a 
high-fat diet (HFD) in separate groups of mice. Transgenic ApoE3*Leiden.huCETP 
(E3L.CETP) mice were used because their lipoprotein metabolism is translational to the 
human situation and these animals are prone to develop obesity, dyslipidemia and NAFLD 
on HFD (16, 17). Chronic exposure to low concentrations of LPS and IL-1β was achieved by 
minipump technology, and metabolically evoked inflammation was induced by feeding 
diets rich in carbohydrates or cholesterol. Prior to analysis of experimental NASH, human 
liver biopsies with and without NASH were analyzed to define hallmarks of inflammation 
of human NASH. Combined histological and biochemical analysis of mouse livers resulted 
in identification of cellular and molecular determinants that are crucial for the transition 





MATERIALS AND METHODS  
Human liver biopsies 
Human liver biopsies were obtained at autopsy for postmortem histological analysis by 
pathologists (Department of Pathology; Leiden University Medical Center/LUMC, Leiden, 
The Netherlands). N=21 specimens with NASH and n=12 control subjects without NASH 
were used for this study (diagnosed by pathologist). Tissue was obtained and handled in 
accordance with the guidelines set by the LUMC medical ethical committee. 
Cardiovascular disease was the predominant cause of death. In all, 40% of the subjects 
were female and 60% male. The average age was 62 years. Cross-sections were stained 
with anti-MPO (A0398, Dako, Glostrup, Denmark) and phospho-p65-NFκB (#3037, Cell 
Signaling, Danvers MA, USA) as described (18). 
 
Animals and diets 
Male ApoE*3-Leiden.huCETP transgenic mice (E3L.CETP) were 10-14 weeks old and 
obtained from an in-house breeding colony (TNO Metabolic Health Research) (18). Briefly, 
ApoE*3-Leiden were crossed with hemizygous human CETP transgenic mice and offspring 
was genotyped using the primers CETP-F sequence: GAATGTCTCAGAGGACCTCCC, CETP-R 
sequence: CTTGAACTCGTCTCCCATCAG; ApoC1-L sequence: GGTCCCGGGCACTTCCC 
TTAGCCCCA; ApoC1-R sequence: TTTGAGCTCGGCTCTTGAGACAGGAA. Furthermore, 
presence of human ApoE3 protein and human CETP protein in plasma was confirmed by 
ELISA.  
    Experiments were approved by an ethical committee on ‘Animal care and 
Experimentation’, Zeist, The Netherlands. Mice were kept on chow diet (Ssniff R/M-H, 
Ssniff Spezialdiäten, Soest, Germany) until the start of the experiment. Animals had free 
access to water and diet during the study period of 16 weeks. The group size was n=9-10. 
One group remained on chow and served as aging control. The other animals received a 
high-fat diet (HFD; 24% w/w lard, Research Diets, New Brunswick NJ, USA) for 10 weeks 
(run-in) and were then matched into groups based on total plasma cholesterol, 
triglycerides and body weight. HFD feeding was continued in all groups. Groups were 
additionally treated with one of the following treatments until week 16: LPS from 
Salmonella minnesota R595 (Lot#30446A1, List-Biological Laboratories, Campbell CA, USA) 
by minipump at 5 µg/day; recombinant murine IL-1β (Lot#030447, PeproTech, Rocky-Hill 
NJ, USA) by minipump at 100 ng/day; dietary carbohydrate (Ensure® Plus in drinking water, 
Abbott Laboratories, Hoofddorp, The Netherlands); dietary cholesterol (1% w/w mixed 
into HFD) (Sigma-Aldrich, Zwijndrecht, The Netherlands). Osmotic minipumps (Alzet, 
Lot#10194-08, Maastricht, The Netherlands) were placed subcutaneously in the back 
region (flow-rate: 0.10 µL/hour, 101 µL total volume) under isoflurane anesthesia. Two 
controls groups were included; they were treated with either HFD+PBS (minipump) or HFD 
only. These groups were comparable in all histological scores and were therefore analyzed 
as one.   
 
Histological and biochemical analysis 
The right median liver lobe (lobus dexter medialis hepatis) was carefully isolated, fixed in 4% 




liver lobes were snap-frozen and stored at -80°C. Hematoxylin-eosin (HE)-stained cross-
sections were scored blindly by a pathologist using an adapted grading method for human 
NASH (19) with specific emphasis on hallmarks of steatosis and inflammation. Briefly, two 
cross-sections were examined per mouse and the level of vacuolization was determined 
relative to the total liver area analyzed, i.e. expressed as a percentage. The extent of 
vacuolization was scored as ‘Slight’ (<5%), ‘Moderate’ (5-33%), ‘Severe’ (34-66%) and 
‘Very Severe’ (>66%). Of note, hepatocellular ballooning (central nucleus, web-like 
structure in cytoplasm) is a hallmark of human NASH but mouse livers merely show 
enlarged hepatocytes containing small intracellular lipid droplets, herein referred to as 
‘hepatocellular hypertrophy’. The extent of enlarged hepatocytes (diameter >1.5 normal) 
was analyzed using the same percentage categories as for vacuolization to provide 
quantitative information about abnormally enlarged cells. Inflammation was scored by 
counting and analyzing the type of inflammatory cells (mononuclear and/or polymorph 
nuclear) in a defined area of five random microscopic fields per animal. Inflammation was 
graded as ‘Normal’ (<0.5 foci), ‘Slight’ (0.5-1.0 foci), ‘Moderate’ (1.0-2.0 foci), ‘Severe’ 
(>2.0 foci). Collagen was stained using Picro-Sirius red staining (Sigma-Aldrich).  
 
Liver lipids  
The intrahepatic concentration of free cholesterol, triglycerides and cholesteryl esters was 
analyzed as described (20). Briefly, 200 µg of frozen liver biopsies were homogenized in 
MilliQ H2O and the protein content was determined. Two µg of cholesterol acetate was 
added to each sample as an internal standard. Lipids were extracted using methanol and 
chloroform. Extracted lipids were then separated by thin layer chromatography using a 
silica-gel-60 pre-coated plate. Plates were incubated at 130°C for 30 min and band 
densities were then quantified (20). In addition, cryostat-sections were stained with Oil-
Red O (Sigma-Aldrich) to identify lipids, and counterstained with hematoxylin (Sigma-
Aldrich) to visualize nuclei.  
 
Immunohistochemical staining  
Paraffin-embedded liver cross-sections were used for analysis of MPO-positive cells 
(neutrophils) using anti-MPO (ab9535-Abcam, Cambridge, UK). After pre-treatment with 
target retrieval solution (3-in-1; Dako) at pH 9.0, cross-sections were incubated with 
primary anti-MPO overnight. Sections were peroxidase blocked in 3% H2O2 in methanol 
for 10 minutes and detected with Dako Envision-Flex amplification kit (Product#K800021). 
For analysis of CD11b, frozen liver samples were used. After fixation with acetone, cross-
sections were incubated with anti-CD11b (Lot#ab8878, Abcam) for one hour followed by 
incubation with biotinylated rabbit anti-rat antibody (Lot#00065538, Dako). 
Immunoreactivity was visualized with streptavidin/HRP (Lot#00057815, Dako) and AEC 
(Lot#10043262, Dako). For all IHC analyses, negative controls were performed by omitting 
the primary antibody.  
 
Analysis of transcription factor activity in liver homogenates  
To determine the amount of activated p65-NFκB, AP-1, STAT3 and C/EBP-β protein in 
livers, protein extracts were prepared using a Nuclear Extract Kit (Cat.#40010, ActiveMotif, 




reagent (Cat#500-0006, Bio-Rad Laboratories-GmbH, Munich, Germany). Six µg of protein 
was used for transcription factor activity analysis using TransAM® kits for NFκB-p65 Chemi, 
c-Jun, STAT3 and C/EBP-β kits (Cat.#40097, 46096, 45196, 44196, ActiveMotif) as reported 
(11, 20). Briefly, the amount of active transcription factor was determined by measuring 
its binding capacity to a consensus binding sequence in presence of a competitor 
oligonucleotide or a mutant (non-competitor) oligonucleotide to control for the specificity 
of DNA binding. Data are provided as relative units.  
 
Plasma parameters, lipoproteins and plasma inflammatory markers 
EDTA (Sarstedt, Numbrecht, Germany) plasma was collected after a 5-hour fast (8 am to 1 
pm). Plasma levels of glucose (Instruchemie, Delfzijl, The Netherlands), insulin (Mercodia, 
Uppsala, Sweden), total cholesterol and triglycerides (Roche Diagnostics, Almere, The 
Netherlands) were measured with commercial kits. HOMA index was calculated according 
to the formula HOMA = fasting plasma glucose (mM) x fasting plasma insulin (ng/mL)/22.5. 
Lipoprotein profile analysis was performed with AKTA-FPLC (18). The plasma levels of E-
selectin and SAA were determined by ELISA (R&D-Systems, Abington, UK for E-selectin, 
Life Technologies, Bleiswijk, the Netherlands for SAA). Plasma ALAT activity was measured 
using a Reflotron® kit (Roche Diagnostics).   
 
Statistics Analysis 
Statistical analyses were performed with StatView software (SAS-Institute, Cary, NL), and a 
P-value <0.05 was considered statistically significant. Differences between groups were 
analyzed using Mann-Whitney non-parametric test for two independent samples. The 
data obtained from histological scoring of livers were analyzed using 2-sided Fisher's exact 




Characterization of the inflammatory component in human NASH 
HE-stained human tissue biopsies were analyzed for steatosis and inflammation. Livers of 
patients with NASH showed pronounced vacuolization compared with controls (Figure 
1A/B). Quantitative analysis revealed that about 40% of the surface area was steatotic 
(P<0.001 versus control; Supplementary Material-A) of which 35% was macrovesicular 
steatosis and 5% microvesicular steatosis. Hepatocellular ballooning was observed in 
NASH livers but not in controls (Figure 1A/B). Also, enlarged hepatocytes containing small 
lipid droplets were observed in NASH specimens only (Supplementary Material-B). NASH 
livers were characterized by lobular inflammation, i.e. an abundant presence of 
mononuclear cells and polymorph-nuclear leukocytes (granulocytes) which formed foci 
(Figure 1A/B). Inflammatory cell foci contained CD68-positive cells of the 
monocytes/macrophage lineage (not shown) as well as granulocytes with MPO-positive 
immunoreactivity (neutrophils), a hallmark of human NASH (Figure 1C/D). NASH livers 
also showed a pronounced expression of p65-NFκB (in inflammatory foci and steatotic 




(Figure 1E/F). Fibrosis was present in most (73%) human NASH specimens, and in none of 





































Figure 1: Analysis of inflammation in human NASH. Representative photographs of control livers (n=12, panels 
left) were compared to NASH specimens (n=21, panels right). (A/B) HE staining showed pronounced 
vacuolization in NASH livers which was associated with inflammatory cell aggregates (solid arrow) and 
hepatocellular ballooning (magnified in insert). (C/D) Immunostaining showed inflammatory cell foci (arrows) 
containing myeloperoxidase (MPO)-positive cells in NASH. (E/F) Immunostaining of p65-NFκB-positive cell 
clusters (arrows) in NASH (magnified in insert). (G/H) Picro Sirius red staining demonstrated NASH with fibrosis in 










Effects of HFD feeding and addition of inflammatory triggers on the 
development of experimental NASH  
To gain insight into the nature of the inflammatory trigger that may underlie the 
development of BS into NASH, we evaluated the effects of different inflammatory stimuli 
superimposed on HFD feeding. Treatment with inflammatory stimuli was started after a 
10-week run-in period on HFD, which resulted in BS and moderate pericentral 
hepatocellular vacuolization (Supplementary Material-C). Lobular inflammation was not 
observed after 10 weeks of HFD run-in.  
    HFD feeding was continued for six more weeks and experimental groups additionally 
received either PBS (minipump control), LPS (minipump), IL-1β (minipump), dietary 
carbohydrate (Ensure®) or dietary cholesterol. A second control group was continued on 
HFD only. A separate group was fed chow during the complete experimental period (16 
weeks) and served as a reference. All interventions were well-tolerated and the 
superimposed inflammatory triggers did not affect the daily food intake relative to HFD 
control, i.e. calorie intake was comparable between the groups (on average 12 kcal/day 
per animal) except for the HFD+carbohydrate group (16 kcal/day per animal). At sacrifice, 
livers were immediately prepared for histological examination and biochemical analysis of 
active p65-NFκB. Representative photomicrographs of livers are shown in Figure 2A-F. 
Reference mice on chow had normal livers without steatosis or inflammation (Figure 2A). 
The two control groups, i.e. HFD feeding alone and HFD+PBS-minipump treatment, were 
comparable and showed moderate steatosis with vacuolization of the pericentral zone 
and the midzone as well as hepatocellular hypertrophy (individual data provided in 
Supplementary Material-D). Livers of these groups hardly contained inflammatory foci, 
demonstrating that HFD feeding per se is not sufficient to induce a NASH-like phenotype 
within a period of 16 weeks (Figure 2B).  
    Consistent with the low abundance of cellular inflammation in HFD-treated mice, the 
level of transcriptionally active p65-NFκB protein measured by TransAM® was very low 
(1.1×10
5 
relative units, RLU) (Figure 3A). Treatment with the inflammatory triggers LPS, IL-
1β, carbohydrate and cholesterol resulted in significantly higher levels of activated p65-
NFκB protein in mouse livers. The p65-NFκB activating effects of the different 
inflammatory stimuli were statistically comparable. This demonstrates that p65-NFκB was 
activated at least 5-fold or more in liver at the end of the study relative to HFD alone.  
    Histological analysis of experimental NASH allowed quantification of the effects of the 
different inflammatory triggers on vacuolization, hypertrophy and inflammation 
compared with HFD alone (Figure 3A-C; individual histological scores see Supplementary 
Material-D/E). Chronic exposure to LPS did not further aggravate vacuolization and 
hypertrophy relative to HFD control (Figures 2C and 3B/C). The inflammatory cell content 
of LPS-treated animals was higher than in controls treated with HFD only. Inflammatory 
cells were mainly mononuclear and diffusely distributed, and polymorph nuclear cells 



































Figure 2: Histological presentation of experimental NASH. Representative photomicrographs are shown at 200-
fold magnification. Mice were treated with (A) chow (reference group), (B) HFD (control group) and HFD plus 
additional inflammatory stimuli (C) LPS, (D) IL-1β, (E) dietary carbohydrate and (F) dietary cholesterol. 
Inflammatory infiltrates are indicated with arrows. 
 
 
vacuolization than HFD control mice (Figure 2D and 3B). Hepatocellular hypertrophy was 
not observed with IL-1β. Similar to LPS, the inflammatory cell content was higher than in 
HFD controls, but again inflammatory cells were predominately of the mononuclear type 
and diffusely distributed across the liver. Inflammatory cell foci were frequently found in 
close proximity to vascular structures. 
    In contrast to LPS and IL-1β, the metabolic stimuli (carbohydrate and cholesterol) clearly 
promoted the development of a NASH-like phenotype and resulted in pronounced 







pronounced micro-vacuolization and enlarged hepatocytes containing small lipid droplets, 







































Figure 3: Quantitative analysis of experimental NASH. Quantification of (A) activated p65-NFkB measured by 
TransAM® in liver homogenates, (B) vacuolization and (C) hepatocellular hypertrophy as percentage of the total 
liver area analyzed (%). (D) Number of inflammatory foci per microscopic field. (E) Quantitative analysis of the 









Supplementary Material-D). Quantification of hepatocellular vacuolization and 
hypertrophy revealed that carbohydrate feeding increased these parameters significantly 
and about 4-fold (P<0.05) relative to HFD (Figure 3B/C). Mixed-type inflammatory cells (i.e. 
mononuclear and polymorph nuclear cells) were present and inflammatory cell foci were 
observed.  
    Cholesterol-treated livers resembled carbohydrate-treated livers and also showed 
extensive micro and macro-vacuolization with large vacuoles in pericentral and periportal 
zones. Livers had a significantly increased content of inflammatory cell foci (Figure 2F). 
The effects of cholesterol on vacuolization, hypertrophy and inflammation were all 
significant (Figure 3B-D) and statistically comparable to the effect of the other metabolic 
trigger, carbohydrate.  
    Biochemical analysis of the intrahepatic triglyceride concentrations (Figure 3E) and 
parallel Oil Red O staining (not shown) were in line with the histological analyses and 
confirmed that only the metabolic triggers, carbohydrate and cholesterol, promoted a 
transition of BS to NASH. Most of the mice did not develop fibrosis within the study period: 
only one mouse (cholesterol treated group) did develop NASH with fibrosis (Sirius red 
collagen staining, not shown). 
 
Effect of non-metabolic and metabolic inflammatory triggers on 
inflammatory cells and inflammatory pathways  
Experimental livers were further analyzed histologically and biochemically to identify 
determinants that distinguish the metabolic triggers from LPS and IL-1β. A more refined 
histological analysis of inflammatory cells present in liver revealed that LPS and IL-1β 
treatment led to an almost exclusive recruitment of mononuclear cells; whereas 
carbohydrate and cholesterol treated livers contained mixed-type inflammatory cells 
including polymorph nuclear cells (Figure 4G). Consistent with this observation, more 
MPO-positive cells (neutrophils) were observed in the groups exposed to carbohydrate or 
cholesterol but not in those treated with LPS or IL-1β (Figure 4A-F). Immunohistochemical 
analysis of the monocyte/macrophage marker CD68 revealed no difference among the 
experimental groups, except a slight increase in the IL-1β-treated (1.5-fold) and 
cholesterol-treated (2-fold) groups (not shown). Furthermore, the number of 
Mac1/CD11b-positive cells did not differ between the groups (not shown). Together, this 
shows that an abundant presence of neutrophils, a hallmark of human NASH, 
discriminates the two metabolic inflammatory triggers from the two non-dietary triggers 
(LPS and IL-1β).  
    To gain more insight into the molecular effects of the different triggers we analyzed 
transcription factor activity downstream of specific inflammatory pathways by TransAM® 
technology. Independent of the type of inflammatory trigger, the activity of C/EBP-β 
tended to be lower than in HFD controls (Supplementary Material-F). The transcriptional 
activity of STAT3 was slightly increased in the LPS- and IL-1β-treated groups but the effects 
did not reach statistical significance (Supplementary Material-G). Treatment with 
carbohydrate and cholesterol significantly increased the transcriptional activity of AP-1, an 
effect that differentiated the metabolic triggers from LPS and IL-1β (Figure 4H). With 




IL-1β and plasma SAA levels were increased by IL-1β, carbohydrate and cholesterol 
































































Figure 4: Characterization of inflammation in experimental NASH. Immunohistochemical staining of MPO in (A) 
chow reference, (B) HFD control and HFD plus (C) LPS, (D) IL-1β, (E) carbohydrate or (F) cholesterol. Inflammatory 
cell foci (arrows) containing MPO-positive cells. (G) Relative contribution of mononuclear cell foci and mixed-
type inflammatory cell foci to the overall content of inflammatory cells for each group (H) Transcriptional activity 




Table 1:  Experimental treatments have a differential effect on risk factors of NASH. Parameters shown were 
determined in fasting plasma at the end of the experimental period (week 16). Intrahepatic lipids were 
determined in freshly prepared tissue homogenates. Values are means ± SEM. Significance is indicated *P<0.05, 




Effect of non-metabolic and metabolic inflammatory triggers on risk 
factors associated with NASH  
Table 1 shows data of risk factors that are typically associated with NASH development in 
humans, e.g. body weight, visceral fat mass, plasma lipids, fasting glucose and insulin, and 
ALAT. These risk factors were not affected by LPS. IL-1β treatment also did not affect 
these parameters, except a slight increase in triglycerides and a decrease in glucose. In 
contrast, the metabolic triggers worsened risk factors that are typically associated with 




Body weight [g] 39.9±0.9 39.9±1.5 37.3±2.0 47.6±1.2*** 42.1±2.0 
Visceral fat [g] 0.7±0.1 0.7±0.1 0.7± 0.1 1.1±0.1** 0.7±0.1 
Cholesterol [mM] 4.7±0.3 4.2±0.3 4.8±0.4 6.5±0.6* 16.2±2.0*** 
Triglycerides [mM] 1.4±0.3 1.6±0.2 2.1±0.3* 4.3±0.6*** 3.4±0.7** 
Fasting glucose [mM] 13.5±0.9 13.3±0.6 10.9±0.9* 17.2±0.8** 14.4±0.7 
Insulin [ng/mL] 1.15±0.3 1.37±0.3 2.41±0.6 4.28±0.9** 1.15±0.3 
Intrahepatic free cholesterol  
[µg/mg protein] 
14.1±0.7 16.6±0.9* 14.5±0.7 17.2±0.9* 20.1±1.6** 
Intrahepatic cholesterol 
ester [µg/mg protein] 
12.8±0.8 14.5±1.5 12.4±1.4 20.4±2.9* 48.0±4.0*** 
ALAT [U/L] 76±16 76±22 59±15 176±66* 151±41 
E-selectin [ng/mol] 30±7 33±1 66±2*** 31±1 31±1 





NASH development in humans. Carbohydrate treatment resulted in an increased body 
weight (47.6 ± 1.2 g; P<0.001) and visceral fat mass (1.1 ± 0.05 g; P<0.01) beyond that of 
HFD controls. Also, plasma cholesterol and triglyceride concentrations were significantly 
higher in carbohydrate-treated animals. Increased fasting plasma glucose (17.2 ± 0.8 mM; 
P<0.01) and insulin (4.28 ± 0.9 ng/mL; P<0.05) levels indicated insulin resistance 
(HOMAcarbohydrate= 3.3 versus HOMAHFD control= 0.9). Treatment with cholesterol had a 
marked adverse effect on plasma cholesterol and triglycerides and little effect on the 
other risk factors. Also, intrahepatic free cholesterol and cholesterylester levels were 
increased. Lipoprotein profile analysis revealed that the observed increase in plasma 
cholesterol was confined to VLDL/LDL-sized particles. All treatment groups showed a 
relative decrease in HDL compared to HFD control animals (Figure 4I). Plasma ALAT levels 





There is ample evidence that development of NASH is driven by chronic inflammation but 
the nature of the inflammatory component is not very clear (1-5, 21), and possible 
inflammatory triggers have not been investigated systematically. The present study 
examined the influence of metabolically evoked inflammation (carbohydrate, cholesterol) 
and non-metabolic inflammatory triggers (LPS, IL-1β) on the development of experimental 
NASH. Herein, we present the first head-to-head comparison of these triggers, revealing 
that they differ in their potency to stimulate progression of steatosis and induction of 
NASH. Only the metabolic triggers aggravated steatosis and led to an infiltration of 
neutrophils as well as activation of AP-1, a hallmark of lipotoxicity (22). Furthermore, they 
induced metabolic risk factors (insulin resistance, dyslipidemia) associated with NASH 
development in humans, which were not observed for the non-metabolic triggers.  
    The HFD control group that remained on HFD during the complete experimental period 
did not show inflammatory cell infiltrates, had low AP-1 and NFκB levels and did not 
progress from steatosis to NASH. Treatment with metabolic or non-metabolic 
inflammatory triggers activated hepatic NFκB significantly and comparably. Despite this 
clear pro-inflammatory effect in liver, LPS and IL-1β-treated mice did not progress to NASH. 
Thus, simultaneous HFD feeding and activation of hepatic NFκB per se in livers with 
established steatosis is not sufficient to induce NASH development, indicating that 
additional inflammatory factors or pathways are involved. Livers of LPS and IL-1β-treated 
groups exhibited cell infiltrates consisting almost exclusively of mononuclear cells, with 
hardly any mixed-type infiltrates, a characteristic feature of biopsy-proven human NASH 
(21). The selective effect of endotoxin on recruitment of mononuclear cells is in line with 
human and rodent studies in which elevated LPS activity in serum was associated with 
macrophage-mediated chronic inflammation and increased levels of monocyte 
chemoattractant protein-1 (23, 24). Thus, chronic LPS and IL-1β exposure may merely 
activate and recruit specific populations of inflammatory cells to liver and the absence of 
neutrophil infiltrates indicates these triggers by themselves do not cause hepatocellular 
damage. Consistent with this notion we observed no increase in ALAT when mice were 




an ‘exogenous’ form of inflammation while the two metabolic triggers employed herein 
affect liver metabolism (20) and ‘endogenous’ inflammatory processes related to it (12, 
14), possibly causing liver damage. Lipotoxicity and/or the relatively high levels of free 
cholesterol observed in these groups may constitute causes of liver damage. 
    Neutrophil infiltration is an important hallmark of biopsy-proven NASH in humans (21) 
that distinguishes subjects with NASH from those without, independent of obesity (25). It 
is not clear whether neutrophils are innocent bystanders or causally involved in the 
pathogenesis, and investigators have only recently begun to characterize the role of 
neutrophils in NAFLD. The molecular mechanisms that allow neutrophils to home to the 
liver are also not well understood (26). We observed a marked infiltration of neutrophils 
with metabolic triggers despite low E-selectin levels. In accordance with our observations, 
adhesion of neutrophils within liver sinusoids is thought to be independent of selectins 
and differs fundamentally from other tissues (26). The activation of AP-1 may explain why 
metabolic inflammatory triggers stimulate neutrophil recruitment: the main 
chemoattractants for neutrophils in mice, keratinocyte cytokine (KC)(CXCL-8/IL-8 in 
humans) and macrophage inflammatory protein-2 (MIP-2), are transcriptionally regulated 
by NFκB and AP-1 (27). Transcription of MIP-2 depends on a simultaneous activation of 
both transcription factors, i.e. a condition that was achieved with two metabolic triggers 
in the present study but was absent in the case of the two non-metabolic triggers. Further 
support for a crucial role of the AP-1 signaling pathway in NASH comes from knock-out 
studies: phosphorylation of the AP-1 subunit c-Jun is diminished in Jnk1-deficient mice 
and these mice show a reduced development of steatohepatitis (28).  
    Of note, the two metabolic triggers induced different factors that are known to be risk 
factors for NASH in humans, i.e. adiposity/insulin resistance (carbohydrate) and 
dyslipidemia (cholesterol). This suggests that the pathogenic processes leading to liver 
damage, neutrophil infiltration and AP-1 activation may differ between these triggers. 
Because plasma levels of HDL were reduced by both metabolic as well as non-metabolic 
triggers, it is unlikely that HDL has a major role in the pathogenic processes mediating the 
transition from steatosis to NASH. Our data also do not indicate a major role for the 
inflammatory pathways leading to activation of STAT3 or C/EBP-β.  
    Treatment with inflammatory stimuli was started once steatosis was already manifest 
(after 10 weeks of HFD feeding) and reportedly still reversible (29), in order to mimic a risk 
population with established steatosis (21, 30). HFD feeding alone causes metabolic stress 
and renders livers susceptible to injury (13, 20) and the superimposed insults represent 
‘second hits’. Importantly, feeding of a HFD alone only resulted in a steatotic liver within 
the study period and did not cause NASH or cellular inflammation. This has also been 
observed in other HFD-feeding studies of comparable lengths of time using diets with 
similar content of fat, i.e. ≤25% w/w. This equals about 45% energy from fat (20) which is 
reached in human diets in Finland and Crete (31). Of note, experimental diets that contain 
very high, supraphysiological quantities of fat (e.g. >50% energy) as well as experimental 
diets deficient in methionine and choline (MCD diets) may develop a more severe and 
different liver pathology. The translational character of such studies is debated because 
MCD-fed mice lose weight due to a vastly lower caloric intake and do not become insulin 




    It is generally assumed that chronic activation of NFκB in the liver is a main driver of the 
transition from BS to NASH. In the present study we compared different NFκB-inducing 
inflammatory triggers (head-to-head and superimposed on HFD) regarding their ability to 
induce this transition to NASH. We observed that activation of NFκB in the liver per se 
(upon stimulation with LPS or IL-1β) does not promote a transition from BS to NASH. By 
contrast, metabolic inducers of inflammation like cholesterol and carbohydrate had a 
greater ability to induce a human NASH-like phenotype. This suggests that chronic 
inflammation caused by metabolic triggers activates additional inflammatory pathways 
and biological processes than LPS or IL-1β. To our knowledge, this is the first study that 
compares metabolic inflammatory triggers (high carbohydrate, cholesterol) to non-
metabolic (classical) inflammatory chronic triggers (LPS, IL-1β) in a head-to-head approach, 
and that defines molecular differences between ‘metabolic’ and ‘non-metabolic’ 
inflammatory triggers. More specifically, we show that metabolic triggers activate AP-1 in 
the liver and lead to neutrophil infiltration, both of which could be causative factors in the 
development of NASH. These mechanistic insights as well as the experimental conditions 
defined herein may help to further elucidate the etiology of NASH and contribute to 
development of therapeutic strategies directed at attenuating metabolic overload and 
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Supplemental Figure A/B: Histological quantification of vacuolization (A) and hepatocellular hypertrophy (B). 
The percentage of A) vacuolization (micro- and macrovacuolization) and B) hypertrophic cells was analyzed in 
human liver sections. Hepatocellular hypertrophy is defined as enlargement of hepatocytes (>1.5 normal 
diameter) and characterized by small lipid droplets in the cytoplasm of the hepatocytes.  
Values are means ± SEM. ***P≤0.001 indicates statistical significance between human control livers and NASH 
livers tested by Mann-Whitney test. *P≤0.05 indicates statistical significance between human control livers and 
NASH livers tested by Wilcoxon matched-pairs signed rank test. Wilcoxon testing was used because hypertrophy 














Supplemental Figure C: Histological presentation of steatosis in ApoE*3L.CETP mice after 10 weeks of HFD 
feeding (end of run-in).  Animals developed simple steatosis during the run-in period on HFD. This condition 



















































Supplemental Figure D: Histological analysis of individual mice and their NASH pathology.  The first column 
specifies the experimental groups and rows represent individual mice. Livers (two cross-sections per animal) 
were analyzed for centrilobular vacuolization (CHV), midzonal vacuolization (MHV), periportal vacuolization 
(PHV), hepatocellular hypertrophy (HHP) and inflammatory cell clusters (foci). Depending on the type of 
inflammatory cells in a cluster, a distinction was made between mononuclear inflammatory cell clusters (MNC) 
and mixed-type (mononuclear and polymorph) nuclear cell clusters (MIC). The color code (from green to red) 
represents the severity of a parameter as indicated in the columns at the right. 


















































Supplemental Figure E: Histological presentation of a mouse liver with NASH (as a reference). The different 
inflammatory cells present in NASH (polymorph nuclear cell; monocyte/macrophage; lymphocyte and Kupfer 
cells) are indicated with arrows as specified above. These hallmarks of inflammation were not found after 10 













Supplemental Figure F/G: Activity of transcription factors C/EBP-β and STAT3 using TransAM® analysis. There 
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Background: The pathogenesis of NASH involves a lipid component (steatosis) and an 
inflammatory component but it is unclear how they are related with each other. The 
present time-course study aims at defining the time points at which microvesicular and 
macrovesicular steatosis emerge during NASH development and how these forms of 
steatosis are linked to critical events of inflammation, that is formation of inflammatory 
cell aggregates, activation of NFκB and AP-1 pathways, and liver fibrosis.  
Method: ApoE3Leiden.CETP transgenic mice were fed a NASH-inducing high-fat diet 
containing 1% (w/w) cholesterol (HFC) for 12 weeks. Groups of mice were sacrificed in 
monthly intervals and compared to groups of control mice. The pathogenesis was 
analyzed by histological and biochemical methods, and microarray pathway analysis. 
Results: Steatosis development started in the pericentral zone and microvesicular 
steatosis preceded macrovesicular steatosis. While microvesicular steatosis reached a 
plateau after 4 weeks, macrovesicular steatosis intensified gradually and continuously 
over time. Microvesicular steatosis significantly correlated with activation of NFκB, which 
represents an early inflammatory event in the pathogenesis, whereas macrovesicular 
steatosis correlated with the number of lobular inflammatory cell aggregates, which 
constitutes a late inflammatory event. The pro-inflammatory regulator AP-1 was activated 
later in time (t=12 weeks) and this activation was accompanied by a strong increase in 
transaminases (ALT, AST) and onset of liver fibrosis.  
Conclusion: Microvesicular steatosis precedes macrovesicular steatosis and is related to 
NFκB activation. The two forms of steatosis differ in their distinct time pattern and 
correlates with specific features of inflammation. A link exists between development of 
macrovesicular steatosis, formation of lobular inflammatory cell aggregates and onset of 






Nonalcoholic fatty liver disease (NAFLD) is associated with visceral obesity and has 
become a global pandemic with an estimated prevalence of more than 25% in many 
countries (1). NAFLD covers a spectrum of liver damage ranging from simple steatosis 
(NAFL) to nonalcoholic steatohepatitis (NASH) and liver fibrosis (2). The disease frequently 
coexists with dyslipidemia and insulin resistance but the exact processes underlying the 
pathogenesis of NAFLD are not well understood.  
    Typically, patients remain asymptomatic during the early stages of the disease and 
NAFLD is often diagnosed at a late stage, when the liver is already severely and irreversibly 
damaged (liver fibrosis, cirrhosis). Hence, little is known about the early, potentially 
reversible, disease processes and their relationship over time. This study concentrates on 
the early events of NAFLD development and the processes which have a role in the 
transition of NAFL to NASH, with particular emphasis on the time sequence of these 
events over time.   
    An important early histological hallmark of NAFL is the accumulation of lipids in liver 
cells, referred to as microvesicular and macrovesicular steatosis. In addition to this lipid 
component, an inflammatory component is evoked which drives the pathogenesis 
towards NASH and liver fibrosis (3, 4). A defining characteristic of this inflammatory 
component in NASH is the formation of immune cell aggregates in liver, i.e. lobular 
inflammatory clusters composed of neutrophils and macrophages (5), as well as the 
stimulation of specific inflammatory pathways that result in activation of NFκB and AP-1, 
two transcriptional master regulators of inflammatory genes contributing to liver fibrosis 
(6). Based on clinical observations and experimental models in animals, it has long been 
thought that steatosis precedes inflammation (reviewed in the reference (7)), but it is still 
unclear how they are linked and whether microvesicular or macrovesicular steatosis (or 
both) are related to the onset of the inflammatory component of the disease. To explore a 
putative interrelationship, the present longitudinal study aimed at defining the time 
points at which microvesicular and macrovesicular steatosis emerge during NAFLD relative 
to the onset of inflammation. In subsequent biochemical and histological analyses we 
examined possible correlations between a specific form of steatosis and the specific 
hallmarks of liver inflammation, i.e. formation of inflammatory cell aggregates, NFκB and 
AP-1 activation, liver fibrosis.  
    To study the relationship between steatosis and inflammation, a diet-inducible model of 
NAFLD was used, ApoE3Leiden.CETP transgenic mice (E3L.CETP) (8). E3L.CETP mice 
express human transgenes the gene products of which are involved in lipid transport 
(APOE*3, APOC1, CETP). The model mimics human lipoprotein metabolism and animals 
develop human-like dyslipidemia when treated with a high fat diet (9). E3L.CETP mice 
were fed an established NASH-inducing HFD containing 1% cholesterol (HFC) (8) for 12 
weeks and compared to littermates fed the same diet without cholesterol (HFD) which 
merely induces a stage of NAFL in this period. Factors that potentially contribute to the 
transition from NAFL to NASH can thus be defined by comparing the effects of HFC and 
HFD. Groups of mice were sacrificed in monthly intervals up to the stage at which NASH 




grading system for human NAFLD (8). Histological analyses and biochemical 
measurements in conjunction with microarray data of this time course enabled us to 
demonstrate that specific links exist between microvesicular and macrovesicular steatosis 
and liver inflammation.  
 
 
MATERIALS AND METHODS  
Animals and diets  
Experiments were approved by an independent Animal Care and Use Committee and were 
in compliance with European Community specifications regarding the use of laboratory 
animals. Human CETP transgenic mice that express cholesteryl ester transfer protein 
(CETP) under control of its natural flanking regions (strain 5203) (10) were obtained from 
Jackson Laboratories (Bar Harbor, MC) and cross-bred with APOE*3Leiden mice to obtain 
heterozygous E3L.CETP mice (9, 11). All animals were housed in a temperature-controlled 
room on a 12 hour light-dark cycle and had free access to food and water. Male E3L.CETP 
mice (16-19 weeks of age) received a low fat diet (LFD; 10 kcal% lard, Research Diets, New 
Brunswick, NJ, USA) for a 4-week run-in period, after which they were matched for body 
weight, plasma cholesterol and triglycerides into two experimental groups and dietary 
treated for 12 weeks. Control animals (HFD, n=40) received a high fat diet (HFD; 45 kcal % 
lard, Research Diets, New Brunswick, NJ, USA) for 12 weeks. To induce NASH, another 
group of mice (HFC, n=30) were fed a HFD supplemented with 1% (w/w) cholesterol 
(Research Diets, USA) for 12 weeks. In addition, a reference group (REF, n=5) remained on 
LFD until the end of the study and served as aging control group. Food intake and body 
weight were monitored throughout the study. Every 4 weeks, EDTA plasma samples were 
collected from the tail vein after 5h of fasting. At the time points t=0, 4, 8 and 12 weeks 
n=10 HFD mice and n=10 HFC mice were sacrificed by CO2 asphyxiation. The medial liver 
lobe was fixed in formalin and embedded in paraffin for histological analysis of NASH and 
the left lobe was snap frozen in liquid nitrogen and stored at -80°C for liver lipid and 
biochemical analyses. The adipose tissue was collected, weighed and also stored at -80°C.  
 
Histological assessment of NASH 
NASH development was assessed in haematoxylin and eosin-stained (Sigma-Aldrich) liver 
sections (3 μM) by analysis of steatosis, inflammation and fibrosis, the key features of 
NASH. Steatosis was determined at a 40 × magnification by analysis of macrovesicular and 
microvesicular steatosis (8), expressed as the percentage of the total liver slice area 
affected. Hepatic inflammation was analyzed by counting the number of inflammatory foci 
per field at a 100 × magnification (view size 3.1 mm
2
) in five different fields per specimen 
in a random way, and was expressed as the average number of foci per field. Hepatic 
collagen content was stained histochemically using Picro-Sirius Red staining (Chroma, 
WALDECK-Gmbh, Münster, Germany). Hepatic fibrosis was identified at 40 x magnification 
and analyzed by scoring whether pathologic collagen staining was absent (grade 0; only in 
vessels) or collagen staining observed within perisinusoidal or periportal area (grade 1), 





Liver lipid analysis 
The intrahepatic concentration of free cholesterol, triglycerides, and cholesteryl esters 
was analysed as described (8). Briefly, lipids were extracted from liver homogenates using 
the Bligh and Dyer method and separated by high performance thin layer chromatography 
(HPTLC) on silica gel plates. Lipid spots were stained with colour reagent (5 g of 
MnCl24H2O, 32 ml of 95–97% H2SO4 added to 960 ml of CH3OH:H2O 1:1 v/v) and 
triglycerides, cholesteryl esters and free cholesterol were quantified using TINA version 
2.09 software (Raytest, Straubenhardt, Germany).  
 
Analysis of transcription factor activity in liver homogenates 
To determine the amount of activated p65-NFκB and AP-1 in livers, protein extracts were 
prepared using a Nuclear Extract Kit (cat. no. 40010; ActiveMotif, Rixensart, Belgium) as 
reported (12). The protein content of the extracts was determined with Bio-Rad dye 
reagent (cat. no. 500-0006; Bio-Rad Laboratories GmbH, Munich, Germany). Six 
micrograms of protein was used for transcription factor activity analysis using TransAM® 
kits for NFκB-p65 Chemi, c-Jun (AP-1) kits (cat. no. 40097 and 46096; ActiveMotif) as 
reported (13). Briefly, the amount of active transcription factor was determined by 
measuring its binding capacity to a consensus binding sequence in the presence of a 
competitor oligonucleotide or a mutant (non-competitor) oligonucleotide to control for 
the specificity of DNA binding. 
 
Analysis of plasma parameters  
EDTA (Sarstedt, Numbrecht, Germany) plasma was collected after a 5h fast (0800–1300 
hours). Plasma levels of total cholesterol, triglycerides (Roche Diagnostics, Almere, The 
Netherlands), and insulin (Mercodia, Uppsala, Sweden) were measured with commercial 
kits. Plasma glucose was determined using the ‘Freestyle glucose measurement system’ 
from Abbott (Heerlen, The Netherlands). Homeostasis model assessment (HOMA) index 
was calculated according to the formula: HOMA=fasting plasma glucose (mM) × fasting 
plasma insulin (ng/ml)/22.5. Plasma alanine transaminase (ALT) (GPT, cat. no. 10745138) 
and aspartate aminotransferase (AST) (GOT, cat. no. 10745120) activities were measured 
using Reflotron® kits (Roche Diagnostics). 
 
Microarray hybridisation and data analysis  
Microarray gene expression analysis was performed essentially as reported in (14, 15). 
Briefly, total RNA was extracted from individual livers using glass beads and RNAzol 
(Campro Scientific, Veenendaal, The Netherlands). After quality control of RNA integrity 
using RNA 6000 Nano Lab-on-a-Chip kit and a bioanalyzer 2100 (Agilent Technologies), 
biotinylated cRNA was prepared with an Illumina® TotalPrep™ RNA Amplification Kit 
(Ambion, art. no. AM-IL1791. Biotinylated cRNA was hybridized onto the MouseRef-8 
Expression BeadChip (Illumina) by a service provider (Service XS, Leiden, the Netherlands). 
Genomestudio v1.1.1 software (Illumina) was used for subsequent gene expression 
analysis as described (15). Differentially expressed probes were identified using the limma 
package of R/Bioconductor. Differentially expressed probes were selected based on the 
cut-off value False discovery rate (FDR) <0.05. Selected differentially expressed probes 




(http://www.ingenuity.com). Upstream regulator analysis was performed as reported (12, 
15) to determine the activation state of transcription factors based on the observed 
differential gene expression. A positive (negative) activation Z-score indicates activation 
(inhibition) of a particular transcription factor. An activation Z-score <-2 or >2 indicates 
significant activation or inhibition of a pathway or process. 
 
Statistics Analysis 
Statistical analyses were performed with Graphpad Prism software (version 5.03, 
Graphpad Software Inc., La Jolla, USA). Changes over time (versus baseline t=0) or 
different between groups of HFD versus HFC at each time point) were statistically 
analysed using Mann-Whitney non-parametric test. Association between two parameters 
were analysed by Spearman's rank correlation coefficient. A P-value <0.05 was considered 




HFC induces adiposity and circulating risk factors of NAFLD 
Table 1 shows the development of body weight and visceral fat over time in groups of 
mice treated with HFD and HFD supplemented with cholesterol (HFC). Body weight 
increased strongly during HFD from 29.8 g at the start to 46.5 g in week 12 and this 
increase was comparable for HFC (47.6 g at end of study). Body weight gain was paralleled 
by a marked  increase in ectopic visceral fat: compared with t=0, the mass of the major 
visceral fat depots (i.e. epidydimal and mesenteric fat together) increased more than 3-
fold, from 0.27 g to 1.02 g in the HFD group, and the HFC group showed a comparable 
increase.  
    Plasma cholesterol levels were 5.5 mM at t=0 and remained stable during HFD feeding 
(5.9 mM at endpoint), but HFC feeding strongly increased plasma cholesterol reaching a 
level of 25.9 mM in week 12 (Table 1). Plasma triglycerides were 3.3 mM at t=0 and 
decreased during HFD feeding to 2.1 mM (in week 12) while HFC-treated animals 
exhibited pronounced hypertriglyceridemia of 6.7 mM at the end of the study.  
    Fasting plasma glucose and fasting plasma insulin increased comparably in HFD and HFC 
treated groups: fasting glucose was 10.7 mM at t=0 and reached 17.0 mM in HFD and 16.0 
mM in HFC after 12 weeks of diet feeding. Fasting insulin increased from 0.7 mM to 5.8 
mM in HFD and to 4.4 mM in HFC. The HOMA increased in HFD and HFC treated groups 
significantly, indicating that both diets induced insulin resistance.  
    Subsequent analysis of liver enzymes showed a significant decrease in AST and ALT 
during HFD treatment, while HFC had an opposite effect and increased AST significantly, 
particularly between week 8 and 12 (Table 1).  Also, ALT significantly increased by HFC in 
week 12, which indicated that long-term HFC diet feeding causes liver damage. 
    Collectively, these data demonstrated that the HFC diet induced experimental 
hypercholesterolemia and hypertriglyceridemia in the context of obesity and insulin 






Table 1:  Body weight, plasma and liver lipids and liver injury marker over time. Parameters shown were 
determined in fasting plasma over time. Intrahepatic lipids were determined in freshly prepared tissue 
homogenates. Values are means±SEM. Significance is indicated *P<0.05, versus t=0 control, 
#
P<0.05 versus HFD 




Time course analysis of microvesicular and macrovesicular steatosis  
HE-stained liver cross-sections were used for histological evaluation and quantification of 
microvesicular and macrovesicular steatosis over time. HFD treatment merely resulted in 
bland steatosis (mild NAFL) while HFC induced pronounced steatosis. Independent of the 
type of diet, steatosis started in the pericentral area, and the diets generally induced more 
microvesicular steatosis than macrovesicular steatosis. Steatosis development was 
accompanied with formation of inflammatory cell aggregates (from 8 weeks onwards) in 
the HFC group specifically (Figure 1 A), which is a defining characteristic of NASH in 
humans. HFC but not HFD induced onset of fibrosis at week 12 as shown by the 
development of perihepatocellular patches of collagen (Sirius Red staining; Figure 1B).   
    Refined and quantitative analysis of steatosis development over time revealed that 
microvesicular and macrovesicular steatosis developed simultaneously in control mice on 
HFD: both forms of steatosis were induced by HFD at week 8 and remained at a stably 
elevated until week 12 (microvesicular steatosis: 21% of the surface area; and 
macrovesicular steatosis: 10%,) (Figure 2A/B). By contrast, HFC rapidly induced 
microvesicular steatosis (already after 4 weeks) which covered about 51% of the surface 
area, i.e. about twice as much than observed with HFD. Notably, HFC-induced 
microvesicular steatosis did not further progress after week 8, while HFC-induced 
macrovesicular steatosis showed a continuous increase until the end of the study. For 
instance, between week 8 and 12, HFC-induced macrovesicular steatosis almost doubled 
(from 14% to 24% of the surface area), while it remained unchanged in the same period 
with HFD treatment (Figure 2B).  
    Collectively, the comparative analysis of steatosis development by HFD and HFC 
revealed two differences which characterize the NASH-inducing diet HFC: 1) 
Microvesicular steatosis developed more rapidly (week 4) and stabilized at a higher (2-
fold) absolute level. 2) Macrovesicular steatosis increased gradually throughout study. The 
 
t=0 
t=4 t=8 t=12 
 HFD HFC HFD HFC HFD HFC 
Body weight [g] 29.8 ± 0.6 38.5 ± 1.1* 37.2 ± 0.7* 43.8 ± 1.4* 43.3 ± 1.1* 46.5 ± 1.7* 47.6 ± 2.0* 
Liver [g] 1.76 ± 0.10 1.51 ± 0.08 1.83 ± 0.09
#
 1.87 ± 0.23 2.41 ± 0.20*
#
 2.06 ± 0.16 3.12 ± 0.20*
#
 
Visceral fat [g] 0.27 ± 0.02 0.51 ± 0.06* 0.50 ± 0.08* 0.85 ± 0.11* 0.79 ± 0.11* 1.02 ± 0.12* 0.82 ± 0.11* 
Cholesterol [mM] 5.52 ± 0.30 4.95 ± 0.18 13.09 ± 0.88*
#
 5.69 ± 0.33 17.88 ± 1.98*
#
 5.86 ± 0.32 25.91 ± 2.03*
#
 
Triglycerides [mM] 3.28 ± 0.20 1.76 ± 0.10 2.89 ± 0.24
#
 1.61 ± 0.16 2.77 ± 0.42 2.11 ± 0.26 6.65 ± 1.09* 
Fasting glucose [mM] 10.74 ± 0.41 13.76 ± 0.53* 13.62 ± 0.48* 14.74 ± 0.53* 15.17 ± 0.51* 16.99 ± 0.50* 15.99 ± 0.71* 
Insulin [ng/mL] 0.72 ± 0.11 2.84 ± 0.39* 1.98 ± 0.30* 4.62 ± 0.66* 2.25 ± 0.42*
#
 5.83 ± 0.75* 4.37 ± 0.75* 
HOMA 0.4 ± 0.1 3.1 ± 0.2* 1.3 ± 0.2*
#
 2.9 ± 0.5* 1.9 ± 0.3* 4.5 ± 0.6* 3.2 ± 0.6* 
ALT [U/L] 122 ± 10 96 ± 8 151 ± 40 94 ± 23 101 ± 22 86 ± 11* 305 ± 54*
#
 






time course also showed that HFC-induced microvesicular steatosis (week 4) preceded the 





























Figure 1: Histological analysis of liver cross-sections over time. Paraffin-embedded livers from the HFC group 
(upper rows) and the HFD group (lower rows) were stained with HE (A) for general histological analysis or with 
Sirius Red (B) for analysis of collagen. For each diet and time point n=10 livers were analyzed. The figure shows 
representative photomicrographs for each time point (t=0, 4 weeks, 8 weeks, 12 weeks). LFD=low fat control diet; 
HFD=high fat diet; HFC=high fat diet containing 1% cholesterol. 
 
 
Time course analysis of intrahepatic liver lipids  
Changes in major liver lipids (triglycerides, TG; cholesterol esters, CE; free cholesterol, FC) 
were analyzed next. TG were the most abundant form of liver lipids with baseline levels of 
83 µg/mg protein, followed by CE (18 µg/mg protein) and FC (17 µg/mg protein). HFD 
feeding resulted in slight increase of liver TG (not significant effect) at week 8 and 12. HFD 
did not affect the concentrations of CE and FC, indicating that the steatosis in HFD group is 
mainly attributable to an accumulation of TG (Figure 2C).  
A: HE 
t=0 
t=4 t=8 t=12 
t=4 t=8 t=12 
B: Sirius Red 
t=4 t=8 t=12 





    By contrast, HFC strongly induced TG, CE and FC with significant effects already after 4 
weeks (for TG and CE) indicating that steatosis induced by HFC is more complex than with 
HFD because it also involves accumulation of CE and FC. The increase in liver CE in 
particular paralleled the time profile of microvesicular steatosis (Figure 2D). FC were 
































Figure 2: Quantitative histological analysis of steatosis and liver lipids. HE-stained liver cross-sections of the 
time course were analyzed histologically to determine the level of microvesicular steatosis (A), macrovesicular 
steatosis (B) during HFC and HFD diet feeding at the time points indicated. Liver lipids were analyzed 
biochemically in homogenates prepared from frozen livers. The concentration of triglycerides (C), 
cholesterylesters (D) and free cholesterol (E) were determined during the time course. LFD=low fat control diet; 
HFD=high fat diet; HFC=high fat diet containing 1% cholesterol. Data represent means ± SEM; *P<0.05 HFC 





































Time course analysis of cellular and molecular inflammation in relation to 
steatosis 
As specifically the HFC diet caused inflammation and NASH, we next evaluated the 
development of cellular and molecular inflammation in the HFC group in order to define a 
possible relationship with specific forms of steatosis.  
    Quantification of inflammatory cell aggregates in liver cross-sections demonstrated that 
HFD treated mice hardly developed lobular cellular inflammatory aggregates throughout 
the study while HFC strongly induced lobular inflammation already after 4 weeks, showing 
a marked further increase between 8 and 12 weeks (Figure 3A). To analyze whether an 
association exists between the level of micro-/macrovesicular steatosis and the hepatic 
content of inflammatory cells, the individual steatosis data were correlated to the 
corresponding inflammatory cell counts. This analysis revealed a significant positive 
correlation between inflammatory cell aggregates induced by HFC and macrovesciular 
steatosis (r=0.4489; p=0.0128) (Figure 3B). The association between steatosis and 
inflammatory cell aggregates was specific for macrovesicular steatosis because there was 
no correlation with microvesicular steatosis (not shown).  






















Figure 3: Quantitative histological analysis of steatosis and liver lipids. Inflammatory cell aggregates (A) were 
counted in HE-stained liver cross-sections. (B)  Spearman's rank correlation analysis of macrovesicular steatosis 
and inflammatory cell aggregates (data from HFC treated animals). (C) Transcriptional activity of p65-NFκB 
determined by TransAM® assay in freshly prepared liver homogenates. (D)  Spearman's rank correlation analysis 
of microvesicular steatosis and p65-NFκB activity (data from all HFD and HFC animals). Data represent means ± 



















To analyze molecular inflammation, the transcriptional activity of NFκB and AP-1, two 
important regulators of inflammatory gene expression, was quantified in freshly prepared 
liver homogenates using TransAM® assay. HFD activated NFκB transiently (only in week 4) 
whereas HFC-stimulated NFκB activation was much stronger and persisted until the end of 
the study (Figure 3C). The time pattern of HFC-induced NFκB activation resembled those 
of microvesicular hepatocellular steatosis suggesting a relationship between 
microvesicular steatosis and NFκB activation. Indeed, the individual microvesicular 
steatosis scores were positively correlated with NFκB activity data of corresponding mice 
(Figure 3D). This correlation was highly significant (P=0.0001) and specific for 
microvesicular steatosis (no correlation existed between macrovesicular steatosis and 
NFκB activity).   
    Subsequent analysis of the transcriptional activity of AP-1 in HFD and HFC treated livers 
showed that AP-1 activity was below the detection limit of the assay until week 8. 
Thereafter, a modest AP-1 activation was observed in some animals of the HFC group at 
week 12 (not shown).  Altogether, these data demonstrate that macrovesicular steatosis is 
positively correlated to cellular inflammation in developing NAFLD and that microvesicular 
steatosis has a positive correlation with NFκB activity. 
 
 
HFC feeding results in AP-1 activation and fibrosis at the end of the study 
For a more refined analysis of liver inflammation microarray gene expression analysis was 
performed in corresponding livers of the time course. Gene enrichment analysis 
confirmed a marked increase in inflammatory processes between week 8 and 12 and the 
number of differentially expressed genes associated to the ‘inflammatory response 
pathway’ increased strongly over time (i.e. 74 genes at t=4 weeks, 160 genes at t=8 weeks 
and 546 at t=12 weeks) (not shown). Consistent with this, AP-1 was significantly activated 
at the last time point (t=12 weeks; Z=3.499; P-value=1.40E-08) (Table 2) and 
transcriptionally active based on the expression changes of 87 target genes (Figure 4A). 
Also between t=8 weeks and t=12 weeks, the process of hepatic fibrosis was significantly 
activated including ‘hepatic stellate cell activation’ and ‘myofibroblast activation’ shown in 
Figure 4B. Among the genes upregulated in these pathways were 16 pro-fibrotic genes 
controlled by AP-1. The gene expression changes were confirmed histologically by grading 
of collagen deposition upon Sirius Red staining) (Figure 1B). There was no difference 
between HFD and HFC until week 8, but at the end of the study, in week 12, HFC 
significantly induced fibrosis (Figure 4C). This induction paralleled the observed marked 
increase in macrovesicular steatosis and the elevation of ALT and AST in the circulation at 
this time point.  The two liver damage markers correlated significantly with the individual 
fibrosis scores, i.e. ALT (r=0.6991; P<0.001) and AST (r=0.6921; P<0.001) further 









Table 2:  Transcription factor activation analysis. Analysis of the activity of upstream regulators based on 
expression of their target genes using microarray gene expression data. A positive Z-score indicates activation of 
a transcription factor by HFC relative to HFD. A Z-score ≥2 indicates significant activation. The gene expression 
levels of some of these transcription factors (Nfκb1, Rel A, c-jun,) was significantly upregulated (FDR<0.05). 
 
Upstream regulator Predicted state Activation Z-score P-value of overlap 
NFκB (complex) activated 5.833 5.49E-12 
NFκB1 activated 3.077 6.50E-05 
RelA activated 3.921 6.97E-04 
    
AP-1 (complex) activated 3.910 2.36E-04 
c-Jun activated 3.499 1.48E-10 
JunB activated 1.883 4.54E-06 
c-Fos activated 1.747 3.77E-11 












Figure 4: Onset of fibrotic gene expression and liver fibrosis after 12 weeks of HFC feeding. (A) Gene set 
enrichment analysis of microarray data showing 87 significantly differentially expressed target genes of c-jun at 
t=12 weeks. Upregulation is indicated in red and downregulation in green. (B) Activation of the process ‘Early 
signaling events in hepatic stellate cells’ showing upregulation of many profibrotic genes (in red). These 
induction was observed at t=12 weeks but not earlier time points. Other profibrotic processes were also 
activated (see supplementary information). (C) Histological grading of liver fibrosis based on Sirius Red-stained 












This longitudinal study analyzed the relationship between development of micro- and 
marcovesicular steatosis and inflammation in the pathogenesis of NAFLD using a diet-
inducible model of disease. We observed that steatosis started in the pericentral zone and 
that microvesicular steatosis and macrovesicular steatosis developed in a different way 
over time: Microvesicular steatosis was induced rapidly (already after 4 weeks) and 
preceded macrovesicular steatosis which developed more slowly. While microvesicular 
steatosis remained at a high elevated level throughout the study, macrovesicular steatosis 
developed gradually and continuously over time. The amount of microvesicular steatosis 
correlated with activation of NFκB, which represents an early inflammatory event in liver 
tissue, whereas macrovesicular steatosis correlated with the number of inflammatory cell 
aggregates in the liver, which constitutes a late inflammatory event of lobular 
inflammation. The activation of the pro-inflammatory regulator AP-1 also occurred at a 
late time point (t=12 weeks) and was accompanied by a marked increase in transaminases 
(ALT, AST) as well as an onset of liver fibrosis. 
    The development of liver steatosis (NAFL) in the control group was comparable to other 
studies in which mice were treated with high fat diets for 12 weeks (12, 16). 
Supplementation of 1% cholesterol to this diet (HFC) resulted in disease progression 
towards a fatty inflamed liver (NASH) with early fibrosis. This was achieved in the presence 
of combined obesity, insulin resistance and dyslipidemia (mainly (VLDL and LDL) which are 
documented risk factors of NASH in humans (1, 17). While obesity and insulin resistance 
were comparable in HFD and HFC groups, total plasma cholesterol was significantly higher 
(> 4-fold) in HFC which provides an indication that this risk factor may have contributed 
predominantly to disease progression towards NASH under the conditions employed. 
Consistent with this, Wouters and coworkers have shown that dietary cholesterol can be 
an important risk factor for the progression to hepatic inflammation, possibly in the form 
of modified plasma lipoproteins (18). It is also possible that dietary cholesterol exerts a 
direct effect on hepatic lipid and cholesterol metabolism thereby promoting lipid 
accumulation, lipotoxicity and local hepatic inflammation (19-21).   
    A systematic time-resolved analysis of the development of distinct forms of steatosis 
(microvesicular and macrovesicular steatosis) in relation to inflammation has not been 
documented so far. It has long been thought that liver steatosis and inflammation develop 
sequentially (e.g. ‘two hit’ hypothesis), but more recently a simultaneous development of 
steatosis and inflammation is also proposed (3, 17, 22). The present study shows that a 
more refined description of steatosis and inflammation is more accurate, because 
microvesicular steatosis and macrovesicular steatosis develop sequentially. In the case of 
inflammation, the early event of NFκB activation clearly precedes the formation of 
inflammatory cell aggregates and activation of AP-1. Notably, the level of microvesicular 
and macrovesicular steatosis correlates with NFκB activation and cellular inflammation, 
respectively, which supports the view that specific forms of steatosis are paralleled by 
specific inflammatory events.  
    We observed that microvesicular steatosis precedes macrovesicular steatosis, the latter 
of which is a hallmark of NASH pathology in humans (1). The exact role of microvesicular 




associated with mitochondrial stress, dysfunction or injury and this form of steatosis is 
observed in pediatric Reye syndrome and genetic diseases such as carnitine deficiency 
(23). It is possible that this mitochondrial impairment represents an early event of 
metabolic incompetence of the liver and mitochondrial dysfunction is associated with a 
pro-oxidative and pro-inflammatory state of organs and activation of NFκB (19, 24) which 
is consistent with our observations. The exact processes underlying the activation of 
inflammatory cascades under this condition and the molecules which operate at the 
interface between metabolism and inflammation are unknown. One of the possible 
mediators is the inflammasome which can sense specific lipids that accumulate in 
steatotic livers (e.g. palmitic acid as well as small cholesterol crystals) (21, 25) and which 
evokes local tissue inflammation through the production of IL-1β and IL-18 via a caspase-
1-dependent enzymatic process.  
    The animal model used herein, E3L.CETP mice, develops about two times more 
microvesicular steatosis than macrovesicular steatosis when fed the HFC diet. 
Microvesicular steatosis already developed with HFD under conditions of NAFL, and 
macrovesciular steatosis developed only when cholesterol was supplemented to the diet 
to induce progression of the pathogenesis towards NASH. Other diet-inducible transgenic 
models of NAFLD such as LDLR
-/- 
mice develop more macrovesicular steatosis, resembling 
the pathology of human NASH (26, 27). Since all these models share the same C57BL.6 
background, it is amenable that the transgenes present in E3L.CETP mice are responsible 
for extensive development of microvesicular steatosis. Because E3L mice which lack CETP 
do also predominantly develop microvesicular steatosis (12), it is likely that other human 
transgenes, i.e. APOE3 and human APOC1 which are expressed by E3L and E3L.CETP mice, 
are responsible for the susceptibility to develop microvesicular steatosis. It is unclear 
whether small lipid droplets that characterize microvesicular steatosis can fuse to form 
larger lipid droplets as seen in livers with macrovesicular steatosis, or whether 
macrovesicular and microvesicular steatosis develop independently from each other (4). 
Little is known about the pathological implications of microvesicular and macrovesicular 
steatosis, and a more recent experimental evidence provides an indication for a tight 
relationship between macrovesicular steatosis and fibrosis: A comparison of different 
strains of rats with either solely microvesicular steatosis (Lewis rats), pure macrovesicular 
steatosis (Sprague Dawley rats) and mixed-type steatosis (Wistar rats) showed that 
Sprague Dawley rats had the highest degree of hepatocyte damage and fibrosis (28). This 
is consistent with our observation that HFC induced macrovesicular steatosis between 8 
and 12 weeks which is accompanied by a marked increase of the injury markers ALT and 
AST, activation of AP-1 and formation of liver fibrosis in this period. 
    In all, the dietary conditions employed herein allowed a time-resolved study of NAFLD in 
the context of combined visceral obesity, insulin resistance and dyslipidemia i.e. hallmarks 
of the disease in humans that are not or only inadequately mimicked in models using diets 
deficient in methionine and choline or in chemically-induced fibrosis models (e.g. CCL4 
model). The study demonstrates that steatosis itself develops sequentially (first 
microvesicular, then macrovesicular) and so does inflammation (first NFκB, then 
inflammatory aggregates, then AP-1 and fibrosis). Better insight into the sequence of 
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Background & Aims: Anthocyanins may have beneficial effects on lipid metabolism and 
inflammation and are demonstrated to have hepatoprotective properties in models of 
restraint-stress- and chemically-induced liver damage. However, their potential to protect 
against non-alcoholic steatohepatitis (NASH) under conditions relevant for human 
pathogenesis remains unclear. Therefore, we studied the effects of the standardized 
anthocyanin-rich extract Mirtoselect on diet-induced NASH in a translational model of 
disease.  
Methods: ApoE*3Leiden mice were fed a Western-type cholesterol-containing diet 
without (HC) or with 0.1% (w/w) Mirtoselect (HCM) for 20 weeks to study effects on diet-
induced NASH.  
Results: Mirtoselect attenuated HC-induced hepatic steatosis, as observed by decreased 
macro- and microvesicular hepatocellular lipid accumulation and reduced hepatic 
cholesteryl-ester content. This anti-steatotic effect was accompanied by local anti-
inflammatory effects in liver, as demonstrated by reduced inflammatory cell clusters and 
reduced neutrophil infiltration in HCM. On a molecular level, HC-diet significantly induced 
hepatic expression of pro-inflammatory genes Tnf, Emr1, Ccl2, Mpo, Cxcl1 and Cxcl2 while 
this induction was less pronounced or significantly decreased in HCM. A similar quenching 
effect was observed for HC-induced pro-fibrotic genes, Acta2 and Col1a1 and this anti-
fibrotic effect of Mirtoselect was confirmed histologically. Many of the pro-inflammatory 
and pro-fibrotic parameters positively correlated with intrahepatic free cholesterol levels. 
Mirtoselect significantly reduced accumulation and crystallisation of intrahepatic free 
cholesterol, providing a possible mechanism for the observed hepatoprotective effects. 
Conclusions: Mirtoselect attenuates development of NASH, reducing hepatic lipid 
accumulation, inflammation and fibrosis, possibly mediated by local anti-inflammatory 










Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver 
disease in Western countries [1, 2]. It constitutes a spectrum of liver injury, ranging from 
the clinically benign intrahepatic accumulation of lipids (steatosis), to the more 
progressive non-alcoholic steatohepatitis (NASH). In addition to hepatic lipid 
accumulation, NASH is characterised by hepatic inflammation, i.e. infiltration of immune 
cells [3] and can further progress to fibrosis, cirrhosis and hepatocellular carcinoma. 
Although the mechanisms by which NASH progresses are not completely understood, it is 
thought that dysregulation of cholesterol homeostasis and subsequent accumulation of 
free (unesterified) cholesterol are linked to the pathogenesis of NASH in humans 
(reviewed in reference [4]). In line with this notion, emerging experimental evidence 
implicates free cholesterol as a potential trigger of inflammation [5] as well as a possible 
driving factor in the development of fibrosis [6, 7]. A recent study in experimental and 
human NASH revealed that intrahepatic accumulation of free cholesterol can lead to the 
formation of cholesterol crystals in hepatocyte lipid droplets, which may form an 
important trigger for the progression of simple steatosis to NASH [8]. 
    The anthocyanins, a subclass of the polyphenols, comprise a large group of bioactive 
compounds that are considered to have many health-promoting effects [9], including 
cholesterol-lowering [10, 11] and anti-inflammatory effects [12] which may mediate 
potential hepatoprotective properties [13]. Here we studied the effects of the 
standardised anthocyanin-rich bilberry (Vaccinium myrtillus L.) extract Mirtoselect on the 
development of NASH. This extract has been demonstrated to reduce circulating makers 
of inflammation in humans [14, 15] and has beneficial effects in restraint-stress- [16, 17] 
and chemically-induced [18] models of liver damage. However, its hepatoprotective 
potential in diet-induced metabolic inflammation and liver disease is unclear. Therefore 
we studied effects of Mirtoselect on NASH in ApoE*3Leiden (E3L) mice, a translational 
model of disease [19]. These mice develop diet-induced dyslipidaemia and inflammation 
on a high-fat/high-cholesterol diet [20], and ultimately develop NASH with fibrosis. Earlier 
studies have shown that E3L mice are sensitive to nutritional [21] and pharmacological 
[19] interventions, and show human-like responses to hypolipidaemic compounds [19, 
22]. 
    Combined histological, biochemical, and gene expression analyses revealed that 
Mirtoselect reduces development of NASH, attenuating both steatosis and inflammation 
as well as the development of hepatic fibrosis. These effects were associated with a 
reduction in hepatic free cholesterol accumulation and cholesterol crystal formation.  
 
 
MATERIALS AND METHODS  
Animal experiments 
Experiments were approved by an independent Animal Care and Use Committee and were 
in compliance with European Community specifications regarding the use of laboratory 
animals. ApoE*3Leiden mice (E3L) were used because they allow study of diets and 




Female E3L mice were fed a Western-type diet (15% cocoa butter, 1% corn oil, 40.5% 
sucrose, 20% acid casein, 10% corn starch and 6.2% cellulose; diet-T; AB-Diets, Woerden, 
the Netherlands), supplemented with 1% (w/w) cholesterol (Sigma-Aldrich, Zwijndrecht, 
the Netherlands) for 20 weeks. The study included a 4-week run-in during which all mice 
received this diet, after which they were matched for plasma cholesterol and triglycerides 
into 3 experimental groups (n=15/group). Control animals (HC) continued to receive the 
Western-type diet for the remainder of the study, while Mirtoselect-treated animals 
(HCM) received the HC diet with addition of 0.1% (w/w) Mirtoselect (Indena S.A.S., Paris, 
France). This standardised bilberry (Vaccinium myrtillus L.) extract contains 36% 
anthocyanins. An ageing reference group (REF) received the same Western-type diet 
mentioned above, but without cholesterol supplementation. Food intake and body weight 
were monitored throughout the study. Every 4 weeks, blood samples were collected via 
tail vein bleeding after a 4h fast, for isolation of EDTA plasma. Animals were sacrificed by 
CO2 asphyxiation after 16 weeks of dietary treatment to collect livers. The medial lobe was 
fixed in formalin and embedded in paraffin for histological analysis of NASH and the left 
lobe was snap frozen in liquid nitrogen and stored at -80°C for cryosectioning, liver lipid- 
and mRNA-expression analyses. 
 
Histological, biochemical and hepatic gene expression analyses 
A detailed description of (immuno)histological, biochemical, and gene expression analyses 
is provided in (supplement 1). Briefly, development of NASH was assessed histologically 
using an adapted grading method for human NASH [25, 26]. Plasma lipids were 
determined with commercially available enzymatic assays and liver lipids were analysed 
by HPTLC, as described previously [27]. Hepatic gene expression analyses were performed 
by RT-PCR, using TaqMan® Gene Expression Assays (Life Technologies, Bleiswijk, the 
Netherlands) and changes in gene expression were calculated using the comparative Ct 
(ΔΔCt) method, expressed as fold-change relative to REF. Illumina microarray analysis of 
hepatic gene expression was performed following established normalisation and quality 
control protocols  followed by gene enrichment analysis across pathways and biological 
processes as described [23]. p65-NFκB activity was determined in liver homogenates by 
DNA-binding ELISA (TransAM® p65-NFκB Chemi Kit, Active Motif, La Hulpe, Belgium) 
according to manufacturer’s instructions and as described [26]. 
 
Statistical analyses 
All data are presented as mean ± SD. Statistical analyses were performed using SPSS 
software (version 22, IBM, Armonk, USA). For normally distributed variables, significance 
of differences between groups was tested by one-way ANOVA, with Dunnett's Multiple 
Comparison Post-Hoc Test to compare HC vs REF and HC vs HCM. In case of heterogeneity 
between groups, variables were analysed by ANOVA using Brown-Forsythe for differences 
between groups with Dunnett’s T3 Post-Hoc Test. Non-normally distributed variables were 
tested by non-parametric Kruskall-Wallis test followed by Mann-Whitney U. A p-





Mirtoselect attenuates hepatic steatosis and hepatocellular damage 
Treatments were well tolerated and there was no effect of Mirtoselect on food intake or 
body weight (supplement 2a-b). HC-feeding induced hepatosteatosis relative to REF, as 
observed histologically by a non-zonal accumulation of lipid macrovesicles and 
microvesicles in hepatocytes (Figure 1a). Mirtoselect attenuated the development of 
hepatic steatosis (Figure 1a), completely preventing the HC-induced increase in 
macrovesicular steatosis (p<0.001, Figure 1b) and strongly decreasing microvesicular 
steatosis (p=0.027, figure 1c). Analysis of intrahepatic lipid composition revealed that this 
increase in hepatic steatosis in HC was mainly attributable to an accumulation of lipids 
esterified to cholesterol (cholesteryl esters), the concentration of which was significantly 
lower in HCM (p=0.008, Figure 1d). Comparably, hepatic triglyceride levels (i.e. lipids 
esterified to glycerol) tended to build up in HC, but no increase was observed in HCM 
(Figure 1e). In association with steatosis, HC-feeding resulted in a pronounced induction 
of hepatocellular hypertrophy, the development of which was markedly reduced in HCM 
(p=0.034, supplement 3). In HC-fed animals, some of these hypertrophic cells were 
deficient in cytokeratin 18 (CK-18) compared with neighbouring cells (Figure 1f), indicating 
loss of cytoskeletal function and hepatocellular damage as seen in ballooning cells in 
human NASH [28, 29]. In Mirtoselect-treated mice, only very few enlarged CK-18 deficient 
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Figure 1: Mirtoselect attenuates hepatic steatosis in cholesterol-fed E3L-mice. Representative 
photomicrographs of liver sections of reference, high-cholesterol control and Mirtoselect-treated mice (A). 
Mirtoselect attenuated HC-diet-induced macrovesicular (B) and microvesicular (C) steatosis. Hepatic steatosis in 
HC-mice was mainly attributable to accumulation of cholesteryl-esters, the build-up of which was decreased by 
Mirtoselect (D). Hepatic triglycerides tended to accumulate in HC, which was not observed in HCM (E). In HC-fed 
animals, some hypertrophic cells were CK18-deficient compared with neighbouring cells (arrows); presence of 
these cells was reduced in HCM (F). REF: non-cholesterol-fed reference, HC: high-cholesterol control, HCM: high-
cholesterol+Mirtoselect. Data are mean ± SD. *p<0.05, **p<0.01, ***p<0.001 compared with HC. 
 
 
Mirtoselect reduces hepatic inflammation 
In addition to hepatosteatosis, a defining characteristic of NASH is the presence of hepatic 
inflammation, which can be observed histologically as the lobular infiltration of 
inflammatory cells, i.e. inflammatory aggregates containing mononuclear cells (F4/80-
positive cells of the monocyte/macrophage lineage) and polymorph nuclear cells (MPO-
positive granulocytes, i.e. neutrophils). In comparison with REF, the number of 
inflammatory cell aggregates increased strongly in HC, and this HC-induced hepatic 
inflammatory response was fully blunted with Mirtoselect (p<0.001, Figure 2a). 
Investigation of hepatic Emr1 (F4/80) gene expression revealed that the influx of 
inflammatory cells was partly attributable to macrophages, which was supported by 
increased gene expression levels of Ccl2 (MCP-1), a mediator of monocyte recruitment 
(Figure 2b-c). Mirtoselect did not affect expression of Emr1or Ccl2 (Figure 2b-c), indicating 
that its anti-inflammatory effect may impair the influx of another immune cell type. 
Hepatic gene expression analysis of the neutrophil marker Mpo showed that Mpo 
expression was increased in HC animals and this induction was completely prevented in 
HCM animals (p=0.034, Figure 2d). Immunohistochemical staining of MPO-positive cells 
confirmed the mRNA expression data and showed that HC induced neutrophil infiltration, 
which was attenuated by HCM (Figure 2e). In line with these findings, the expression of 
two neutrophil chemoattractants – Cxcl1 and Cxcl2 – was upregulated strongly and 
significantly by HC feeding while induction of these chemokines was less pronounced in 








































Figure 2:  Mirtoselect reduces hepatic inflammation in cholesterol-fed E3L-mice. Number of HC-induced 
inflammatory cell aggregates was reduced by Mirtoselect (A). HC-diet induced Emr1 (B) and Ccl2 (C) gene 
expression was not affected by Mirtoselect. Mirtoselect reduced HC-induced Mpo gene expression (D) and 
number of MPO-positive cells as determined immunohistochemically (E). HC-induced gene expression of 
neutrophil chemoattractants Cxcl1 (F) and Cxcl2 (G) was less pronounced in HCM. REF: non-cholesterol-fed 
reference, HC: high-cholesterol control, HCM: high-cholesterol+Mirtoselect. Data are mean ± SD. *p<0.05, 
**p<0.01, ***p<0.001 compared with HC. 
 
 
Mirtoselect attenuates hepatic fibrosis 
Continued hepatic inflammation is thought to drive the progression of NASH, ultimately 
resulting in the development of hepatic fibrosis. Histochemical staining of hepatic collagen 



































































































































































































characterised by periportal, pericentral and perisinusoidal deposition of collagen. This HC-




























Figure 3: Development of hepatic fibrosis in cholesterol-fed E3L-mice reduced by Mirtoselect. Representative 
photomicrographs of picro-sirius red-stained liver sections show reduction of HC-induced collagen content in 
Mirtoselect-treated mice (A), which was confirmed by biochemical analysis of hepatic collagen content (B). 
Induction of Col1a1 gene expression is prevented by Mirtoselect (C). Gene expression of hepatic stellate cell 
activation marker Acta2 (D) as well as pro-fibrotic cytokines Tgfb1 (E) and Tnf (F) was induced by HC, while this 
induction was less pronounced in HCM. REF: non-cholesterol-fed reference, HC: high-cholesterol control, HCM: 
high-cholesterol+Mirtoselect. Data are mean ± SD. *p<0.05, **p<0.01, ***p<0.001 compared with HC. 
 
 
    In line with these histological observations, biochemical analysis of hepatic collagen 
content revealed a pronounced increase in collagen content in HC compared with REF, 
which was significantly reduced in HCM (p=0.034, Figure 3b) and hepatic gene expression 
analysis of Col1a1 showed significantly increased expression in HC compared with REF, 
while Mirtoselect quenched this effect and significantly reduced Col1a1 expression 
compared with HC (p=0.011, Figure 3c). Additionally, HC diet significantly induced 
expression of the hepatic stellate cell activation marker Acta2 (α-SMA) (Figure 3d), as well 
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as the pro-fibrotic cytokines Tgfb1 (TGF-β) and Tnf (TNF-α) (Figure 3e-f). In line with the 
attenuating effect of Mirtoselect on hepatic fibrosis development, the induction of these 
genes was less pronounced, although non-significantly, in HCM (Acta2: p=0.173, Tgfb1: 
p=0.174, Tnf: p=0.096, Figure 3d-f). Subsequent microarray pathway analysis revealed 
that many genes downstream of TGF-β were affected, indicating strongly and significantly 
activated TGF-β signalling in HC compared with REF (z=7.539, p=2.5E-51). Mirtoselect 
strongly inhibited activation of this pathway (z=-4.862, p=3.3E-20 compared with HC). 
Consistent with this, the process ‘Hepatic fibrosis/hepatic stellate cell activation’, was 
strongly activated in HC compared with REF and Mirtoselect suppressed this activation 
(supplement 4). Together, our data demonstrate that HC-feeding induced 
histopathological and molecular hallmarks of NASH and fibrosis and that Mirtoselect 
significantly attenuated disease development. 
 
Intrahepatic free cholesterol correlates with development of NASH and is 
reduced by Mirtoselect 
To gain more insight into the metabolic-inflammatory processes that drive the 
development of NASH and hepatic fibrosis and the effects of Mirtoselect thereupon, we 
next analysed a possible metabolic trigger of inflammation: cholesterol. HC-feeding 
induced dyslipidaemia with increased plasma total cholesterol compared with REF, 
specifically in the VLDL- and LDL-sized particles. Mirtoselect did not affect circulating 
cholesterol levels or lipoprotein profile (supplement 5) pointing to a hepatoprotective 
effect within the liver tissue. As intrahepatic free cholesterol is a very potent inducer of 
liver inflammation [23] and is elevated intrahepatically in human NASH [30, 31], we 
determined free cholesterol concentrations in freshly prepared liver homogenates and 
correlated them with histology scores and gene expression data. Both hepatic 
inflammation (number of inflammatory clusters observed histologically, p<0.001), and 
hepatic fibrosis (hepatic Col1a1 expression, p=0.007) were positively correlated with 
hepatic free cholesterol levels (Figure 4a-b). Further strengthening this notion, we also 
observed positive significant correlations of hepatic free cholesterol levels with the 
expression level of many of the investigated pro-inflammatory and pro-fibrotic 
parameters (i.e. Ccl2, Cxcl1, Cxcl2, Acta2, Tgfb1 and Tnf, shown in supplement 6). 
Importantly, Mirtoselect fully blunted the disease-associated increase in hepatic free 
cholesterol, the concentrations of which were comparable to REF and significantly lower 
than in HC (p=0.008, Figure 4c). To further examine the link between cholesterol and 
inflammation and the effects of Mirtoselect thereupon we analysed activation of 
inflammatory pathways by microarray as well as biochemically. HC diet significantly 
induced TNF-α and IL-1β signalling (TNF-α: z=7.539, p=2.5E-51; IL-1β: z=6.516, p=4.70E-30; 
vs REF) and activated the downstream pro-inflammatory transcription factor NFκB 
(z=6.245, p=4.82E-14 vs REF). Consistent with this, hepatic free cholesterol levels were 
positively correlated with biochemically measured transcriptional activation of p65-NFκB 
(R
2
=0.51, p=0.021), providing a link between cholesterol and inflammation. Mirtoselect 
significantly reduced p65-NFκB activity relative to HC (fold-change relative to REF: 1.15 ± 
0.11 in HC vs 0.98 ± 0.05 in HCM, p=0.032). 










































Figure 4: Mirtoselect reduces intrahepatic free cholesterol accumulation and crystallisation in cholesterol-fed 
E3L-mice. Intrahepatic free cholesterol levels correlated with hepatic inflammation (inflammatory aggregates per 
field; A) and hepatic fibrosis (Col1a1 expression; B). HC-induced hepatic free cholesterol accumulation was not 
observed in HCM (C). Representative photomicrographs of liver cryosections (same field under bright-field and 
polarised-light microscopy) reveal presence of birefringent crystals in HC that were hardly observed in HCM (D). 
Quantification of birefringent area shows strong HC-induced increase that is not observed in HCM (E). 
Birefringent crystals stained prominently with free-cholesterol staining filipin (same field under polarised-light 
and fluorescent microscopy; F). REF: non-cholesterol-fed reference, HC: high-cholesterol control, HCM: high-
cholesterol+Mirtoselect. Data are mean ± SD. **p<0.01 compared with HC.  
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More detailed analysis of processes that may underlie observed effects of Mirtoselect on 
hepatic cholesterol accumulation showed that plasma markers of cholesterol uptake 
(plant sterols to cholesterol ratio and cholestanol to cholesterol ratio) or cholesterol 
biosynthesis (lathosterol to cholesterol ratio) were not affected in HCM (supplement 7). 
Also, microarray analysis confirmed absence of an effect of Mirtoselect on cholesterol 
biosynthesis but revealed a significant activation of FXR in HCM (z=2.190, p=7.64E-03) and 
showed that genes involved in bile acid synthesis, bile acid conjugation and bile salt 
secretion (e.g. Bsep, Cyp27a1) were upregulated in HCM.  
    Refined microscopic analysis of liver cross-sections under polarised light revealed that 
HC-feeding caused pronounced formation of large birefringent crystals within a 
considerable amount of the macrovesicular lipid droplets, while these crystals were hardly 
observed in Mirtoselect-treated animals (even in the few regions containing 
macrovesicles, Figure 4d-e). These birefringent crystals stained positively with filipin 
(Figure 4f), which forms a fluorescent complex with free cholesterol specifically, indicating 
that the observed birefringence is attributable to crystallised free cholesterol. Detailed 
examination of the liver cross-sections under bright field and polarised light microscopy 
revealed that many of the hepatocytes containing these crystals were devoid of normal 
cellular morphology and organisation. The prevention of this intrahepatic cholesterol 






We investigated the potential hepatoprotective properties of a standardised anthocyanin-
rich extract (Mirtoselect) in a diet-induced, translational model of NASH with fibrosis. We 
show that Mirtoselect protects against the development of NASH, reducing hepatic 
steatosis, hepatic inflammation and hepatic fibrosis, associated with decreased 
accumulation and crystallisation of intrahepatic free cholesterol. The observed 
hepatoprotective effects of Mirtoselect were achieved at a dosage that translates to an 
anthocyanin intake of around 300 mg/day in humans, an intake that is achievable by diet 
[12, 32, 33].  
    HC diet-feeding induced intrahepatic lipid accumulation characterised by macro- and 
microvesicular steatosis, which was mainly attributable to an increase in lipids esterified 
to cholesterol. Mirtoselect strongly reduced this intrahepatic accumulation of lipids. 
Experimental support for these observed anti-steatotic effects is provided by results from 
earlier studies that report improved hepatic cholesterol homeostasis in rodents treated 
with similar concentrations of anthocyanin-rich extracts [11, 34] or individual 
anthocyanins [35]. Although these studies were not performed under conditions leading 
to NAFLD/NASH, they do provide a possible mechanism for the observed reduction in 
intrahepatic cholesterol: intervention with anthocyanins was found to increase bile acid 
synthesis [34, 35] and faecal sterol excretion [11, 35], thereby decreasing intrahepatic 
cholesterol accumulation [11, 35] which is consistent with our observations of FXR 
activation by Mirtoselect. Although it is the anthocyanin fraction of Mirtoselect that is 




these anthocyanins or other possibly bioactive constituents (alone or in combination), 
may be responsible for the observed effects. 
    In addition to reducing hepatic steatosis Mirtoselect also attenuated hepatic 
inflammation, completely preventing the HC-induced increase in inflammatory cell 
aggregates. This anti-inflammatory effect was largely attributable to an effect specifically 
on the influx of MPO-positive neutrophils, the infiltration of which is recognised as a 
defining characteristic of inflammation in human NASH [36]. The exact role of neutrophils 
in the pathogenesis of NASH remains to be elucidated [37], but their ability to release a 
potent cocktail of reactive oxygen species and proteases implicates them as potential 
cause of extensive tissue damage [38] that may contribute to amplification of the 
inflammatory response as well as development of fibrosis. We observed a marked 
reduction of neutrophils in livers of Mirtoselect-treated mice, but only a modest effect on 
the hepatic expression of neutrophil chemoattractants Cxcl1 and Cxcl2, suggesting 
additional mechanisms outside the liver. Indeed, it has been demonstrated that 
anthocyanins can attenuate the induction of chemokine receptors such as CXCR2 [39], 
which is required for neutrophil chemotaxis. 
    Although inflammation is recognised to play an important role in the development of 
NASH, the nature of the trigger for this inflammatory component remains unclear. 
Lipotoxicity caused by the build-up of toxic lipid species is thought to play an important 
role, but the specific lipid species that mediate hepatic lipotoxicity have not been 
identified with certainty [40]. While triglycerides are the main accumulating lipid species 
in human NASH, recent studies have implicated free cholesterol as a potential trigger for 
disease progression [4]. The experimental conditions chosen for the present study 
emphasize the role of cholesterol in NASH, and limit the study of hepatic triglyceride 
accumulation. Results from epidemiological studies that link dietary cholesterol intake to 
increased risk and severity of NAFLD [41, 42] and cirrhosis [43] provide indications that 
cholesterol may play a causal role in NASH development. In support of this notion, free 
cholesterol is increased intrahepatically in human [30, 31] and experimental NASH [44] 
and modulation of hepatic free cholesterol levels by diet [44] or pharmacological 
intervention [45] is closely linked to the severity of experimental NASH. Furthermore, 
there are indications that cholesterol-lowering agents (e.g. statins, ezetimibe) may 
improve NASH in patients with hypercholesterolaemia [46, 47]. Mechanistic studies have 
shown that free cholesterol accumulation in Kupffer cells [48] and hepatic stellate cells 
(HSC) [6, 7] promotes inflammation and exacerbates fibrosis (e.g. increased TNF-α and 
CCL2 expression by Kupffer cells and increased COL1A1 expression in HSC). Results from 
the study described herein show that intrahepatic free cholesterol levels are positively 
correlated with many factors that contribute to or reflect progressive development of 
NASH (e.g. Ccl2, Cxcl1, Cxcl2, Col1a1, Acta2, Tnf, and Tgfb1). The observed activation of 
inflammatory signalling routes (IL-1β, TNF-α, TGF-β) by HC as well as the positive 
correlation between free cholesterol and NFκB activity, point to NFκB activation as an 
effector of cholesterol-induced inflammation, which is in line with previous observations 
[23, 27]. Mirtoselect decreases the build-up of this cytotoxic lipid species and associated 
NFκB activation, thereby providing a possible explanation for its beneficial effects on 




    A recently emerging mechanism of cellular toxicity associated with free cholesterol 
accumulation is intracellular cholesterol crystallisation, which can happen when the 
concentration of free cholesterol reaches a very high level [49]. Cholesterol crystals, 
particularly when they are very small (nm range), can trigger inflammation through 
inflammasome activation [5, 50]. Besides putative pro-inflammatory effects of cholesterol 
crystals [5, 50], it is plausible that the sheer size of the intrahepatocellular cholesterol 
crystals observed in the present study (with diameters ranging up to 50 µm) would also 
cause extensive physical damage to the cells containing them. Indeed, the formed 
cholesterol crystals may damage cells by physically disrupting the integrity of intracellular 
structures [49], in line with observations in the present study. Furthermore, cellular 
damage can result in the release of damage associated molecular patterns (DAMPs), 
which leads to neutrophil recruitment [37] further enhancing the inflammatory response. 
Additional support for this mechanism is provided by results from human studies that 
demonstrate that cholesterol crystals distinguish NASH from simple steatosis [8] and that 
this accumulation and crystallisation of free cholesterol within steatotic hepatocytes may 
be an important trigger for disease progression. 
    Overall, we show that Mirtoselect has beneficial effects in NASH, improving hepatic 
steatosis, inflammation and fibrosis. Furthermore, we demonstrate the presence of 
cholesterol crystals and associated tissue damage in NASH and show that dietary 
intervention with Mirtoselect prevents this accumulation and crystallisation of free 
cholesterol, providing a possible rationale for its hepatoprotective effects. Given the 
moderate dose of Mirtoselect used, this study suggests that intervention with naturally 
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Background and aims: Salsalate is an anti-inflammatory drug that was recently found to 
exhibit beneficial metabolic effects on glucose and lipid metabolism. Although its utility in 
the prevention and management of a wide range of vascular disorders as well as of type 2 
diabetes and metabolic syndrome has been suggested before, the potential of salsalate to 
protect against non-alcoholic steatohepatitis (NASH) remains unclear. The aim of the 
present study was therefore to ascertain the effects of salsalate in the development of 
NASH. 
Methods: Transgenic APOE*3Leiden.CETP mice were fed a high fat high cholesterol diet 
with or without salsalate for 12 and 20 weeks. The effects on body weight, plasma 
parameters, liver histology and hepatic gene expression were assessed. 
Results: Salsalate prevented weight gain, improved dyslipidemia and insulin resistance 
and ameliorated diet-induced non-alcoholic steatohepatitis, as shown by decreased 
hepatic micro- and macrovesicular steatosis, reduced hepatic inflammation and reduced 
development of fibrosis. Salsalate affected lipid metabolism by increasing β-oxidation and 
decreasing lipogenesis, as shown by the activation of PPAR-α, PGC1-β, RXR-α and 
inhibition of MLXIPL/ChREBP controlled genes, respectively. Inflammation was reduced by 
down-regulation of the NFκB pathway and fibrosis development was prevented by down-
regulation of TGF-β signaling.  
Conclusions: Salsalate was shown to exert a preventive effect on the development of 









Owing to the worldwide epidemic of obesity, and the abundance of energy-rich diets with 
high levels of sugars and saturated fat, non-alcoholic fatty liver disease (NAFLD) is 
increasingly common. In fact, NAFLD is now considered to be the manifestation of the 
metabolic syndrome in the liver and has become the most prevalent form of chronic liver 
disease. Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD, characterized by 
steatosis in concert with inflammation, which can progress to liver fibrosis and cirrhosis. 
To date, no single therapy has been approved for the treatment of NASH. Considering that 
NASH has serious adverse effects on health, including hepatic failure, development of 
novel therapies that effectively reverse hepatic fat accumulation and inflammation is 
evidently needed.  
    Salsalate is an anti-inflammatory agent that has been used in the clinic for several 
decades to treat rheumatoid arthritis, osteoarthritis, and related rheumatic conditions. 
The drug is a dimer of two molecules of salicylate that are linked by an ester bond. The 
anti-inflammatory effects of salsalate and salicylate are both believed to be attributable to 
inhibition of the activity of cyclooxygenase (COX), a key enzyme in biosynthesis of 
proinflammatory prostanoids [1, 2]. In contrast to salicylate, salsalate is well tolerated and 
considered to be relatively safe for long-term use. Recent studies have shown that 
salsalate exhibits beneficial effects on glucose and lipid metabolism. In clinical studies, 
administration of salsalate decreased fasting glucose and HbA1c levels in obese non-
diabetics as well as type 2 diabetics, and improved insulin sensitivity [3, 4]. Furthermore, 
decreases in circulating triglyceride and free fatty acids levels have been reported [5, 6]. In 
aggregate, these data suggest that this particular combination of effects, i.e. anti-
inflammatory effects and beneficial effects on glucose and lipid metabolism, renders 
salsalate an optimal candidate for treatment of NASH. 
    To test this hypothesis, we investigated the effect of salsalate on NASH development 
and liver fibrosis using APOE*3Leiden.CETP mice [7-9]. These mice are prone to develop 
dyslipidemia, obesity and NAFLD on a high fat/high cholesterol diet, and ultimately 
develop NASH with fibrosis. Earlier studies have shown that these mice demonstrate 
human-like responses to different anti-diabetic and hypolipidemic drugs [9-13]. 
 
 
MATERIALS AND METHODS  
Animals and induction of NASH and liver fibrosis  
Homozygous human cholesteryl ester transfer protein (CETP) transgenic mice (strain 
5203) [9, 14] were obtained from Jackson Laboratories (Bar Harbor, MC) and cross-bred 
with APOE*3Leiden mice (E3L) [15] in our local animal facility at TNO to obtain 
heterozygous E3L.CETP mice. All animals were housed in a temperature-controlled room 
on a 12 hour light-dark cycle and had free access to food and water. Animal experiments 
were approved by the Ethical Committee on Animal Care and Experimentation (Zeist, The 
Netherlands), and were in compliance with European Community specifications regarding 
the use of laboratory animals. To assess the effect of salsalate on progression of obesity, 




mice were fed a high fat, high cholesterol diet (HFC: 45 kcal% fat derived from lard 
supplemented with 1% (w/w) cholesterol, Research Diets, New Brunswick, NJ, USA) with 
(n=8) or without (HFC control group, n=9) 1% (w/w) salsalate (2-carboxyphenyl salicylate, 
TCI Europe N.V., Zwijndrecht, Belgium) for 12 weeks. In addition, five age-matched male 
E3L.CETP mice on a low fat diet (LFD: 10 kcal% lard, Research Diets, New Brunswick, NJ, 
USA) were also included (LFD control group, n=5). In a second experiment we assessed 
whether salsalate would still be able to prevent onset of NASH and liver fibrosis, also after 
a longer induction period of NASH. To do so, 11-18 weeks old male E3L.CETP mice were 
fed the HFC diet with (n=8) or without (n=12) 0.33% (w/w) salsalate for 20 weeks. Because 
of the profound effects of salsalate in the first (short-term) study, the drug dose was 
lowered pharmacologically (by factor 3).  
 
Analysis of plasma parameters 
Blood was collected from the tail vein after 5 h fasting (with food withdrawn around 08.00 
am) into EDTA-coated tubes (Sarstedt, Nümbrecht, Germany). Plasma glucose was 
determined using the ‘Freestyle glucose measurement system’ from Abbott (Abbott Park, 
IL, USA). Plasma insulin was measured by ELISA (Mercodia AB, Uppsala, Sweden). 
Homeostasis model assessment (HOMA) was used to calculate relative insulin resistance 
(IR). Five hours fasting plasma insulin and fasting blood glucose values were used: IR = 
[insulin (ng/ml) x glucose (mM)] /22.5. Plasma total cholesterol and triglycerides were 
determined using a commercially available kit (Roche Diagnostics, Basel, Switzerland). The 
distribution of cholesterol of the various lipoproteins was determined in plasma pooled 
per group after separation of lipoproteins by fast-performance liquid chromatography 
(FPLC) using a Superose 6 column [11]. Plasma alanine transaminase (ALT) and aspartate 
aminotransferase (AST) were measured using a Reflotron® kit (Roche diagnostics, Basel, 




Liver samples (of lobus sinister medialis hepatis and lobus dexter medialis hepatis) were 
collected (in non-fasted mice), fixed in formalin, paraffin embedded and sections were 
stained with hematoxylin and eosin (H&E) and Sirius Red. H&E stained cross-sections were 
scored using an adapted grading system of human NASH [16, 17]. In short, the level of 
macrovesicular and microvesicular steatosis was determined at 40 to 100 x magnification 
relative to the total liver area analyzed, which is, expressed as a percentage. Inflammation 
was scored by counting the number of aggregates of inflammatory cells per field using a 
100 x magnification (view size of 3.1 mm
2
). The average of five random fields was taken. 
Relative values against the average of the HFC control group were calculated. Hepatic 
fibrosis was identified using Sirius Red stained slides and evaluated using an adapted 
grading system of human NASH [16, 18]. In short, the presence of pathologic collagen 
staining was scored as either absent (0), observed within perisinusoidal/perivenular or 
periportal area (1), within both perisinusoidal and periportal area (2), bridging fibrosis (3), 
or cirrhosis (4). Furthermore, the level of collagen deposition in the perisinusoidal area 
was determined relative to the total perisinusoidal area analyzed, expressed as a 




measure for collagen) and proline (as a measure for total protein) content of liver tissue 
using high performance liquid chromatography (HPLC) as previously described [19] and 
subsequent calculation of the ratio hydroxyproline above proline. 
 
Hepatic lipid analysis 
Liver samples of lobus sinister lateralis hepatis were collected and the intrahepatic 
concentration of triglycerides, free cholesterol and cholesteryl esters was determined as 
described previously [10]. Approximately 50 mg of tissue was homogenized in phosphate 
buffered saline and samples of the homogenate were taken for measurement of protein 
content. Lipids were extracted and separated by high performance thin layer 
chromatography (HPTLC) on silica gel plates. Lipid spots were stained with color reagent (5 
g MnCl2 ̣.4H2O, 32 mL 95-97% H2SO4 added to 960 mL of CH3OH:H2O 1:1 v/v) and 
quantified using TINA® version 2.09 software (Raytest, Straubenhardt, Germany). 
 
Gene expression analysis 
The probe-level background subtracted expression values were used as input for lumi 
package [20] of the R/Bioconductor (http://www.bioconductor.org; http://www.r-
project.org) to perform quality control and a quantile normalization. Unexpressed probes 
(p>0.01) were removed from further analysis, and 12947 probes remained in the analysis. 
Differentially expressed probes were identified using the limma package of 
R/Bioconductor [21, 22] calculated P-values <0.001 were used as threshold for 
significance. Selected differentially expressed probes (DEPs) were used as an input for 
pathway analysis through Ingenuity Pathway Analysis suite (www.ingenuity.com, accessed 
2014).  
    Upstream regulator analysis was performed using the Ingenuity Pathway Analysis (IPA) 
software. This analysis determines the activation state of transcription factors based on 
the observed differential gene expression. This results in an overlap p-value and activation 
z-score for each transcription factor in the IPA knowledgebase. The overlap p-value 
indicates the significance of the overlap between the known target genes of a 
transcription factor and the differentially expressed genes measured in an experiment. 
The activation z-score indicates activation (positive z-score) or inhibition (negative z-score) 
of a particular transcription factor. An activation z-score <-2 or >2 indicates significant 
inhibition or activation of a pathway or process. 
 
Statistical analysis 
Statistical differences between groups were determined by using the non-parametrical 
Mann-Whitney test for independent samples. A P-value < 0.05 was considered statistically 






Salsalate prevents weight gain and improves glycemic control and 
hyperlipidemia 
To induce obesity, insulin resistance and hyperlipidemia, E3L.CETP mice were fed a HFC 
diet for 12 weeks. The HFC feeding resulted in an increased body weight (with 45%, 
p<0.01) and elevated plasma insulin (8.0-fold, p<0.001), cholesterol (4.1-fold p<0.001) and 
triglyceride levels (2.7-fold, p<0.01) when compared with age-matched control E3L.CETP 
mice on LFD, while plasma glucose levels remained similar (Table 1). The HFC diet led to 
an increased liver weight (2.0-fold, p<0.01) and analysis of liver enzymes showed a 
concomitant increase in plasma ALT (8.9-fold, p<0.001) and AST (3.6-fold, p<0.001) as 
compared to the LFD mice, indicating that the HFC diet caused liver damage (Table 1).  
    Salsalate treatment profoundly curtailed weight gain, resulting in a significantly lower 
body weight after 12 weeks of treatment as compared to the HFC control group (with -
41%, p<0.001; Table 1). This decrease was at least partly due to a lower fat mass as 
reflected by a decrease in perigonadal fat pad weight with salsalate (with -83%, p<0.001, 
data not shown). Fasting plasma glucose and insulin levels were significantly lower as 
compared to HFC control group after treatment with salsalate (with -36% and -89%, 
respectively, both p<0.01; Table 1). Salsalate significantly decreased insulin resistance as 
reflected by the homeostasis model assessment (HOMA) index (with -91%, p<0.01), 
normalizing it to similar levels as age matched control mice on LFD. Plasma lipids were 
also improved by salsalate treatment: more specifically, salsalate significantly decreased 
plasma cholesterol and triglycerides as compared to the HFC control group (with -72% and 
-91%, respectively, both p<0.001; Table 1), mainly due to a reduction in VLDL and LDL, 
while HDL-cholesterol was slightly increased (Supplemental Figure 1). Furthermore, liver 
weight, plasma ALT and AST were all significantly lower in the salsalate treated groups as 




Salsalate prevents hepatic steatosis and inflammation 
NASH development was histologically evaluated using H&E and Sirus Red stained liver 
cross-sections. HFC feeding induced pronounced steatosis, while treatment with salsalate 
fully prevented this induction resulting in a similar histological appearance as observed in 
the LFD group (Figure 1). Quantitative analysis revealed that in the HFC group about 85% 
of the surface area was steatotic, of which 60% consisted of microvesicular steatosis and 
25% of macrovesicular steatosis (Figure 2ab). Treatment with salsalate completely 
prevented the development of micro- and macrovesicular steatosis (resulting in an 
average surface area of 0.1% and 0%, respectively, both p<0.001). Biochemical analysis of 
intrahepatic liver lipids was in line with the histological analysis and revealed that HFC 
feeding resulted in a significant increase in hepatic triglycerides and cholesterol esters as 
compared to the LFD control group (5.1-fold and 4.1-fold, respectively, both p<0.01) and 






Table 1: Plasma parameters. 
 
 LFD HFC HFC+S 
Body weight (g) 33.8 ± 1.9 49.0 ± 1.4# 28.9 ± 1.1*# 
Plasma glucose (mM) 12.6 ± 0.8 13.1 ± 0.7 8.4 ± 0.7*# 
Plasma insulin (ng/mL) 0.6 ± 0.2 4.8 ± 0.7# 0.5 ± 0.2* 
HOMA 0.4 ± 0.1 2.8 ± 0.4# 0.2 ± 0.1* 
Plasma cholesterol (mM) 6.5 ± 1.0 26.9 ± 1.9# 7.5 ± 0.4* 
Plasma triglycerides (mM) 2.6 ± 0.3 7.2 ± 1.0# 0.6 ± 0.05*# 
Liver weight (g) 1.6 ± 0.1 3.2 ± 0.2# 2.0 ± 0.1*# 
Plasma ALT (U/L) 32.2 ± 7.5 286.6 ± 53.5# 77.4 ± 9.2*# 
Plasma AST (U/L) 131.8 ± 18.3 473.7 ± 70.5# 173.0 ± 9.3* 
Body weight, liver weight and plasma parameters in APOE*3Leiden.CETP mice fed a low fat diet (LFD), a high fat 
and high cholesterol diet (HFC) or a high fat and high cholesterol diet supplemented with salsalate (HFC+S).  
Data are mean ± SEM. * p<0.05 vs. HFC;  
#





















Figure 1: Histological photomicrographs of NASH in mice. Liver histological cross-sections from 
APOE*3Leiden.CETP mice fed a low fat diet (LFD), a high fat and high cholesterol diet (HFC) or a high fat and high 
cholesterol diet supplemented with salsalate (HFC+S) for 12 weeks.  Upper photomicrographs: Hematoxylin and 





























































Figure 2: Hepatocellular steatosis and inflammation. Quantitative analysis of non-alcoholic steatohepatitis in 
APOE*3Leiden.CETP mice fed a low fat diet (LFD), a high fat and high cholesterol diet (HFC) or a high fat and high 
cholesterol diet supplemented with salsalate (HFC+S) for 12 weeks.  Microvesicular (A) and macrovesicular (B) 
steatosis as percentage of total liver area, intrahepatic triglycerides (C), intrahepatic cholesterol esters (D) and 
intrahepatic free cholesterol (E), inflammatory foci per microscopic field (F) and fibrosis score (G) were analyzed. 
Data are mean ± SEM. * p<0.05 vs. HFC;  
#













Salsalate treatment normalized the intrahepatic lipids, resulting in significantly lower 
levels of hepatic triglycerides, cholesterol esters and free cholesterol as compared to the 
HFC group (6.7-fold, 3.2-fold and 2.4-fold decrease, respectively, all p<0.001). HFC feeding 
also induced lobular inflammation, characterized by the presence of mononuclear cells 
and polymorphonuclear cells that formed aggregates, while the livers of the salsalate 
treated mice hardly contained inflammatory aggregates (Figure 1). Quantification of 
lobular inflammation showed that the HFC feeding resulted in a significant increase in the 
number of aggregates as compared to the LFD control group (8.0-fold, p<0.001). Salsalate 
treatment fully blunted this HFC induced inflammation as shown by a significantly lower 
number of inflammatory aggregates relative to HFC group (10.2-fold decrease, p<0.001; 
Figure 2f). Twelve weeks of HFC feeding induced onset of fibrosis, as shown by the 
patches of collagen deposition (Figure 1; Sirius Red staining). Fibrosis evaluation according 
to human grading scores revealed that some fibrosis was located within perisinusoidal and 
periportal area for all groups (score F2 for all groups). No bridging fibrosis was seen. 
However, the amount of perisinusoidal fibrosis (expressed as a percentage) significantly 
differed between groups and was significantly reduced in the salsalate treated group as 
compared to HFC group (7.5-fold decrease, p<0.05; Figure 2g). 
 
Salsalate affects expression of genes involved in lipid metabolism, 
inflammation and energy metabolism 
To further investigate the mechanism by which salsalate affects NASH development, 
transcriptome analysis of liver tissue was performed. Genes that were differentially 
expressed in the salsalate treated group relative to the HFC control group were used for 
analysis of biological processes. Enrichment analysis identified seventy biological process 
categories that were significantly changed by salsalate. A subset of these biological 
process categories, including several with relevance to NASH development, is shown in 
Figure 3a. The categories ‘Lipid Metabolism’, ‘Inflammatory Response’, ‘Energy 
Production’ and ‘Connective Tissue Disorders’ were found to be predominanty affected by 
salsalate treatment. We subsequently analyzed these four processes each in more detail 
by performing an upstream regulator analysis that determines the activation state (z-
score) of the transcription factors involved, based on the changes in expression of their 
target genes. For each category, the transcription factors that significantly affect a 
pathway and have relevance to NASH development are shown in Table 2. The 
transcriptomics analysis revealed that salsalate affected lipid metabolism by increasing β-
oxidation, as shown by the activation of PPAR-α, PGC1-β and RXR-α controlled genes. 
Especially PPAR-α is one of the most important transcription factors in lipid metabolism 
and activation promotes uptake and utilization of fatty acids by upregulation of genes 
involved in fatty acid transport, binding and activation, and peroxisomal and 
mitochondrial fatty acid β-oxidation. Furthermore, salsalate inhibited lipogenesis as 
shown by the inhibition of MLXIPL/ChREBP, the major transcription factor for activation of 
triglyceride synthesis. Inflammation was evidently inhibited by salsalate, since almost all 
transcription factors in the inflammatory response process were found to be inactive 
when compared with HFC. The NFκB pathway plays a central role in NASH development 




Most of the transcription factors in energy production were activated and in general the 
effects of salsalate were directed at mitochondrial activation and peroxisomal and 
mitochondrial β-oxidation. We also performed an upstream regulator analysis for the 
process ‘Connective Tissue Disorders’, since this might provide more insight in pathways 
contributing to the development of hepatic fibrosis. Salsalate inhibited most transcription 
factors in this category, including AP-1, an important regulator of differentiation, 
proliferation and apoptosis. Moreover, salsalate inhibited TGF-β signaling. TGF-β 
stimulates the proliferation and activation of fibroblasts, which deposit connective tissue 
and plays an important role in fibrosis. To investigate the effects of salsalate on expression 
of genes pertaining to fibrosis in more detail, a pathway analysis was performed (Figure 
3bcd). The significant expression changes upon salsalate treatment in genes belonging to 
generic sequence of events from liver injury to fibrogenesis are presented in Figure 3b and 
demonstrate the cell specific down-regulation of fibrogenic genes in the liver. More 
specifically, the early signaling events in hepatic stellate cells (Figure 3c), containing PDGF, 
TGF-β, IGF-1 and ET-1 and associated down-stream factors were down-regulated by 
salsalate. Furthermore, also in already activated stellate cells, salsalate was able to down-
regulate genes involved in fibrogenesis (Figure 3d). All together, these expression changes 




















































Figure 3: Enriched biological processes and hepatic fibrosis pathway analysis. A selection of significantly 
enriched biological processes (-log (p-value)) (A) in livers of APOE*3Leiden.CETP mice fed a high fat and high 
cholesterol diet supplemented with salsalate for 12 weeks relative to high fat and high cholesterol diet fed 
control group. Pathway analysis (B,C,D) showing statistically significant hepatic gene expression changes in 






Table 2: Hepatic gene expression. 
 
Effect of salsalate on hepatic gene expression involved in lipid metabolism, inflammatory response, energy 
production and connective tissue disorders. APOE*3Leiden.CETP mice received a high fat, high cholesterol diet 
with or without salsalate for 12 weeks. Data represent predicted activation state (z-score) of the upstream 
regulators, based on the expression changes of known target genes. The overlap p-value indicates the 
significance of the overlap between the known target genes of a transcription factor and the differentially 




Salsalate prevents hepatic fibrosis 
In a second experiment the HFC induction period of NASH was prolonged (to 20 weeks) to 
evaluate whether salsalate would still be able to prevent onset of NASH and liver fibrosis, 
also after a longer metabolic overload. Again salsalate treatment led to a significantly 
lower body weight, plasma insulin, cholesterol and triglycerides levels as compared the 
HFC control group (with -26%, -81%, -45% and -76%, respectively, all p<0.01; data not 
shown). Histological evaluation of the liver confirmed the results of the first experiment 
and demonstrated that salsalate attenuated NASH development in this experiment as 
well, also after the longer NASH induction period and at the lower dose used (Figure 4). 
Quantitative analysis showed that microvesicular steatosis and macrovesicular steatosis 
were significantly lower in the salsalate treated group as compared to the HFC group (with 
86%, p<0.05 and 98%, p<0.001, respectively; Figure 5ab).   
Activation z-score p-value of overlap Function
Lipid metabolism
PPARA 5.567 2.65E-86 Major regulator of lipid metabolism
PPARGC1B 2.724 7.19E-11 Involved in fat oxidation
RXRA 2.417 1.93E-35 Required for PPARA transcriptional activity on fatty acid oxidation genes
ESRRA 2.215 1.73E-11 Regulator of gluconeogenesis and fatty acid metabolism
NR5A2 2.065 2.34E-08 Regulator of cholesterol and bile acid metabolism
MLXIPL -2.194 3.82E-05 Activator of triglyceride synthesis
SERTAD2 -2.000 4.43E-04 Modulates fat storage by down-regulating adipocyte lipolysis
Inflammatory response
NFkB (complex) -6.676 1.40E-43 Key regulator of immune and inflammatory responses
NFKB1 -3.427 1.46E-29 DNA binding subunit of the NFkB protein complex
NFATC2 -3.313 5.31E-11 Pays a central role in inducing gene transcription during the immune response
IRF1 -3.252 1.33E-15 Regulator of immune response, apoptosis and DNA damage
NFKBIA -3.186 4.70E-32 Inhibitor of NFkB
REL -3.064 5.83E-12 Important role in B-cell survival and proliferation
CEBPD -2.883 1.54E-10 Regulator of immune and inflammatory responses
RELA -2.862 8.80E-36 Involved in NFκB heterodimer formation, nuclear translocation and activation
Nfat (family) -2.611 1.09E-03 Family of transcription factors important in immune response
USF2 -2.567 6.67E-05 Binds to a symmetrical DNA sequence that is found in viral and cellular promoters
SQSTM1 -2.566 1.93E-06 Activator of the NFkB signaling pathway
STAT1 -2.175 4.63E-25 Important for cell viability in response to different cell stimuli and pathogens
Energy production
PPARA 4.788 4.19E-39 Regulates the peroxisomal beta-oxidation pathway of fatty acids
INSR 4.588 1.33E-23 Insulin receptor that plays a key role in the regulation of glucose homeostasis
ESRRA 3.069 9.85E-16 Regulator of mitochondrial biogenesis and oxidative phosphorylation
PPARGC1A 2.729 6.67E-19 Regulator of mitochondrial biogenesis and function.
PPARGC1B 2.592 1.65E-08 Involved in non-oxidative glucose metabolism and energy expenditure
FOXO1 2.400 1.89E-09 Regulator of gluconeogenesis and glycogenolysis by insulin signaling
PCK1 -2.646 2.94E-13 Main control point for the regulation of gluconeogenesis
SERTAD2 -2.000 2.08E-06 Inhibitor of thermogenesis and oxidative metabolism
Connective tissue disorders
SMAD7 2.054 9.33E-12 Inhibitor of TGF-β signaling
TGFB1 -3.838 2.90E-52 Controls cell growth, cell proliferation, cell differentiation and apoptosis
SMAD3 -2.758 1.12E-11 Regulator of TGF-β mediated transcription
STAT3 -2.558 6.13E-17 Key regulator for cell growth and apoptosis























Figure 4: Histological photomicrographs of NASH in mice. Liver histological cross-sections from 
APOE*3Leiden.CETP mice fed a high fat and high cholesterol diet (HFC) or a high fat and high cholesterol diet 
supplemented with salsalate (HFC+S) for 20 weeks.  Upper photomicrographs: Hematoxylin and eosin (H&E); 
lower photomicrographs: Sirius Red staining; magnification 200x. 
 
 
Also lobular inflammation, quantified as the number of inflammatory aggregates, was 
significantly lower in the salsalate treated group relative to the HFC group (with -87%, 
p<0.001; Figure 5c). Twenty weeks of HFC feeding resulted in distinct fibrosis located in 
perisinusoidal/perivenular and periportal area (Figure 4; Sirius Red staining). In all animals 
at least some periportal and perisinusoidal fibrosis was seen (stage 2), but the extent of 
perisinusoidal fibrosis was profoundly reduced by salsalate treatment (4.1-fold decrease, 
p<0.01; Figure 5d). We also analyzed fibrosis quantitatively by measuring the ratio of 
hydroxyproline (as a measure for collagen) above proline (as a measure for total protein). 
The hydroxyproline/proline ratio was significantly lower (with 33%, p<0.01) in the 
salsalate treated group as compared to the HFC group (Figure 5e). Collectively, these data 
demonstrated that salsalate was able to attenuate different aspects of NASH, which are 






















Figure 5: Hepatocellular steatosis, inflammation and fibrosis. Quantitative analysis of non-alcoholic 
steatohepatitis in APOE*3Leiden.CETP mice fed a high fat and high cholesterol diet (HFC) or a high fat and high 
cholesterol diet supplemented with salsalate (HFC+S) for 20 weeks.  Microvesicular (A) and  macrovesicular (B) 
steatosis as percentage of total liver area, inflammatory foci per microscopic field (C), percentage perisinusoidal 
fibrosis (D), and the hydroxyproline/proline ratio (E)  were analyzed. Data are mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001. 
 
     
DISCUSSION  
 
In this study, we demonstrate for the first time that the treatment of obese, dyslipidemic 
and insulin-resistant E3L.CETP mice with salsalate markedly ameliorates diet-induced non-
alcoholic steatohepatitis and reduces the development of hepatic fibrosis. Bio-informatics 
analysis of the gene expression data identified regulatory pathways and upstream 
regulators in the liver that are specifically influenced by salsalate. 
    Surprisingly, hardly any preclinical or animal studies have been performed to evaluate 
the potential of salsalate as a treatment for NASH and liver fibrosis, although its utility in 
the prevention or management of a wide range of vascular disorders as well as of type 2 
diabetes and metabolic syndrome and NAFLD has been suggested before [23, 24]. Only 
one study showed that salsalate can ameliorate hepatic steatosis in rats that were fed a 
high fat diet [25]. In this study rats received a high fat diet for 8 weeks and the salsalate 
treated group received salsalate mixed in the high fat diet for an additional 6 weeks. The 
authors did not report whether inflammation was induced by the diet nor the effects of 
salsalate there upon, but the duration of the diet was probably too short in this model to 







confirm the beneficial effects of salsalate on steatosis. In addition, in our mouse model we 
were able to model not only steatosis, dyslipidemia and insulin resistance, but also hepatic 
inflammation and the natural progression of NASH to fibrosis, and we demonstrated the 
beneficial effects of salsalate on all these different aspects of NASH. 
    The mechanisms responsible for the beneficial metabolic effects of salsalate are not 
fully defined. The anti-inflammatory effects are believed to be attributable to inhibition of 
pro-inflammatory mediators such as the prostaglandins [1], but also inhibition of 
neutrophil activation has been reported as an alternative mechanism [27]. Inhibition of 
the NFκB inflammatory pathway by salsalate has been shown in several rodent studies 
[25, 28] as well as in humans [5]. In addition, studies in humans have shown that salsalate 
can increase resting energy expenditure [5, 29]. Our data support the notion that salsalate 
inhibits the NFκB pathway and corroborate the increase in energy metabolism. 
Furthermore, our data revealed an important role for PPAR-α mediated pathways with 
regard to the beneficial effects of salsalate on lipid metabolism. 
    Recent clinical studies have shown that salsalate improved inflammatory parameters, 
glycemica and insulin resistance in pre-diabetic and type 2 diabetic patients [6, 30]. 
Furthermore, a few clinical trials have been performed that investigated the impact of 
salsalate on vascular function [31] and currently a clinical trial is being performed that is 
using salsalate to target inflammation in cardiovascular disease (TINSAL-CVD study). In the 
latter trial, salsalate will be given for 30 months in participants with cardiovascular 
disease. This trial is estimated to be completed in 2015 and will provide information of the 
effects of salsalate in relation to NAFLD/NASH as well, since as a secondary outcome 
measure, the effects of salsalate on fatty liver via computerized tomography and on levels 
of AST and ALT will be evaluated. Although the pleiotropic effects of salsalate, i.e. anti-
inflammatory effects and recently described beneficial effects on lipid and glucose 
metabolism, renders salsalate an excellent candidate for treatment of NASH, not many 
designated clinical studies have been performed that evaluate the potential beneficial 
effects of salsalate on NASH. To our knowledge, only one clinical study aiming to find 
effects of salsalate on NASH has been reported [32]. In this study salsalate did not change 
severity of fatty liver nor ALT and AST levels. However, the treatment period was only one 
month and salsalate did not affect blood glucose and triglyceride levels, while several 
other studies have reported significant decreases in plasma glucose and triglyceride levels 
upon salsalate treatment [6, 31]. 
    In summary, we reproduced NASH development with progression to fibrosis in HFC fed 
APOE*3Leiden.CETP mice, a model that is characterized by obesity, metabolic anomalies 
and histopathological features similar to those observed in human NASH. In this model, 
salsalate exerted a preventive effect on the development of NAFLD and progression to 
steatohepatitis and fibrosis. We infer that salsalate may be pharmacologically useful for 
preventing the progression of steatohepatitis and fibrosis, and a promising therapeutic 
agent for human NASH. Further clinical studies are warranted to investigate the putative 
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Supplemental Figure 1: Lipoprotein profile. Lipoprotein profiles of APOE*3Leiden.CETP mice a low fat diet (LFD), 
a high fat and high cholesterol diet (HFC) or a high fat and high cholesterol diet supplemented with salsalate 
(HFC+S) for 12 weeks. The distribution of cholesterol over the individual lipoprotein profiles in pooled plasma 
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Background: Chronic metabolic overload results in lipid accumulation and subsequent 
inflammation in white adipose tissue (WAT), often accompanied by non-alcoholic fatty 
liver disease (NAFLD). In response to metabolic overload, the expression of genes involved 
in lipid metabolism and inflammatory processes is adapted. However, it still remains 
unknown how these adaptations in gene expression in expanding WAT and liver are 
orchestrated and whether they are interrelated. 
Methodoloy/Principal Findings: ApoE*3Leiden mice were fed HFD or chow for different 
periods up to 12 weeks. Gene expression in WAT and liver over time was evaluated by 
micro-array analysis. WAT hypertrophy and inflammation were analyzed histologically. 
Bayesian hierarchical cluster analysis of dynamic WAT gene expression identified groups 
of genes (‘clusters’) with comparable expression pattern over time. HFD evoked an 
immediate response of five clusters of ‘lipid metabolism’ genes in WAT, which did not 
further change thereafter. When the storage capacity of WAT became exceeded (>6 
weeks), inflammatory clusters were induced. Promoter analysis of clustered genes 
resulted in specific key regulators which orchestrate the metabolic and inflammatory 
responses in WAT. Some master regulators played a dual role in control of metabolism 
and inflammation. When WAT inflammation developed (>6 weeks), genes of lipid 
metabolism and inflammation became also affected in corresponding livers. These hepatic 
gene expression changes and, in particular the underlying transcriptional responses, were 
remarkably similar to those detected in WAT. 
Conclusion: In WAT, metabolic overload induced an immediate, stable response on 
clusters of lipid metabolism genes and induced inflammatory genes later in time. Both 
processes were controlled and interlinked by specific transcriptional regulators. When 
WAT inflammation began, the hepatic response to HFD resembled that in WAT. In all, 
WAT and liver respond to metabolic overload by adaptations in expression of gene 










The obesity epidemic has become the most important nutritional problem worldwide. The 
increasing prevalence of obesity has been ascribed to excessive and unhealthy eating and 
reduced physical activity [1] and carries with it increased risks for type 2 diabetes (T2DM) 
and non-alcoholic fatty liver disease (NAFLD) [2-4]. Notably, the existence of metabolic 
pathways that allow excess energy to be stored as fat suggests that obesity may 
realistically be viewed as a biological adaptation in times of energy surplus. However, in 
case of prolonged excess energy supply white adipose tissue (WAT) capacity may 
exceeded [5, 6] and the liver may serve as an alternative depot for free fatty acids [7, 8]. 
The resulting metabolic overload of the expanding WAT and subsequently liver is 
accompanied by local metabolic stress and triggers tissue inflammation [9].   
    Several studies in mice have demonstrated that the expression of genes of lipid 
metabolism and inflammation is adjusted in several organs in response to chronic high-fat 
diet (HFD) feeding [10-12]. These studies are often static and focus on a single organ 
which is analyzed at one particular time point, typically at a later stage in the disease 
process when histopathological effects of HFD can be detected (e.g. crown-like structures 
in WAT, inflammatory gut, hepatic steatosis). Accordingly, many gene expression studies 
and sophisticated microarray analyses link late stage histological outcomes to gene 
expression changes of the same (late) time point. However, significant effects on gene 
expression are likely to start early and change over time. Hence, there is limited 
understanding of the early events in expanding WAT and in what way lipid metabolism is 
related to the onset of inflammation during obesity development. Some studies 
investigated the expression changes of individual inflammatory genes and pathways over 
time [13-15], but they did not explore whether groups of genes (‘gene clusters’) change in 
concert and thus do not provide insight into the global adaptations and possible common 
transcriptional regulation of clustered genes. 
    Bayesian hierarchical cluster analysis [16] allows global analysis of dynamic gene 
expression data of thousands of genes simultaneously to find patterns in the data that are 
not predicted by the experimenter’s current knowledge or preconceptions. For instance, 
complex gene expression time series can be analyzed to identify genes with similar 
expression patterns that group into clusters because of common transcriptional regulation. 
Cluster analysis of the expanding WAT requires dynamic high-quality microarray datasets 
with multiple early time points, which are scarce [13]. In the present study we 
investigated two important processes in WAT expansion using cluster analysis: the global 
adjustment of genes of ‘lipid metabolism’ and the induction of ‘inflammatory genes’, and 
their interrelationship. Because transcriptional control mechanisms are instrumental for 
adjustment of lipid metabolism as well as inflammatory gene expression [17], we 
examined whether the genes of the identified clusters share common transcriptional 
regulation, viz. via key master regulators.  
    Metabolic overload of WAT upon HFD feeding is, at a later stage, supposed to be 
accompanied by multiple metabolic and inflammatory effects in the liver [7]. It is 
presently unknown whether the effects on genes of metabolism and inflammation are 




    WAT and liver tissues and corresponding dynamic genomics datasets from a 12- week 
HFD feeding experiment [13] in APOE*3Leiden transgenic mice were used. APOE*3Leiden 
mice have a humanized lipoprotein metabolism and develop obesity, insulin resistance 
and NAFLD during HFD feeding [18-20]. Bayesian cluster analysis in conjunction with 
promoter analysis and biochemical measurements showed that adjustment of lipid 
metabolism and onset of inflammation in WAT occurs sequentially and is orchestrated by 
specific master regulators that also control comparable changes in lipid metabolism and 
inflammation in the liver later in time. 
 
 
MATERIALS AND METHODS  
Mouse study and micro-array data 
Tissues and micro-array data from a larger time course study in APOE*3Leiden mice in the 
context of HFD-induced insulin resistance were used [13]. These micro-array datasets 
(liver and WAT) are freely available on ArrayExpress at the following URL 
http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1039/. Animal experiments 
were approved by the Institutional Animal Care and Use Committee of The Netherlands 
Organization for Applied Scientific Research (TNO), and were in compliance with European 
Community specifications regarding the use of laboratory animals as reported [13]. 
Briefly, 12 weeks old mice were fed HFD containing (all w/w) 24% fat from beef tallow (of 
which 12% saturated fatty acids), 24% casein and 20% dextrose (diet number 4031.05; 
Hope Farms, Woerden, The Netherlands; metabolizable energy: 19.4 MJ/kg; exact diet 
composition is provided in Table S1) for 12 weeks [13]. Mice were sacrificed at t=0 and 
after 1, 6, 9 and 12 weeks of HFD feeding (n=15/group). Epididymal adipose tissue and 
corresponding livers of a subset of animals (n=8) per time point were used for microarray 
analysis. Our present data are from this subset of animals. A separate control group (n=6) 
was fed chow (sniff® R/M-H; metabolizable energy: 12.8 MJ/kg; Sniff Spezialdiäten GmbH, 
Soest, Germany) for the entire study period and served as a reference for the effect of 
aging. 
 
Histological analysis of tissues  
Paraffin-embedded sections of adipose tissue and liver were used for 
(immuno)histological examination [13]. Liver tissue sections were 5 µm thick and stained 
with hematoxylin phloxine saffron (HPS). Non-alcoholic fatty liver disease was analyzed as 
described [21] and vacuolization (micro- and macrovaculolization) and hepatocellular 
hypertrophy were scored. Sections of epididymal adipose tissue were prepared following 
a similar procedure [22] and stained with HPS for computer-assisted morphological 
assessment of adipocyte size and analysis of macrophage accumulation in crown-like 
structures essentially as reported [20]. CCR2 positive cells were detected using antibody 
(Abcam ab21667, Cambridge, UK). 
 
Microarray data analysis and Bayesian hierarchical clustering   
Quality control analyses and specific protocols for RNA extraction, RNA integrity 




quality control of microarray data was performed using BioConductor packages including 
simpleaffy and affyplm, through the NuGO pipeline that is available as a Genepattern 
procedure on http://nbx2.nugo.org [24]. Thirty-eight adipose tissue samples passed the 
quality control criteria and raw signal intensities (from CEL files) were normalized using 
the GCRMA algorithm (gc-rma slow). Probesets were remapped and annotated into Entrez 
gene-ids using the custom MBNI CDF-file, version 9.0.1. The final dataset contained the 
expression values of 12492 adipose tissue genes represented by unique Entrez gene-ids 
[25]. Expression data were logtransformed for further analysis of gene expression levels. 
Microarray gene expression data were confirmed by quantitative real-time PCR for a 
selection of genes using established protocols and primer/probe sets [13].  
    For this study, two sets of genes with either lipid metabolism ontology (n=235) or 
inflammation ontology (n=216) were defined. These genes were differentially expressed 
at one or more time points (q<0.05 ANOVA) and are listed in Table S2. The time course 
expression data of these genes was subjected to Bayesian hierarchical clustering to 
structure the data and identify distinct clusters of genes with comparable expression 
profiles [26].  
 
Gene enrichment analysis 
Changes in gene expression were visualized using GeneSpring GX version 10.0 (Agilent 
Technologies, Santa Clara, CA, USA) and this tool was also used to show the identified 
gene clusters. An enrichment analysis was performed for the gene lists of each cluster 
using the DAVID functional enrichment tool [27]. Default settings for enrichment analysis 
in DAVID were used. The total list of genes was used as input and the most enriched 
functional gene sets (based on Gene Ontology ‘protein domains and pathways’) are 
reported. These functional gene sets contain at least three genes from a particular gene 
cluster and are more enriched in the cluster than in the input data set (% genes in cluster 
≥ 1.3 x % genes in input gene list). 
    To define the transcription factors that are responsible for control of a particular cluster 
of genes, the genes of each cluster were subsequently analyzed in Bibliosphere 
(Genomatix GmbH, Munich, Germany) with respect to a) shared transcription factor 
binding sites in their promoter regions and b) co-citation analysis (level B2, co-citation 
restricted to sentences with a function word). Promoters were defined as 500 bp 
upstream and 100 bp downstream of the Transcription Start Site of the gene transcript. 
Default settings of the software were used to perform an overall analysis of the promoters 
of the genes for common transcription factors. The following criteria were used to define 
the key transcription factors: a) the transcription factor binding sites have to be present in 
at least three genes of a cluster and b) are more frequently found in the genes belonging 
to the cluster of interest than in the total list of input genes (%genes in cluster ≥ 1.3 x % 
genes in input gene list). 
 
Comparison of gene expression changes in adipose tissue and liver  
Liver and white adipose tissue (WAT) were compared with respect to differentially 
expressed genes (DEGs relative to the zero time point) and Venn diagrams were prepared 
to illustrate overlapping genes. A cutoff of FDR P-value < 0.05 was used to define DEGs in 




    The upstream regulator analysis function of Ingenuity Pathway Analysis (IPA) software 
and the Ingenuity knowledge base were used to analyze the relationship between 
upstream transcription factors and expression changes of target genes. To test whether a 
particular transcription factor identified in WAT was also involved in the liver, we analyzed 
the hepatic transcriptome for differentially expressed target genes of this transcription 
factor. A P-value P<0.05 indicated that more liver target genes were differentially 
expressed than expected by chance. Ingenuity Pathway Analysis was also used to test 
whether a particular transcription factor is activated (positive Z-score >2) or inhibited 
(negative Z-score <-2) based on the direction of gene expression changes of its target 
genes.  
 
Transcription factor analysis 
Biochemical transcription factor activity was determined in liver homogenates essentially 
as previously described [13, 28], using TransAM® kit Hnf4α (no. 46296, Active Motif 
Europe, Rixensart, Belgium). Briefly, liver homogenates were prepared using the Nuclear 
Extract Kit (no. 40010, Active Motif, Rixensart, Belgium). Equal amounts of protein (10 
μg/well) of the liver homogenates were used to determine the amount of active 
transcription factor. Control tissues of reference mice on chow were used to correct for 




HFD feeding of APOE*3Leiden mice results in obesity and onset of white 
adipose tissue inflammation 
APOE*3Leiden mice had an average body weight of 29.2 ± 2.6 g at the start of the 
experiment (t=0). Animals became obese during HFD feeding and gradually gained 8.30 ± 
2.0 g of weight during the experimental period of 12 weeks (Figure 1A) while body weight 
of control mice on chow remained stable (0.23 ± 0.63 g weight gain; not shown). The daily 
energy intake per mouse was comparable between the groups fed HFD (15.0 ± 0.9 
kcal/day) and chow (14.6 ± 3.0 kcal/day). The HFD-evoked increase in body weight was 
accompanied by an increase in WAT mass as exemplified by epididymal fat mass (Figure 
1B). Histological analysis of epididymal WAT revealed a significant increase in adipocyte 
size upon HFD feeding relative to chow-fed controls (4431 ± 140 versus 1665 ± 310 µm
2
; 
P<0.005) demonstrating adipocyte hypertrophy during fat accumulation and obesity 
development (Figure 1C/1D). In HFD fed mice, immune cells accumulated in WAT at 12 
weeks and first crown-like structures were observed (Figure 1C/1E) pointing to an onset 
of WAT inflammation. Immunochemical analysis demonstrated that accumulating cells in 
HFD-treated mice were Ccr2-positive (Figure 1E) while Ccr2-positive cells were hardly 
found in age-matched chow control mice. Together, these data demonstrate that 12 
weeks of HFD feeding in ApoE*3Leiden mice resulted in metabolic changes (lipid storage 








Figure 1: HFD feeding leads to obesity and onset of adipose tissue inflammation. APOE*3Leiden transgenic 
mice were fed a HFD for 12 weeks and sacrificed at the time points indicated. The average body weight at the 
start (t=0) of HFD feeding was 29.2 g. A, Body weight gain over time. B, Mass of the epididymal adipose tissue 
depot during obesity development. Data are presented as mean ± SEM. C, Histological analysis of adipose tissue 
at start (t=0) and after 12 weeks of HFD or chow feeding (reference for the effect of aging). D, HFD feeding 
results in adipocyte hypertrophy. Computer-assisted quantification of average adipocytes size (P<0.05). E, 
Marked accumulation of CCR2 positive cells (arrows) in the HFD fed group. 
 
 
Identification of genes with a similar time profile during HFD feeding 
To gain insight into the global effects of HFD feeding on metabolism and inflammation in 
WAT, two sets of genes (i.e. 235 genes with ‘lipid metabolism ontology’ and 216 genes 
with ‘inflammation ontology’ as defined in Table S2 and Methods) were subjected to 








grouped into gene clusters based on a concerted dynamical expression over time. Genes 
with a comparable expression pattern across time grouped into specific clusters: Six 
clusters of lipid metabolism genes (Figure 2) and four clusters of inflammatory genes 
(Figure 3) were defined. Each cluster showed a distinct and specific time profile suggesting 
that genes within a cluster share common transcriptional regulation.  
    Overall, HFD feeding had an early effect on the genes of lipid metabolism and most 
gene expression changes already occurred within the first week. The majority of the genes 
of ‘lipid metabolism’ clustered in cluster B and C (165 out of 235). After a slight 
adjustment in gene expression in week 1, these genes hardly changed over time (Figure 
2). The expression changes were somewhat more pronounced in other lipid gene clusters 
(A, D, E and F), but the main effect also occurred in the first week. It is striking that most 
‘lipid metabolism’ genes are rapidly adjusted in the first week and do not adapt to any 
further extent at the later time points, even when WAT hypertrophy and inflammation are 
developing. Table 1 shows that the genes of clusters with somewhat more dynamic 
expression patterns can be assigned to specific biological processes (gene enrichment 
analysis). For instance, the genes of cluster A were associated with sphingolipid and 
ceramide metabolism.  

























Figure 2: Cluster analysis of genes of lipid metabolism. Bayesian cluster analysis of genes with ‘lipid metabolism’ 
gene ontology resulted in 6 clusters (A, B, C, D, E, and F) with distinct time profiles. Individual gene expression 



























Figure 3: Cluster analysis of inflammatory genes. Bayesian cluster analysis of genes with ‘inflammation’ gene 
ontology resulted in 4 clusters A, B, C and D with distinct time profiles. Individual gene expression profiles are 
shown as dotted lines. The bold line represents the cluster average. 
 
 
    In contrast to the genes involved in lipid metabolism, the mRNA expression level of 
inflammatory genes increased markedly after week 6 (inflammation clusters C and D in 
Figure 3). This suggests that factors encoded by these genes may reflect or contribute to 
the observed onset of WAT inflammation. Indeed, among the upregulated genes were the 
complement factors C1qa, C1qb, C1qc, C3a receptor-1 and C5a receptor-1, the cytokines 
Cxcl1/KC, Ccl5/Rantes, Ccl6, Ccl7/Mcp3 and Ccl9/Mrp2, the inflammation markers 
orosomucoid-1, orosomucoid-3, granzyme A and neutrophil cytosolic factor 1 
(Nrf1/p47/phox), the macrophage-associated markers CD11b/Mac1, CD11c, 
CD18/integrin beta-2, the inflammasome component ASC and the chemokine CXC motive 
receptor-2 (Ccr2), which is consistent with the observed accumulation of Ccr2-positive 
cells. Gene enrichment analysis confirmed that these genes belong to processes that 
promote WAT inflammation such as leukocyte mediated immune response, cytokine 
activity, complement activation, acute inflammatory response, and cell adhesion (Table 
2). Some of the genes encode for inflammatory factors that can be secreted into plasma 








Prediction of transcription factors that control the WAT response to HFD 
feeding 
To identify transcription factors that can orchestrate the observed changes in gene 
expression profiles in WAT, we analyzed the promoter regions of clustered genes to 
identify putative common (shared) transcriptional regulators (last column of Tables 1 and 
2). Transcriptional binding sites for Jun, Sp1, Stat1, Nfĸb and Pparγ were frequently 
identified in the promoter regions of the ‘lipid metabolism’ genes in cluster A, i.e. the 
genes that are related to sphingolipid and ceramide metabolism. Srebf1, Srebf2, Pparγ 
and Hnf4α were identified as common regulators of the ‘lipid metabolism genes’ of cluster 
F. Transcriptional master regulators of the inflammatory genes in cluster D are Pparγ, 
Sfpi1, Stat6 (cluster C), and Sp1, Fos, Vdr, Esr1, Creb1, Gata1, Smad2 (Table 2).  
 
 
Table 1: Genes of lipid metabolism with dynamic changes over time. Only the genes of cluster A, D, E and F 
show dynamic changes in expression during the study period. The pattern of the expression changes is described 
in the second column. Gene clusters are associated with specific biological processes (obtained by gene 
enrichment analysis) and clustered genes share common transcriptional regulators. These common transcription 
factors were predicted by promoter analysis and are listed in the last column. 
 
Cluster Pattern of time profile Enrichment analysis of biological processes TF 
Cluster A: 20 genes slight decrease in week 1; Sphingolipid metabolic process Jun 
 slight increase > week 9 Ceramide metabolic process Sp1 
   Stat1 
   Nfĸb1  
   Pparγ        
Cluster D: 29 genes slight increase in week 1 Steroid biosynthetic process Pparα       
  Cholesterol biosynthetic process Nfĸb1 
  Cholesterol metabolic process Pparγ       
  Isoprenoid metabolic process  
  Oxidoreductase activity  
Cluster E: 11 genes Continuous decrease Steroid metabolic process Esr1          
  Hormone metabolic process Stat5β 
  Reproduction  
  Oxidoreductase activity  
Cluster F: 10 genes pronounced increase in Cholesterol absorption Srebf2 
 week 1, then slight increase Cholesterol metabolic process Nr1h2 
  PPAR signaling pathway Pparγ 
  Lipid binding Srebf1 
  Lipid transport Hnf4α 
  Lipoprotein metabolic process Sp1 
  Glucose metabolic process Nr1h3 






Table 2: Inflammatory genes with dynamic changes over time. The genes of cluster C and D are characterized 
by dynamic changes in expression during HFD feeding. The pattern of the expression changes is described in the 
second column. Gene clusters are associated with specific biological processes (obtained by gene enrichment 
analysis) and clustered genes share common transcriptional regulators.  Common transcription factors (TF) 
predicted by promoter analysis are provided in the last column. 
 
Cluster Description Enriched processes TF  
Cluster C: 34 genes slight decrease in first  Inflammatory response; Pparγ 
 week; pronounced  Leukocyte mediated immune  Sfpi1 
 increase >week 8   response; Stat6 
  Cytokine activity; Pax5 
  Extracellular region; Etv6 
  B cell mediated immunity; Pparα 
  Complement activation  
Cluster D: 25 genes slight increases early  Inflammatory response; Sp1 
 in time; pronounced  Acute inflammatory response; Fos 
 increase >week 6 Extracellular space; Creb1 
  Cytokine activity; Myc 
  T cell proliferation; Vdr 
  Cell adhesion Rarα 
   Esr1 
   Ar 
   Gata1 
   Smad2 
    Of note, some transcription factors like Pparγ, Esr1 and Sp1 have a dual role and 
regulate the expression of genes involved in lipid metabolism and inflammatory genes 
indicating that these transcription factors operate at the interface of metabolism and 
inflammation which are thus molecularly interlinked at the level of transcription.   
 
 
Key regulators predicted in WAT are also involved in altered liver gene 
expression 
The livers of the same mice used for the above WAT analysis were examined histologically 
and using microarrays. Figure 4 shows that HFD feeding but not chow feeding resulted in 
pronounced micro- and macrovacuolization as well as hepatocellular hypertrophy, 
demonstrating onset of NAFLD at 12 weeks. Analysis of hepatic gene expression revealed 
that the genes of lipid metabolism and inflammatory genes were hardly affected until 
week 6 but thereafter (Figure 5A/5B). To evaluate whether this response to HFD feeding 
is related to the effects observed in WAT, we compared the gene expression changes in 
both tissues over time.  
    Until week 6, only a few differentially expressed genes were found in both tissues, but 
the number and percentage of common genes (see intersections of Figure 5A and 5B) 
strongly increased in week 9 and 12, i.e. when WAT becomes overloaded and expression 




concept that WAT serves as a first buffer to cope with metabolic overload and that the 
hepatic response is delayed and resembles that of WAT when the storage capacity of WAT 
is exceeded [5, 6]. At week 12, more than 50% of the liver genes with ‘lipid metabolism’ or 
‘inflammation’ ontology are also affected in WAT. Analysis of all DEGs irrespective of their 
ontology confirms the relationship between both tissues (245 genes in intersection, 484 
liver-specific, 784 WAT-specific in week 12; data not shown). 
    At the level of transcriptional regulators, the response of both tissues was even more 
comparable as demonstrated by Bayesian clustering analysis and, as an alternative 
approach, analysis of target genes. Cluster analysis showed that the gene expression 
changes until week 9 were modest in liver in comparison with WAT (Figure S1). Similar to 
WAT, some clusters showed an immediate response to HFD and gene expression did not 
further change thereafter. Lipid metabolism gene cluster D in the liver had a comparable 
profile to cluster F of WAT and the predicted transcriptional regulators (Pparγ, Nr1h2, 
Srebf2, Hnf4α, Nr1h3) were the same. The predicted transcriptional regulators for the 
inflammatory genes of cluster C in the liver (Ar, Creb1, Esr1, Fos, Myc, Pparγ, Rarα, Sfpi1, 
Stat6) also overlapped with those predicted for inflammatory genes in WAT.  
 
Figure 4: Histological analysis of livers. Hallmarks of non-alcholic fatty liver disease were scored in the livers of 
the mice that were used for WAT analysis. A, Representative photomicrographs of liver cross-sections after 12 
weeks of HFD shows pronounced liver steatosis characterized by micro- and macrovacuolization and 
hepatocellular hypertrophy. B, Quantitative analysis of total vacuolization and hypertrophy. Data are presented 
as mean ± SEM. *P<0.05. 
 
 
    In addition to this, we analyzed the target genes of the master regulators predicted in 






of the effect on target gene expression showed that the transcription factors Hnf4α, Esr1, 
Fos, Myc, Pparα, Pparγ, Srebf1 and Srebf2 affected their target genes significantly (all 
P<0.05), and Creb1 and Jun with borderline significance (P=0.07). Biochemical analysis of 
the transcriptional binding activity of Hnf4α in liver protein homogenates confirmed its 
activation (Figure 5C). Of note, a particular transcription factor may affect a different set 
of genes in WAT and the liver as illustrated in Figure 5D for Srebf2.  
Figure 5: Comparison of gene expression in liver and WAT over time and analysis of transcriptional regulators. 
Venn diagrams of genes with A, ‘lipid metabolism’ gene ontology or B, ‘inflammation’ gene ontology. Time 
course analysis of the genes that were differentially expressed genes at a particular time point. The intersection 
represents the number of ‘overlapping genes’, ie. genes that were affected in both tissues. C, Quantitative 
analysis of the transcriptional activity of HNF4α by TransAM analysis at t=0 and t=12 weeks of HFD feeding 
relative to reference mice on chow to correct for aging. *P<0.05. D, Differentially expressed target genes of 
Srebf2 in WAT and liver. Srebf2 is significantly involved in the control of target genes (P<0.05 for both WAT and 
liver). In both tissues, the calculated Z-score was positive (3.7 for liver and 4.3 for WAT) indicating that Srebf2 is 







    Overall, the gene expression effects evoked by HFD in WAT and liver become 
increasingly comparable showing similar transcriptional responses in both tissues. This 
indicates that the factors that sense metabolic overload are highly conserved among 





The effect of metabolic overload on WAT and liver was analyzed in a mouse model that 
responds to HFD feeding with WAT expansion, metabolic stress, inflammation and 
development of NAFLD. Using Bayesian hierarchical clustering we showed that the 
expression of genes of lipid metabolism is rapidly adjusted upon HFD feeding (already 
within one week). Cluster analysis revealed that these genes hardly change in expression 
later in time, despite the observed pronounced WAT expansion and the onset of 
inflammation from week 6 onward. By contrast, many inflammatory genes strongly 
increase in their expression at >6 weeks (e.g. inflammatory clusters C and D), and these 
genes also encode for inflammatory factors that can be secreted into the circulation. This 
inflammatory response is observed when adipocytes become hypertrophic suggesting 
that adipose tissue expandability becomes inadequate and the storage capacity of WAT 
reaches its limit [5, 6]. Promoter analysis defined a rather small set of about 25 
transcriptional master regulators including Pparγ, Hnf4α, Sp1, Jun/Fos, Esr1, Srebf2, 
Nr1h2, Sfpi1, Fos, Smad2, Sp1, Gata1 that orchestrate the adaptation of lipid metabolism 
and induce inflammation. Some of the identified transcription factors (Pparγ, Esr1, 
Jun/Fos) control the adjustment of lipid metabolism-related and inflammatory genes 
supporting the view that metabolism and inflammation are molecularly interlinked in WAT 
[29].  
    Notably in liver, only a small number of genes of lipid metabolism and inflammation are 
affected up to week 6. Thereafter, when WAT has become inflamed, a marked increase in 
the number of differentially expressed genes involved in hepatic lipid metabolism and 
inflammation was observed. Comparison of liver and WAT revealed a remarkable overlap 
in gene expression and transcriptional regulation at >6 weeks. Together this shows that 
HFD feeding results in rapid adaption of WAT lipid metabolism which is not further 
adjusted during fat storage. When WAT inflammation begins, the gene expression and 
transcriptional responses of WAT and liver start to resemble each other. This indicates 
that the fundamental principles of how metabolically active organs cope with HFD 
overload are conserved. 
    We found that Pparγ [30], Srebf1 and Srebf2 [31], and Nr1h3/Nr1h2 (also referred to as 
Lxrα/Lxrβ [32, 33] may explain the observed gene expression changes. Indeed, these 
transcription factors are well-established regulators of lipid metabolism and their 
identification confirms the validity of the approach applied. The ‘lipid metabolism’ genes 
with the largest changes grouped in lipid gene cluster F. Genes in this cluster are not only 
involved in lipid metabolism but also in lipid absorption and glucose metabolism and could 
reflect a reprogramming of WAT from early time points onward to cope with HFD 
overload. Potential transcription factors regulating this reprogramming include Srebf1, 




transcription factor HNF4α as a regulator of energy metabolism in human adipose tissue 
[34], and activation of LXRα and LXRβ has been shown to affect lipid and glucose 
metabolism as well as the inflammatory state simultaneously [28, 35]. 
    We also identified several transcription factors typically associated with inflammation 
(Jun, Stat1, Stat5β) in the promoter elements of genes associated with general 
sphingolipid metabolism and, more specifically, ceramide metabolism. This finding 
supports the notion that molecular links exist between lipid metabolism and inflammatory 
signaling cascades and that these processes are interlinked and hence, may influence each 
other [23, 29, 36]. Boini and coworkers have shown that HFD-treated mice have increased 
levels of ceramide in WAT and in plasma [37, 38]. In another study, the ceramide 
concentrations in human WAT were positively correlated with the inflammatory state of 
the tissue, independent of obesity [39].  
    The inflammatory/immune response genes of the inflammatory gene clusters C and D 
showed a pronounced increase in expression from week 6 onward. One of the genes 
encodes for Ccl5/Rantes which promotes macrophage recruitment in adipose tissue [40]. 
Indeed, the gene expression levels of CD11b/Mac1, a marker expressed on macrophages 
and neutrophils, were also increased showing a similar time pattern. Of note, the 
expression of another inflammatory gene, Cxcl1/KC, intensified also from week 6 
onwards. This coincides with the development of insulin resistance in WAT of 
APOE*3Leiden mice under the experimental conditions employed herein [13]. Cxcl1/KC 
stimulates the infiltration of neutrophils into WAT [41] and represents the mouse ortholog 
of human interleukin-8, but the exact role of this factor in the pathogenesis of insulin 
resistance remains to be established. The observation that neutrophil cytosolic factor 1 
(Nrf1/p47/phox) expression levels also increase suggests that (infiltrating) neutrophils 
may have a role early in the disease process. Of note, also the expression levels of 
granzyme A, a protease present in granules of cytotoxic T-cells and NK cells, increased 
strongly from week 6 onwards. Because immune cells accumulate in WAT during HFD 
feeding, it is thus likely that changes in inflammatory gene expression may, at least partly, 
be a reflection of the changes in cellular composition of the tissue. Interestingly, we also 
found a gradual increase in expression of the inflammasome adaptor ASC. ASC is 
necessary for assembly of inflammasome complexes, which activates the inflammatory 
cytokines IL1 and IL18 from their propeptides in response to saturated fatty acid overload, 
thereby linking lipid metabolism and inflammation and promoting the development of 
insulin resistance in T2DM [42]. Promoter analyses of clustered inflammatory genes 
revealed that a large number of these genes share Fos, Smad2, Stat6 and Pparα as 
transcriptional regulators, which is in accordance with their established roles in 
inflammatory signaling cascades [43-46].  
    In several clusters, the transcriptional regulators Pparγ, Sp1, estrogen receptor 1 (Esr1) 
and Jun/Fos were identified as central underlying transcriptional regulators that may 
explain the gene expression changes of both lipid metabolism genes and inflammation-
related genes. In accordance with their suggested overarching role, Pparγ, Sp1 and Esr1 
are indeed involved in cell differentiation, cell cycle and growth and immune response 
processes [23, 30, 47, 48]: Pparγ is implicated in adipogenesis and insulin signaling of 
adipocytes as well as in the control of the inflammatory state of infiltrating 




transcription of low density lipoprotein receptor (LDLR) [50], retinoic acid receptor-alpha 
(Rarα) [51] and c-Fos [52]. Another transcription factor that may constitute a link between 
lipid metabolism and inflammation is c-Jun as established previously for WAT and liver 
[23, 36, 53].    
    A limitation of the present study is that the transcriptional regulator prediction method 
predicts the binding of the transcription factors only from the existence of the binding 
motifs in the regulatory elements of genes, i.e. it employs available knowledge about the 
regulation of these genes. Although the results of this bioinformatical approach are 
certainly indicative, the involvement of many of these transcription factors has not been 
experimentally proven under the experimental conditions employed and there is a recent 
recognition that only a small portion of the putative motif may actually be occupied by the 
transcription factors based on recent ChIP-seq studies. 
    Because WAT and liver tissue have evolved from common ancestral structures 
(mesoderm) it has been proposed that they may share similar functional units to control 
key metabolic and immune processes [29, 54]. Indeed, our results show that the factors 
important for regulation of gene expression in WAT were also affected in liver, suggesting 
a considerable consistency between both responses to HFD-induced metabolic overload. 
Some of the master regulators identified in WAT in the present study (Jun, Fos, Rarα, 
Pparα, Stat1, Stat5, Sp1) were also reported to control liver lipid metabolism and/or the 
inflammatory responses of the liver in experimental diet-induced cardiovascular disease 
[23]. A tight relationship between WAT dysfunction and the pathogenesis of NAFLD has 
been reported recently [55], suggesting comparable control of inflammatory gene 
expression in metabolically active organs [29]. This interrelationship could possibly be 
exploited in the future to monitor the condition of the liver via biopsies taken from WAT 
because they are more accessible. Our findings correspond with the view that the control 
mechanisms of metabolic and inflammatory homeostasis in WAT and liver share 
similarities and that a distortion of the mechanisms that control metabolic adaptation 
may also affect the inflammatory tone of a tissue [9, 29].  
    Collectively, this study demonstrates that high fat feeding evokes an immediate, stable 
response of lipid metabolism genes. Later in time, when the storage capacity of WAT 
becomes limited, inflammatory genes are induced in WAT (>6 weeks). When WAT began, 
genes of lipid metabolism and inflammation also became affected in corresponding livers. 
The hepatic response to HFD, in particular the underlying transcriptional responses, were 
remarkably similar to those detected in WAT. In all, WAT and liver respond to metabolic 
overload by adaptations in expression of (clusters of) genes controlling lipid metabolism 
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Obesity-related albuminuria is associated with decline of kidney function and is 
considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney 
dysfunction include low-grade inflammation, insulin resistance and adipokine 
dysregulation. Here, we investigated the effects of two pharmacological compounds with 
established anti-inflammatory properties, rosiglitazone and rosuvastatin, on kidney 
dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP transgenic 
mice were fed standard chow, a lard-based HFD, HFD + rosuvastatin or HFD + rosiglitazone 
for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and 
adipokines; and renal pathology. Rosiglitazone but not rosuvastatin prevented HFD-
induced albuminuria and renal fibrosis and inflammation. Also, rosiglitazone prevented 
HFD-induced KIM-1 expression, while levels were doubled with rosuvastatin. This was 
mirrored by miR-21 expression, which plays a role in fibrosis and is associated with renal 
dysfunction. Plasma insulin did not correlate with albuminuria. Only rosiglitazone 
increased circulating adiponectin concentrations. In all, HFD-induced albuminuria, and 
renal inflammation, injury and fibrosis are prevented by rosiglitazone but not rosuvastatin. 
These beneficial effects of rosiglitazone are paralleled by lowered miR-21 expression and 
selectively enhanced plasma adiponectin levels rather than lowered insulin levels or a 








Obesity rates are rapidly rising worldwide in almost all populations and age groups, largely 
due to increased availability and consumption of calorie-dense foods with a high-fat, high-
sugar content and lack of physical activity (1). Obesity-related fat accumulation, especially 
in visceral depots, is associated with an increased risk of a number of pathologies, 
including insulin resistance (IR) (2) and (micro)albuminuria (3). Albuminuria has been 
associated with a decline of kidney function and is now being recognized not only as an 
important risk factor for future cardiovascular events (4, 5), but is also considered a first 
sign of diabetic nephropathy (6). With the recent rise in the prevalence of obesity, there is 
an urgent need for a better understanding of why a relationship exists between obesity 
and albuminuria and how obesity-related albuminuria develops. Suggested factors linking 
obesity to albuminuria include systemic chronic low-grade inflammation, IR, and specific 
adipocyte-derived adipokines. 
    Chronic low-grade inflammation, as evidenced by elevated plasma levels of acute-phase 
inflammatory markers, including C-reactive protein (CRP), a commonly used marker for 
systemic inflammation in humans (7), is thought to play an important role in the 
development of both IR and nephropathy. To show a causative relationship between 
these risk markers and kidney disease, an intervention directed at reduction of systemic 
inflammation should in turn at least partly diminish IR and prevent albuminuria. If that 
were true, interventions that reduce systemic inflammation and insulin are attractive 
candidates for preventive treatment of patients at risk for developing (diabetic) 
nephropathy. 
    Another explanation for renal disease in obesity may be related to the notion that 
adipocytes are an active endocrine cell type (8, 9). Adipocytes secrete several bioactive 
factors (adipokines) that reportedly play a role in maintaining metabolic health (reviewed 
in (9)). Obesity frequently leads to a dysregulation of adipokine secretion from fat depots 
(9) and thus may be associated with metabolic diseases. Of the numerous factors that are 
regulated with increased visceral obesity, one of the best characterized is adiponectin. 
Recent clinical studies suggest that lowered plasma levels of adiponectin may play a key 
role in the development of obesity-related albuminuria (10). Adiponectin is thought to 
regulate the function of podocytes, a renal cell-type that plays a significant role in the 
glomerular filtration barrier (11). Indeed, studies in adiponectin knockout mice indicate 
that absence of adiponectin can contribute to the initial development of albuminuria (10). 
Further evidence for beneficial effects of adiponectin on kidney functioning was sought by 
increasing plasma levels by administration of exogenous adiponectin, but these efforts 
were hampered by inherent difficulties in producing functional recombinant adiponectin, 
combined with the brief circulating half-life of adiponectin (12). Therefore, efforts to 
increase adiponectin levels have also been focused on increasing the production of 
endogenous adiponectin by adipose tissue. Since the human and mouse adiponectin 
promoter contains binding sites for peroxisome proliferator-activated receptor gamma 
(PPAR-γ), pharmacological activation of PPAR-γ offers the opportunity to enhance 
endogenous plasma levels of adiponectin and thereby to further substantiate a protective 




    To gain more insight into the role of inflammation and adiponectin in metabolic-stress-
induced albuminuria, renal inflammation and fibrosis in the context of IR, we used a 
human CRP transgenic (huCRPtg) mouse model. The huCRPtg mouse carries a transgene 
containing the human CRP gene, the 5’ flanking promoter region and all known human 
CRP gene regulatory elements (13). These mice have been successfully employed to 
monitor systemic inflammation and to determine the effects and mechanisms of drugs 
like statins and fibrates in reducing inflammatory process (14). In a recent study (15), we 
demonstrated that by feeding a high-fat diet (HFD), huCRPtg mice showed metabolic-
stress-induced systemic inflammation and developed osteoarthritis. Interventions with a 
statin (rosuvastatin) and a PPAR-γ activator (rosiglitazone) reduced systemic inflammation 
as indicated by decreased human CRP levels and concomitantly inhibited the development 
of osteoarthritis. Here we have used this mouse model to evaluate whether suppression 
of HFD-induced systemic inflammation by rosuvastatin and rosiglitazone also improves 
albuminuria, renal inflammation and fibrosis under conditions of obesity and IR. An 
integral part of the study was to assess a putative role of adiponectin, which is induced by 
rosiglitazone. 
 
MATERIALS AND METHODS  
Animal experiments 
Experiments were approved by the institutional Animal Care and Use Committee of TNO 
and were in compliance with European Community specifications regarding the use of 
laboratory animals. All sample materials and organs required for this study were obtained 
from TNO-Biosciences, Leiden. Minor parts of the results (in particular body weight 
development over time) were published previously, where indicated, but are presented 
here as well for clarity (15). 
    HuCRPtg mice (13, 14) on a C57BL/6 background were characterized by PCR and ELISA 
for huCRP expression. Mice were housed in groups under standard conditions with a 12-h 
light-dark cycle and had free access to water and food. Mice of 12 weeks of age were fed 
either standard lab chow (ssniff® R/M-H, ssniff Spezialdiäten, Soest, Germany) or chow 
supplemented with 0.01% (w/w) rosuvastatin (“Crestor®”, AstraZeneca, Zoetermeer, the 
Netherlands) (t=0). After 4 weeks (t=4) the diets were changed and mice were divided into 
4 groups consisting of 9 mice per group. Mice that had been fed chow were randomly 
distributed into 3 groups. Group 1 consisted of control mice that remained on the 
standard chow diet. Group 2 was switched to a high-fat (lard) diet (HFD) (23.6% fat / 45% 
kcal% fat D12451, Research Diets, New Brunswick, New Jersey) and mice in group 3 were 
fed HFD containing 0.018% (w/w) rosiglitazone (HFD+Rosi) (Avandia, GSK, London, United 
Kingdom). Group 4 consisted of mice that had been fed standard chow supplemented 
with 0.01% (w/w) rosuvastatin (AstraZeneca), and were switched after 4 weeks to HFD 
containing 0.005% (w/w) rosuvastatin (HFD+Rosuva). The reason to lower the dose of 
rosuvastatin is the increased absorption of rosuvastatin in the context of HFD-feeding. The 
rosuvastatin and rosiglitazone doses were based on their anti-inflammatory effects 
observed in previous studies (42, 43). Mice on chow diet (group 1), mice on HFD without 
drugs (group 2) and drug-treated mice on HFD (groups 3 and 4) remained on their 




    Body weight monitoring and blood sampling by tail incision after 4 hours of fasting was 
done at t=0 and weeks 2, 4, 5, 11, 34, and 42. Blood samples were collected in EDTA tubes 
(Sarstedt AG & Co, Nümbrecht, Germany) and centrifuged for 10 minutes at 6000 rpm, 
after which plasma was collected and immediately stored at −80°C unsl use. Spot urine 
and serum (after heart puncture) was collected from all animals at the time of sacrifice 
(t=42). Mice were sacrificed by CO2 asphyxiation after a 4-hour fast, and tissues were 
isolated and weighed. Left kidneys were fixed in formalin and embedded in paraffin, and 
right kidneys were snap frozen in liquid N2 and stored at −80°C unsl further use. 
 
Histological, biochemical and gene expression analyses 
A detailed description of biochemical, histological, and gene expression analyses is 
provided in Supplement 3. Briefly, plasma levels of human CRP, E-selectin and adiponectin 
were determined by ELISA (R&D Systems, Abingdon, United Kingdom) and urinary 
albumin/creatinine ratios were determined using commercially available kits (Bethyl 
laboratories, Montgomery, Texas and Exocell, Philadelphia, Pennsylvania). Renal gene 
expression and miR-21 analyses were performed by RT-PCR, using TaqMan® Gene 
Expression Assays (Life Technologies, Bleiswijk, the Netherlands) and changes in 
expression were calculated using the comparative Ct (ΔΔCt) method, expressed as fold-
change relative to chow. Renal injury and fibrosis were determined histologically in 
Periodic acid-Schiff-, Masson’s Trichrome-, and Sirius Red-stained kidney sections. 
 
Statistical analysis 
Data were analyzed with Graphpad Prism software (version 5.03, Graphpad Software Inc., 
La Jolla, California) and SPSS (version 22, IBM, Armonk, New York). Differences between 
groups at one specific time point were analyzed by 1-way ANOVA followed by LSD post-
hoc analysis. To determine the correlation between two parameters, Spearman's 
correlation coefficients were calculated. A p-value ≤0.05 was considered statistically 
significant. All data are presented as mean±SEM. 
 
RESULTS 
Body weight and fat distribution 
HuCRPtg mice were fed a standard chow diet, a lard-based HFD, HFD+0.005% rosuvastatin 
or HFD+0.018% rosiglitazone for 42 weeks to study effects on insulin resistance, plasma 
inflammatory markers and adipokines, and renal pathology (albuminuria, inflammation 
and fibrosis). Body weight at baseline (t=0) was 28.5 ± 0.4 g. The three experimental 
groups that received HFD all showed a gradual increase in body weight over time and all 
had significantly higher average body weights at the end of the experimental period (t=42 
weeks) compared with the group that remained on chow (35.1 ± 0.6 g). Mice treated with 
rosiglitazone had the highest body weight (57.7 ± 3.9 g), which was significantly higher 
than that of the HFD group (41.1 ± 1.6 g) and the rosuvastatin-treated group (46.1 ± 2.4 g) 
(15). 
    All mice fed HFD showed a clear increase in fat mass compared with chow-fed mice, but 
what was most striking were the observed differences in fat mass distribution over the 




in a reduction in visceral fat mass and an increase in subcutaneous fat mass in comparison 
with the HFD group (visceral fat: 0.39 ± 0.06 g vs. 0.65 ± 0.09 g, p<0.01; subcutaneous fat: 
2.93 ± 0.46 g vs. 0.83 ± 0.14 g, p<0.001). In the rosuvastatin group, an increase in 
epididymal fat mass was observed in comparison with both the HFD group (HFD+Rosuva 
vs. HFD, 2.02 ± 0.36 g vs. 1.54 ± 0.11 g, p=0.07) and the rosiglitazone group (HFD+Rosuva 
vs. HFD+Rosi, 2.01 ± 0.0.36 g vs. 1.27 ± 0.10 g, p<0.01). 
     
Figure 1: Effects of rosuvastatin and rosiglitazone on fat distribution. HuCRPtg mice mice were fed chow, high-
fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone for 42 weeks. A: 




Glucose and insulin levels 
Plasma glucose levels were 9.8 ± 0.24 mM at the start of the experiment and increased 
steadily and significantly during the rest of the investigational period for all experimental 
groups: 13.6 ± 0.6 mM (chow), 15.9 ± 0.9 mM (HFD), 14.8 ± 0.8 mM (HFD+Rosuva), and 
14.2 ± 0.7mM (HFD+Rosi) at t=42 (Supplementary Figure 1A). Compared with glucose 
levels, changes in insulin levels over time were more pronounced and differed between 
groups. Average insulin levels were 0.6 ± 0.1 ng/ml at t=0 and rose over time to 3.4 ± 0.6 
ng/ml at t=42 weeks for the chow group and to 4.1 ± 0.3 ng/ml in HFD. Notably, the 






















whereas rosiglitazone treatment markedly and significantly suppressed insulin levels to 
2.3 ± 0.6 ng/ml (p<0.05 compared with HFD) (Supplementary Figure 1B). 
 
Plasma adipokines 
Leptin is an adipokine that is highly specific for adipose tissue. Several studies of obese 
humans have shown a strong and consistent positive relation between plasma leptin 
concentrations and adipose tissue mass (see (16) and references therein). At the start of 
the experiment, plasma leptin levels were low (0.15 ± 0.1 ng/ml) and they increased 
slightly over time in the chow group (4.7 ± 0.8 ng/ml at t=42 weeks) (Figure 2A). After 
starting the HFD, leptin levels gradually and strongly rose in all three groups (Figure 2A). 
At t=42 weeks, leptin levels in the rosiglitazone group had reached values of 35.9 ± 6.9 
ng/ml, higher than those of the rosuvastatin group (30.1 ± 4.2 ng/ml) and the HFD group 
(21.8 ± 3.6 ng/ml, p<0.05). Correlation analysis revealed a strong positive relationship 
between body mass and leptin levels (R
2
=0.8208, p<0.001, Figure 2B), in line with the 





















Figure 2: Effects of rosuvastatin and rosiglitazone on plasma leptin and adiponectin levels. HuCRPtg mice were 
fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone 
for 42 weeks. A: plasma leptin levels over time. B: correlation between plasma leptin and body weight. C: plasma 
adiponectin levels over time. Data are mean ± SEM. 
 
 
    In contrast to leptin, adiponectin levels are usually decreased with increasing obesity 
and associated comorbidities, such as type-2 diabetes (T2D) (17). Grosso modo, 
adiponectin levels remained relatively constant in all treatment groups during the entire 
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µg/ml in HFD, and 10.9 ± 1.1 µg/ml in HFD+Rosuva), except for the rosiglitazone group, 
which showed strongly increased plasma concentrations of adiponectin from t=4 weeks 
onward, reaching average levels of 40.8 ± 3.5 µg/ml (p<0.001 compared with all other 
groups at t=42, Figure 2C). 
 
 
Renal inflammation and renal function 
At the end of the experimental period, the chow group had an urinary albumin/creatinine 
ratio of 151 ± 22 µg/mg. Both the HFD group (396 ± 88 µg/mg, p<0.01) and the Rosuva 
group (361 ± 104 µg/mg, p<0.05) showed a comparable and significant increase in the 
albumin/creatinine ratio compared with the chow group (Figure 3A). In contrast, HFD-fed 
mice treated with rosiglitazone exhibited urinary albumin/creatinine ratios of 129 ± 7 
µg/mg, i.e. similar to those of chow-fed mice, and well below the values seen for the HFD 
and Rosuva groups (p<0.01 compared with HFD, p<0.05 compared with HFD+Rosuva; 
Figure 3A). Notably, urinary albumin levels were not significantly correlated with plasma 
insulin levels (not shown). 
























Figure 3: Effects of rosuvastatin and rosiglitazone on urinary albumin and kidney histology. HuCRPtg mice were 
fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone 
for 42 weeks. A: urinary albumin levels. B: representative photomicrographs of PAS-stained kidney sections 
showing mesanchial expansion (open arrows) and lipid droplets in tubuli (filled arrows). Data are mean ± SEM, 







































    Bright-field microscopy analysis revealed that HFD feeding induced development of mild 
mesangial area expansion and accumulation of lipid droplets in tubuli (Figure 3B). Both 
rosuvastatin and rosiglitazone prevented mesangial expansion. Tubular lipid accumulation 
was also observed in the rosiglitazone-treated group, but was absent in the rosuvastatin-
treated mice. 
    Gene expression analysis revealed that relative mRNA expression levels (expressed as 
fold-change relative to chow) of kidney injury molecule 1 (KIM-1) were markedly 
upregulated in HFD (2.15 ± 0.30, p=0.08 vs. chow, Table 1). Notably, rosuvastatin 
markedly and significantly further increased KIM-1 expression levels (3.56 ± 0.89, p<0.05 
vs. HFD), whereas rosiglitazone kept KIM-1 mRNA levels as low as those found for the 
chow group, i.e. strikingly below values seen for the HFD and HFD+Rosuva groups. 
    A similar picture emerged with respect to the renal mRNA expression levels of the 
endothelial activation marker E-selectin (Table 1). HFD feeding significantly upregulated E-
selectin mRNA expression (2.41 ± 0.72, p<0.001 vs. chow), while rosuvastatin was unable 
to prevent this increase (2.22 ± 0.84, n.s. vs. HFD). In contrast, rosiglitazone treatment 
considerably downregulated E selectin mRNA expression (1.38 ± 0.53, p<0.01 vs. HFD), 
with expression levels similar to those observed in chow-fed mice. 
    The expression of CD68 mRNA, a marker for macrophage infiltration, and VCAM-1 
mRNA, a vascular endothelial activation marker, did not differ significantly between the 
experimental groups (Table 1). 
 
 
Table 1. Effects of rosiglitazone and rosuvastatin on renal mRNA expression. Renal mRNA expression levels of 
endothelial activation markers (E-selectin and VCAM-1), macrophage marker (CD68) and Kidney Injury Marker 
(KIM-1). *P<0.05 vs. HFD. Values are represented as means ± SD. 
 
 Chow HFD HFD+Rosuva HFD+Rosi 
KIM-1 1.00 ± 0.24 2.14 ± 0.83 3.56 ± 2.17* 1.22 ± 0.54* 
E-selectin 1.00 ± 0.33 2.41 ± 0.72 2.22 ± 0.84 1.38 ± 0.53* 
CD68 1.00 ± 0.13 1.19 ± 0.32 1.31 ± 0.22 1.41 ± 0.33 
VCAM-1 1.00 ± 0.22 0.82 ± 0.30 1.10 ± 0.37 0.93 ± 0.26 
 
 
Plasma markers of systemic inflammation 
HuCRP levels were measured to monitor the overall systemic inflammatory state induced 
by HFD, and the effect of interventions with rosuvastatin and rosiglitazone thereupon. As 
reported previously, both rosiglitazone and rosuvastatin exhibited anti-inflammatory 
effects (15). In contrast, only rosiglitazone markedly and significantly reduced the HFD-
induced increase in plasma E-selectin levels at 42 weeks thus reflecting the renal mRNA 
data for E-selectin (Supplementary Figure 2). 
 
Renal fibrosis and miR-21 
Renal fibrosis is a frequent underlying cause of decreased renal function. To gain insight 
into fibrosis development, kidneys were stained with Masson Trichrome and Picro-Sirius 




with the corresponding collagen quantification (as quantified in Picro-Sirius Red-staned 
sections) in Figure 4B. HFD induced the tubular interstitial collagen content (1.11 ± 0.15 %) 
compared with the chow group (0.57 ± 0.10 %; p<0.01, Figure 4B). Notably, while collagen 
content after rosuvastatin treatment was comparable to that in the HFD group (1.27 ± 
0.17 %), rosiglitazone significantly prevented collagen deposition (0.74 ± 0.09 %; p<0.05 
compared with HFD) with levels comparable to those in the chow group. 
    Since miR-21 has been shown to play a pathological role in many forms of fibrosis and 
since its increase is associated with microalbuminuria, inflammation and renal fibrosis (18, 
19), we examined renal miR-21 expression (Figure 4C). Renal miR-21 expression was 
enhanced in HFD compared with chow group (fold-change 1.66 ± 0.29 in HFD, 1.00 ± 0.14 
in chow). Rosuvastatin treatment nearly doubled miR-21 expression (fold-change 3.16 ± 
0.53 relative to chow; p<0.01 compared with HFD) on top of HFD treatment. In contrast, 




























Figure 4: Effects of rosuvastatin and rosiglitazone on kidney fibrosis. HuCRPtg mice were fed chow, high-fat diet 
(HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone for 42 weeks. A: 
representative photomicrographs of kidney sections stained with Masson’s Trichrome showing renal collagen 
deposition. B: quantification of tubular interstitial collagen (Sirius Red staining quantified by ImageJ analysis). C: 
























































































Obesity-related albuminuria is recognized as a sign of declined kidney function. Among 
the factors suggested to connect obesity to kidney dysfunction are low-grade systemic 
inflammation, IR/T2D and adipokine dysregulation. In the current study we sought 
evidence for the role of these obesity-linked factors in the development of aspects of 
renal pathology, viz. albuminuria, inflammation and fibrosis. For this, we employed 
huCRPtg mice under conditions of HFD-induced obesity in conjunction with two 
pharmacological interventions, rosiglitazone and rosuvastatin, with established anti-
inflammatory properties (15), as exemplified by decreased huCRP levels. Our results 
demonstrate that anti-inflammatory rosiglitazone but not anti-inflammatory rosuvastatin 
prevented HFD-induced albuminuria and renal fibrosis, and inhibited expression of the 
renal inflammation marker, E-selectin. Rosiglitazone also prevented the HFD-enhanced 
mRNA expression of KIM-1, while rosuvastatin almost doubled KIM-1 mRNA levels. 
Notably, these beneficial effects of rosiglitazone were paralleled by absence of miR-21 
induction and were associated with selectively enhanced plasma adiponectin levels. No 
correlation was found between plasma insulin levels and urine albumin/creatinine ratios. 
    In our study, we focused on human CRP levels as a marker for systemic inflammation. 
Recently, it has been reported that rosiglitazone treatment reduces plasma CRP levels in 
rats with induced T2D (20). Consistent with these findings, we observed that rosiglitazone 
treatment reduced human CRP levels in HFD-challenged huCRPtg mice indicating that 
rosiglitazone suppresses systemic inflammatory responses (15). Rosiglitazone is a PPAR-γ 
agonist that belongs to the thiazolidinedione class of drugs. It has been reported that in 
patients with T2D, treatment with another thiazolidinedione (pioglitazone) along with 
insulin therapy decreased human CRP levels when compared to insulin treatment alone 
(21, 22). In the current study, rosiglitazone reduced plasma insulin levels and hence 
reduced IR. In contrast, anti-inflammatory rosuvastatin treatment (15) failed to reduce 
circulating insulin levels, which is in line with a recent study showing that rosuvastatin 
failed to improve IR in patients on peritoneal dialysis (23). 
    Rosiglitazone treatment caused a significant increase in body weight in huCRPtg mice 
compared with HFD mice. More specifically, rosiglitazone-treated mice especially had 
increased subcutaneous fat mass compared with HFD mice. Consistent with these 
observations, treatment with PPAR-γ agonists has been shown to improve insulin 
sensitivity despite increasing body fat mass, in particular subcutaneously (22). In contrast, 
an increase in visceral fat has been reported to be highly associated with IR and T2D (21, 
23). Here, we observed that rosiglitazone treatment decreased visceral fat mass. In 
contrast, in rosuvastatin-treated mice the mass and distribution of the fat depots were 
similar to those observed in untreated HFD-challenged mice. 
    We also observed that mice treated with rosiglitazone displayed markedly increased 
plasma levels of adiponectin, a protein predominantly secreted by adipocytes. It is now 
well documented that adiponectin is a cardioprotective adipokine, due to its anti-
inflammatory and insulin-sensitizing properties (24, 25). An inverse relationship between 
adiponectin levels and CVD has been reported (2, 26) in patients with end-stage renal 
disease, and there is increasing evidence that adiponectin plays a protective role in T2D 




damage after HFD challenge (27) whereas treatment with adiponectin inhibits renal 
fibrosis and albuminuria in adiponectin knock-out mice (28). Moreover, enhanced 
expression of adiponectin attenuates inflammation and diabetes development in db/db 
mice (29). 
    Obesity-related albuminuria is now being recognized not only as an indication of 
declined kidney function and a first sign of diabetic nephropathy (10), but also increases 
the risk of CVD (30). If left untreated, patients with albuminuria are more prone to CVD. 
Treatments that reduce albuminuria are therefore inherently renoprotective and would 
improve CVD outcomes (30). We observed that mice on HFD developed mesangial 
expansion, glomerulosclerosis, lipid accumulation and albuminuria. Furthermore, KIM-1, a 
marker of kidney injury (31), was upregulated in mice on HFD. Rosiglitazone treatment 
markedly diminished these HFD-induced renal effects and improved kidney function as 
evidenced by reduced urinary albumin/creatinine ratios and lowered KIM-1 expression. 
Moreover, rosiglitazone treatment strikingly reduced plasma E-selectin levels and, 
similarly, reduced renal E-selectin mRNA expression levels. Conversely, rosuvastatin 
treatment failed to exert any beneficial effects on markers of endothelial activation and 
inflammation in the kidney and did not improve albumin/creatinine ratios. In fact, the 
expression levels of some markers, including E-selectin and KIM-1 were increased in the 
kidneys of rosuvastatin-treated mice when compared with those of chow and HFD-
challenged mice. 
    In a healthy individual, the kidney is able to reabsorb the majority of protein that enters 
the renal filtrate, with only traces being excreted in the urine. In the obese state there are 
two main sites involving two different processes that result in a loss of protein (mainly 
albumin) in the urine, viz. (i) structural changes to the glomerulus allowing more albumin 
to enter the filtrate and (ii) inability of the proximal tubules to endocytose the increased 
protein load (see (8) and references therein). The development of albuminuria is a typical 
characteristic of renal damage (nephropathy (32). Previous studies have demonstrated 
that statins can inhibit tubular reabsorption of filtered albumin (33, 34). Furthermore, this 
notion is supported by a recent study in hypertensive patients demonstrating that statin 
treatment was independently associated with the occurrence of microalbuminuria (35). 
Exposure to raised levels of albumin in the renal tubule has been linked to increased 
proinflammatory and profibrotic changes in the tubulointerstitium (36). 
    Diabetic patients with end-stage kidney disease have a 5-year survival rate of merely 
20% (37). One of the major features of diabetic nephropathy is the presence of fibrosis. 
We observed increased collagen content in the HFD group. Notably, rosiglitazone, but not 
rosuvastatin treatment, prevented the increase in renal collagen deposition, suggesting a 
possible link between renal fibrosis and renal function. MiR-21 is the most substantial 
miRNA involved in many fibrotic diseases and is enhanced after initiation of myocardial 
and pulmonary fibrosis (38, 39). MiR-21 levels are also enhanced in human kidney fibrosis 
(18, 19). Experimental support for a causative role of miR-21 is provided by miR21 
silencing experiments. Silencing of miR-21 by anti-miR-21 oligonucleotide treatment in a 
murine model of Alport nephropathy reduced glomerulosclerosis, interstitial fibrosis, 
tubular injury, and inflammation (41). Similarly, silencing miR-21 in diabetic kidneys of 




    We observed highly enhanced miR-21 levels only after rosuvastatin treatment, whereas 
rosiglitazone prevented its expression and was comparable to the chow group. Notably, 
gene expression of pro-fibrotic genes like α-Sma and Col1α1 (results not shown) was 
unaffected suggesting that miR-21 could be an early marker of the initiating fibrosis in the 
kidneys. 
    In conclusion, our results demonstrate that rosiglitazone reduced HFD-induced insulin 
levels, suppressed the systemic inflammatory response and protected mice from the 
development of albuminuria. Despite its anti-inflammatory properties, rosuvastatin failed 
to improve IR and renal function. Although multiple mechanisms may be involved, 
rosiglitazone treatment was associated with a marked increase in circulating adiponectin 
levels suggesting that this adipokine may have contributed to these effects. Strikingly, the 
beneficial effects of rosiglitazone were paralleled by lowered renal expression levels of 
miR-21; an increase of miR-21 is associated with microalbuminuria development, 
inflammation and renal fibrosis. In all, our findings suggest that increasing adiponectin 
levels could be of clinical importance by improving kidney function and in turn improve 
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Supplementary Figure 1: Effects of rosuvastatin and rosiglitazone on plasma glucose and insulin. HuCRPtg mice 
mice were fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) 







Supplementary Figure 2: Effects of rosuvastatin and rosiglitazone on plasma E-selectin. HuCRPtg mice were fed 
chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone for 




SUPPLEMENT 3: DETAILED MATERIALS AND METHODS 
Plasma analyses  
Human CRP in plasma was quantified by established ELISA (R&D Systems, Abingdon, 
United Kingdom) at t=0 and weeks 2, 4, 5, 11, 34, and 42. Plasma levels of E-selectin (R&D 
Systems), leptin (R&D Systems), and adiponectin (R&D systems) were quantified up to 
t=42 weeks. Plasma insulin levels were determined by ELISA (Mercodia, Uppsala, Sweden) 
and plasma glucose levels were determined by enzymatic assay (glucose hexokinase 
method, Instruchemie, the Netherlands). 
 
Renal RNA and miRNA extraction and gene expression analysis  
Total RNA was extracted from 35-µm thin cryo-sections from kidney using RNeasy Plus 
Mini Kit (Qiagen N.V., Venlo, the Netherlands) according to the manufacturer's 
instructions. Integrity of RNA was determined by agarose gel electrophoresis. RNA 
quantity (OD-260) and quality (OD-260/OD-280) were determined using a NanoDrop1000 
UV-Vis spectrophotometer (NanoDrop Technologies, Rockland, DE, USA) as described 
previously (1). 
    Total RNA was reverse-transcribed using SuperScript® III Reverse Transcriptase 
(Invitrogen, Breda, the Netherlands) and random hexamer primers (Promega, Leiden, the 
Netherlands). TaqMan® Gene Expression Assays (Life Technologies, Bleiswijk, the 
Netherlands) were used to detect the expression of selected target genes. Endogenous 
PPIA (Mm02342430_g1) was used as a housekeeping gene along with the following 
probes for CD68 (Mm00839636_g1), VCAM-1 (Mm00449197_m1), E-selectin 
(Mm00441278_m1), and Kidney Injury Molecule-1 (KIM-1, Mm00506686_m1). Real-time 
PCR was performed in duplicate and the obtained threshold cycle (Ct) values were 
averaged. Relative mRNA levels were calculated using the comparative Ct (ΔΔCt) method, 
expressed as fold-change relative to chow as described previously (2, 3). 
    For miRNA analysis, TaqMan® microRNA Reverse Transcription Kit (Life Technologies) 
and specific miR-21 (002493) TaqMan® probe was used for reverse transcription using 10 
ng of total RNA. Real-time PCR was performed in a 7500 Fast Real-Time PCR machine 
using miRNA TaqMan® probes for miR-21(002493) and the endogenous control sno-202 
(001232). Each sample was run in duplicate and relative miRNA levels were calculated 
using the comparative Ct (ΔΔCt) method, expressed as fold-change relative to chow. 
 
Histology and immunohistochemistry  
For light microscopic examinations, 3-µm renal paraffin sections were stained with 
Periodic acid-Schiff (PAS). In short, paraffin sections were deparaffinized and re-hydrated 
in distilled water. Sections were placed in 0.5% periodic acid solution for 5 minutes. After 
rinsing in distilled water, sections were incubated in Schiff’s reagent (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) for 15 minutes, followed by rinsing in lukewarm water for 5 
minutes. Sections were counterstained with Mayer's haematoxylin for 1 minute and 
washed in tap water. Images were taken with a Leica microscope using QwinV3 software 
(Qwin V3 software, Leica Microsystems Imaging Solutions Ltd., Cambridge, UK). For direct 




Masson’s Trichrome Staining kit (Accustain HT15, Sigma-Aldrich). To quantify renal 
fibrosis, sections were stained with Picro-Sirius Red for collagen content, and the extent of 
fibrosis was quantified at 40x magnification using an automated macro in the image 
processing software ImageJ (version 1.48, NIH, Bethesda, MD, USA). Collagen content was 
expressed as the percentage of the total tissue area that was positively stained. Glomeruli 
and vessels larger than the size of adjacent tubules were excluded when assessing the 
images.  
 
Kidney function measured by albumin/creatinine ratio 
To assess renal function, urinary albumin and creatinine levels were measured using 
commercially available kits. For this, Mouse Albumin ELISA Quantitation Set (Bethyl 
laboratories, Montgomery, Tx, USA) and The Creatinine Companion assay (Exocell, 
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GENERAL DISCUSSION  
 
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver 
disease in modern societies and constitutes an important global health problem. NAFLD is 
a multifactorial disease and encompasses a spectrum of pathologies that range from 
simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and fibrosis. Metabolic 
overload from excessive intake of calorie-dense diets and associated chronic inflammation 
(‘metabolic inflammation’) are thought play a critical role in the development NASH and 
fibrosis. A better understanding of the complex etiology of NAFLD, including the sequence 
of events over time, identification of NASH-promoting disease pathways and the 
inflammatory cross-talk between liver and adipose tissue, is needed to develop tools for 
studying the disease and to come up with first treatment regimens for patients.  
    This chapter discusses the major findings of this thesis in the following order: 1) Chronic 
inflammation exists in various forms and induction of metabolic inflammation depends on 
the nature and intensity of the inflammatory triggers employed; 2) Interrelated 
inflammatory responses in metabolically active tissues and their coordination; 3) 
Implications for human pathophysiology: human data versus data from experimental 
models. 
 
Chronic inflammation exists in various forms and induction of metabolic 
inflammation depends on the nature and intensity of the inflammatory 
triggers employed 
In 2006, Hotamisligil (1) studied chronic inflammation in metabolic diseases and proposed 
a new term for this type of inflammation, ‘metaflammation’. Metaflammation refers to 
inflammation which is metabolically induced or amplified. Obesity is considered to be 
closely associated with sub-acute chronic inflammation, which develops systemically but 
also on tissue level, and this low-grade inflammation is thought to promote the 
development of metabolic diseases. There is strong link between excess calorie intake 
resulting in a condition of chronic energy surplus, and the induction of chronic 
inflammation. Therefore, diet-evoked chronic metaflammation may constitute a crucial 
factor in the progression of bland liver steatosis to NASH. The nature of this chronic 
inflammatory component that drives this transition towards NASH has long been unclear.  
    In Chapter 3 we compared the effects of different inflammatory triggers, among which 
were metabolic inflammatory triggers (dietary carbohydrate, cholesterol) and non-
metabolic (classical) inflammatory triggers (IL-1β, LPS). All these inflammatory triggers 
exhibited a comparable NFĸB-activating effect but this property appeared to be 
insufficient to induce NASH, even when superimposed on HFD feeding. While HFD feeding 
alone merely induced bland liver steatosis, non-metabolic inflammatory triggers 
superimposed on HFD also did not induce a human-like NASH pathology, although 
additional inflammatory pathways (e.g. STAT3) were activated. Surprisingly, metabolic 
triggers of inflammation did promote the progression towards NASH. A common 
denominator the effect of metabolic triggers was the additional activation of the pro-
inflammatory transcriptional master regulator AP-1 and the pronounced infiltration of 




data of Chapter 3 thus demonstrate that chronic liver inflammation exists in different 
forms and that the progression from steatosis to NASH depends on a specific type of 
inflammation, which can be evoked with calorie-dense diets (metabolically inflammatory 
triggers).  
    A next question is related to the dynamics of diet-inducible metabolic inflammation, i.e. 
whether metainflammation is induced gradually up to at a stable, elevated level or 
whether it has a more dynamic patter. In Chapter 3, Chapter 4 and Chapter 6, studies 
with different time periods of HFD+cholesterol feeding were performed. There is a 
positive association between the severity of steatosis and fibrosis and the time of 
treatment with these cholesterol-containing diets. However, the extent of lobular 
inflammation as reflected by the number of inflammatory cells aggregates in liver lobes 
(including neutrophils) showed a more complex pattern over time. In the early phase of 
the pathogenesis (e.g. t=8 w or t=12 w of diet-feeding the number of inflammatory cell 
aggregates strongly increased with time. However, the number of these inflammatory foci 
decreased once fibrosis occurred at the more late stages of the disease, that is after 
t=20w of diet feeding. This counter-intuitive finding could be explained by the 
phenomenon of inflammation resolution (reviewed in (2)) which is frequently associated 
with the process of wound healing. In the early phases of inflammation, infiltrating 
neutrophils reach peak levels and these cells are gradually replaced by other types of 
inflammatory cells (from the macrophages/monocytes lineage) (2). In the late phase of 
tissue inflammation, macrophages or monocytes take a dominant role and the numbers 
neutrophils may decline. Finally, tissue repair mechanisms are mounted including the 
deposition of collagen to stabilize damaged areas within an organ. Consistent with this, 
we observed a decrease of inflammatory cells aggregates and neutrophils alongside with 
an increase of fibrosis in those studies with prolonged HFD+cholesterol feeding, e.g. in 
Chapter 6. Although the studies which are part of this thesis may suggest to some readers 
that inflammation and fibrosis develop independently during the pathogenesis of NASH, it 
is more likely that, during the resolution phase of inflammation, inflammatory processes 
and pro-fibrotic processes are tightly interconnected. Studies of this thesis as well as those 
reported in literature indicate that the interrelationship between diet-induced 
inflammation and fibrosis is very complex and that the dose of the trigger of the 
inflammatory insult in liver (e.g. cholesterol) is critical for processes showing high 
dynamics such as lobular cellular inflammation. For instance, in Chapter 5, we used a 
much lower dose of cholesterol (0.1% w/w) than in Chapter 6 (1% cholesterol, w/w), while 
the length of both studies was comparable (20 weeks). We found that a higher dose of 
cholesterol (1% w/w) did not affect the induction of microvesicular steatosis (±10%) but 
led to two times more macrovesicular steatosis (20% vs 10%), thus a more severe form of 
human-like hepatic steatosis. Furthermore, the higher dose of cholesterol decreased the 
level of hepatic lobular inflammation, which may be unexpected when the concept of 
inflammation resolution is ignored, and increased the level of hepatic fibrosis.  
    Although the mechanism underlying the relationship of hepatic inflammation and 
fibrosis during the progressive stages of NASH is unclear, our studies have demonstrated 
that induction of metabolic inflammation is very dynamical process and that it largely 
depends on the quality and quantity of inflammatory triggers employed. Since these 




interpretation of the results of such studies should consider that an organism mounts 
counter-regulatory processes to resolve inflammation and to restore organ functions. 
Therefore, the outcomes of such studies (and interventions) should not only be 
interpreted and discussed in the light of a pro-inflammatory metabolic condition but 
should also consider that anti-inflammatory processes and tissue-repair pathways can 
take place.  
 
Interrelated inflammatory responses in metabolically active tissues and 
their coordination  
After investigating how inflammation develops in the liver in the context of diet-induced 
obesity, it is intriguing to explore the effects of metabolic overload on other metabolically 
active organs, the more so because it has been unclear in which tissue inflammation does 
start and whether organ-organ cross-talk may contribute to the pathogenesis of NASH.  
    Tracing back the development history of biology, interestingly, in the lower organisms, 
such as Drosophila melanogaster, the metabolic and immune responses are controlled by 
a single organ, the fat body (reviewed in (1)). In higher organisms, this association (and 
hence molecular interaction) between metabolism and inflammation is preserved and also 
can be found in the major metabolic tissues. For example, the liver and white adipose 
tissue (WAT) share the similar immune effector cells, e.g. Kupffer cells and macrophages 
which constitutively reside in these tissues, as well as  metabolic cells, such as hepatocytes 
and adipocytes. Many gene expression studies and microarray analyses demonstrated 
that the expression of genes involved in (lipid) metabolism and inflammation is adjusted 
extensively after long periods of HFD feeding (3, 4). However, significant effects on gene 
expression are likely to start early and may change over time, i.e. may be much more 
dynamical than assumed.  
    Therefore, in Chapter 7, we performed a refined HFD induced time course study in 
which we investigated the early dynamical events of metabolic adaptation in a) the 
expanding WAT and b) the liver. This allowed us to demonstrate that the adjustment of 
lipid metabolism genes is related to the onset of inflammatory gene expression during 
diet-induced obesity, and that a relationship exists between the processes in WAT and 
those occurring later in time in the liver. By means of gene expression analysis and 
histology, we found that lipid metabolism genes in WAT were adjusted in the first place. 
Later in time, when the storage capacity of WAT reached its limit, inflammatory genes 
were expressed in WAT. When WAT inflammation started, genes involved in lipid 
metabolism and inflammation in the liver were adjusted, as demonstrated by analysis of 
gene expression time profiles of WAT and corresponding livers. We showed that the 
transcriptional regulators Jun, Fos, Rarα, Pparα, Stat1, Stat5, Sp1 controlled lipid 
metabolism and the inflammatory responses to HFD feeding in both liver and WAT, which 
is in line with the evolutionary relationship of both tissues described above and the view 
that transcriptional control mechanisms of the metabolic-inflammatory network are 
highly preserved (1).  Because WAT inflammation precedes NAFLD, our studies support 
the view that inflammatory factors released by WAT contribute to the pathogenesis of 
NAFLD. Experimental evidence for a causal role of WAT in the development of NASH has 
not been provided so far and studies on the role of inflamed WAT are subject to future 




affect other tissues, and because chronic HFD-induced metabolic overload is unlikely to be 
restricted to the expanding WAT and the liver only, we investigated whether other organs 
(in particular those with a high blood flow and high density of capillaries) may be effected 
affected as well. As shown in Chapter 8, kidney function deteriorated significantly after 
long-term (40 weeks) HFD feeding and this deterioration appears to be caused, at least 
partly, by chronic inflammation.  
    Hence, metabolic overload evoked inflammation starts locally in WAT and affects, as 
time proceeds, more and more tissues. This concept is visualized in the figure below (see 
Figure 1): metabolic overload (from overnutrition, HFD) leads to expansion of adipocytes 
in WAT. Once further expansion is not possible anymore, low-grade inflammation 
develops which is characterized by local expression of inflammatory mediators (e.g. TNF-α, 
IL-1β, CCL2) and related inflammatory pathways, such as IKK and JNK. Factors released by 
WAT and/or spill-over of lipids now stored in other organs such as liver and kidney 
subsequently triggers a pro-inflammatory response in these tissues. Over time, this local 
chronic inflammation (in WAT, liver and other organs) may intensify and further induce 
recruitment and activation of inflammatory cells. This metaflammation, which is in first 
place a consequence of metabolic overload of the entire organism, is typically not noticed 
for decades and, without resolution, may lead to  chronic metabolic disease, such as 
NAFLD/NASH and chronic kidney disease.    
 
Figure 1:  How different tissues are affected by metabolic overload and metabolic inflammation. 
 
 
Implications for human pathophysiology: human data versus data from 
experimental models 
‘Translational research’ has been discussed and debated in academia, industry and 
government for many decades. In 2008, a report ‘Translational research: Crossing the 
valley of death’ was published in Nature (5) and the author, Declan Butler, addressed the 
chasm that exists between biomedical research and the needs of patients. Due to the 
ethical issues and the inaccessibility of many tissues in humans, experimental studies are 






related to these models is ‘Does the model reflect the human situation?’. Experimental 
models are frequently performed in rodents which differ from humans with respect to 
metabolic activity as well as drug metabolism, immunological properties etc. However, 
when it comes to underlying mechanisms of disease, models can be very similar to human 
pathology, provided that the inducers of the pathogenic pathways are comparable and 
physiologically relevant. We and others have demonstrated that diet-inducible models of 
NAFLD/NASH share defining characteristics of the human pathology, and that there are 
many commonalities between humans and experimental models in animals. In this thesis, 
APOE*3 mice, APOE*3Leiden.huCETP mice or human CRP transgenic mice were used. The 
APOE*3 background allows to mimic human lipid metabolism and animals develop  a 
more human-like lipoprotein profile as well as the risk factors that promote the 
development of NAFLD in the context of visceral obesity and dyslipidemia (6). 
    Furthermore, important hallmarks of human NASH (as defined in human biopsies) 
should be validated in experimental NAFLD/NASH models. It is remarkable that a direct 
comparison between the human NAFLD pathology and the experimentally induced NAFLD 
pathology has not been made, and that there was no generally accepted well-documented 
grading system for experimental NAFLD/NASH. That is why we first characterized the 
steatotic and inflammatory components of NAFLD/NASH in human biopsies (in Chapter 3), 
and evaluated the same components in our experimental NASH model. This resulted in a 
general scoring system for experimental NAFLD/NASH for rodent models of the disease 
which is generic and applicable for a broad spectrum of models (Chapter 2). More 
specifically, the critical histopathological criteria for grading and scoring of macrovesicular 
and microvesicular steatosis, inflammatory cells aggregates, ballooning cells and fibrosis 
were defined by us. Application of the scoring system for examination the longitudinal 
development of disease stages and the efficacy of interventions, allowed us to further 
validate and implement the grading system.  
    In Chapter 4, we, furthermore, tried to establish a link between specific features of 
histopathology and biomedical parameters relevant for the progression of NASH. We 
showed that a correlation exists between macrovesicular steatosis and cellular lobular 
inflammation, and that there is a correlation between microvesicular steatosis and NFĸB 
activation in liver. Our findings shows that the specific forms of steatosis (macrovesicular 
and microvesicular) develop have a distinct developmental pattern over time and that 
they are associated with different cellular and molecular inflammatory events, which 
probably involve different pathways.  
 
Conclusions and future perspectives 
The studies presented in this thesis have generated more insight in the pathogenic 
mechanisms which contribute to obesity-induced NAFLD, in particular the transition from 
NAFL to NASH, and the development of fibrosis. The complex interactions between 
metabolic and inflammatory pathways in key metabolic organs were investigated in detail 
and, overall, our analyses support an involvement of the inflamed WAT in the 
pathogenesis of NAFLD/NASH which adds another layer of complexity. As outlined in 
detail, there are clear differences between NAFLD in humans and the pathology in 
experimental models and experimental models cannot mimic the full spectrum of 




complexity in humans arises from genetic and ethnic differences, but different dietary 
habits and different preference to nutritional components such as dietary fat (e.g. 
consumer oils) both in quality and quantity, as well as differences in organ-crosstalk 
between humans, all of which can hardly be mimicked in a single model of disease. In 
NASH research, the most fundamental questions, which are related to the lipid 
component of the disease and to the complex etiology of the disease still needs to be 
answered. For example, what is the actual potential of steatosis to induce toxic effects in 
liver?, what is the actual cascade of pathologic processes leading to inflammation and 
fibrosis?, and how are these processes related to the events of steatosis? Furthermore, 
observed phenotypic difference in human NASH patients raise the fundamental question 
whether the different phenotypic features that exist in humans are appropriately 
reflected (with respect to the specific molecular events and pathways) in the models?  
    Research can answers questions, but, if well conducted, will lead to more detailed 
questions which will also open new opportunities for better understanding and/or 
treatment of diseases.  
    Let us keep on thinking, as the honored 19
th
 century scientists, trying to find out the 
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Overload of nutrients can lead to diet-induced inflammation, also called metabolic 
inflammation, which is thought to play an important role in many metabolic diseases, 
including the development of nonalcoholic fatty liver disease (NAFLD). NAFLD has become 
the most common chronic liver disease and encompasses a spectrum of pathologies that 
range from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and fibrosis. 
The pathogenesis of NAFLD, including the sequence of events in time and the underlying 
mechanisms that initiate the transition from a fatty liver to NASH and fibrosis, remain 
poorly understood. Effective and reliable therapeutic approaches that are based on the 
understanding of the pathogenesis of NASH are therefore still lacking. 
    After a general introduction of human NASH and experimental NASH in Chapter 1, we 
systematically compared in Chapter 2 human NAFLD liver pathology, using human liver 
biopsies, with liver pathology of several NAFLD mouse models. Based on the features 
pertaining to mouse NAFLD, we aimed at establishing a modified generic histological 
scoring system for NASH that is applicable to broad spectrum of rodent models. 
    In the second part of the thesis, we investigated the progression of NAFL to NASH in 
more detail using diet-induced NASH mouse models. In Chapter 3, we examined the effect 
of metabolic inflammatory triggers (dietary carbohydrate, cholesterol) and non-metabolic 
(classical) inflammatory chronic triggers (IL-1β, LPS) on the progression of bland liver 
steatosis to NASH using high fat diet (HFD)-induced obese APOE*3Leiden.CETP mice. We 
showed that HFD feeding followed by metabolic triggers induced extensive steatosis and 
specific inflammatory components (neutrophils, AP-1) which results in a human-like NASH 
phenotype, while chronic administration of non-metabolic triggers, LPS and IL-1β, did not. 
Because patients remain asymptomatic during the early stages of the disease, NAFLD is 
often diagnosed at a late stage which is accompanied by irreversibly liver damage (liver 
fibrosis, cirrhosis). Hence, little is known about the early, potentially reversible, disease 
processes and their relationship over time. Therefore, in Chapter 4, we concentrated on 
the early events of NAFLD development and the processes ‘steatosis’ and ‘onset of 
inflammation’ with regards to their occurrence and progression over time as well as their 
role in the transition of NAFL to NASH. Based on a systematical and longitudinal analysis of 
liver histology in conjunction with biochemical measurements and microarray data of this 
time course study, we demonstrated that links exist between microvesicular and 
macrovesicular steatosis and specific facets of liver inflammation. We show that the two 
types of steatosis have a distinct time pattern and are associated with the activation of 
specific cellular and molecular inflammatory events. 
    In the third part of the thesis, we aimed to test potential therapeutics for NASH. In 
Chapter 5, a nutritional intervention was performed by treating APOE*3Leiden mice fed a 
high cholesterol diet with a moderate dose of an anthocyanin-rich standardized bilberry 
extract (Mirtoselect). We found that Mirtoselect remarkable attenuates NASH and 
associated fibrosis as shown by an improvement of histological outcomes (steatosis, 
hepatic inflammation and fibrosis) and suppression of hepatocellular inflammation which 
can be explained by an effect on cholesterol handling. In Chapter 6, a pharmaceutical 
intervention was performed by treating APOE*3Leiden.CETP mice fed a high fat, high 




exhibit beneficial metabolic effects on glucose and lipid metabolism. Salsalate exerted a 
preventive effect on onset and progression from NAFL to NASH and fibrosis. More 
specifically, our results showed an improvement of lipid metabolism by increasing β-
oxidation and decreasing lipogenesis. Furthermore, inflammation was reduced (down-
regulation of the NFκB pathway) and fibrosis development was prevented (down-
regulation of TGF-β signaling). 
    In the last part of the thesis, the effects of metabolic overload and metabolic 
inflammation on other tissues were investigated. The effect of metabolic overload on 
white adipose tissue (WAT) and liver was analyzed in Chapter 7, using HFD fed 
APOE*3Leiden mice. These mice respond to HFD feeding with WAT expansion, metabolic 
stress, inflammation and development of NAFLD. In WAT transcriptomics data showed 
that metabolic overload induced an immediate, stable response on clusters of lipid 
metabolism genes and induced inflammatory genes later in time. When WAT 
inflammation began, the hepatic response to HFD resembled that in WAT. Our study 
suggests WAT and liver respond to metabolic overload by adaptations in expression of 
gene clusters that control lipid metabolism and inflammatory processes in an orchestrated 
and interrelated manner.  
    Finally, in Chapter 8, we investigated 1) how metabolic stress-induced inflammation 
exerted an effect on kidney dysfunction, and 2) whether pharmacological interventions 
aimed at suppressing metabolic stress-induced inflammation could improve renal function 
in high fat challenged transgenic mice. We demonstrated that human C-reactive protein 
transgenic (huCRPtg) mice with a HFD feeding showed metabolic stress-induced systemic 
inflammation and developed NASH. Interventions with a PPAR-γ activator (rosiglitazone) 
reduced systemic inflammation, prevented insulin resistance, increased plasma 
adiponectin, and diminished renal fibrosis and improved renal function. In contrast, a 
statin (rosuvastatin) treatment reduced systemic inflammation but did not affect insulin 
resistance or renal function.  
    Taken together, in order to gain more insight into the mechanisms of NASH 
pathogenesis, we started with comparison of human NASH and experimental NASH. 
Subsequently, we provided evidence that activation of AP-1 and associated neutrophil 
infiltration is important for NAFL progression towards NASH and this can be induced 
experimentally by ‘metabolic’ dietary triggers of inflammation. We demonstrated that 
specific links exist between microvesicular/macrovesicular steatosis and 
cellular/molecular inflammation in liver. Furthermore, we explored novel nutritional and 
pharmacological agents as potential strategies to combat NASH. Finally, we investigated 
the effects of high fat diet-induced metabolic overload on the liver in relation to 





NEDERLANDSE SAMENVATTING  
 
Een overmaat aan voedingsstoffen kan leiden tot dieet-geïnduceerde ontsteking. Dit 
wordt metabole ontsteking genoemd en hiervan wordt gedacht dat het een belangrijke rol 
speelt in veel stofwisselingsziekten, waaronder de ontwikkeling van niet-alcoholische 
leververvetting (non-alcoholic fatty liver disease, NAFLD). NAFLD is de meest 
voorkomende chronische leverziekte en omvat een spectrum van ziektebeelden die 
variëren van alleen leververvetting tot niet-alcoholische leververvetting met ontsteking 
(non-alcoholic steatohepatitis, NASH) en bindweefselvorming (fibrose). De ontstaanswijze 
van NAFLD en de onderliggende mechanismen die ten grondslag liggen aan de overgang 
van leververvetting naar NASH en fibrose zijn onduidelijk. Om deze reden ontbreken 
effectieve en betrouwbare behandelingsstrategieën die ingrijpen op de ontstaanswijze 
van NASH.  
    Na een algemene introductie over humaan en experimenteel NASH in hoofdstuk 1, 
hebben we in hoofdstuk 2 de leverpathologie van humaan NAFLD met behulp van 
humane leverbiopten systematisch vergeleken met de leverpathologie van enkele NAFLD 
muismodellen. Op basis van de kenmerken van NAFLD van muizen, beoogden we een 
aangepast algemeen histologisch scoresysteem voor NASH te definiëren dat toepasbaar is 
voor knaagdiermodellen.  
    In het tweede deel van het proefschrift bestudeerden we meer in detail de progressie 
van NALFD naar NASH met behulp van dieet-geïnduceerde NASH muismodellen. In 
hoofdstuk 3 onderzochten we het effect van stimuli van metabole ontsteking 
(koolhydraten en cholesterol in dieet) en chronische, niet-metabole (klassieke) stimuli (IL-
1β, LPS) op de progressie van louter leververvetting naar NASH in door hoog vet-
geïnduceerde obese APOE*3Leiden.CETP muizen. We toonden dat een hoog vet dieet 
gevolgd door stimuli van metabole ontsteking, vervetting (steatose) en specifieke 
ontstekingscomponenten (neutrofielen, AP-1) induceert. Dit resulteert op een NASH dat 
lijkt op dat van de mens, terwijl een langdurige toediening van niet-metabole stimuli, LPS 
en IL-1β hier niet toe leidt.  
    Doordat patiënten asymptomatisch blijven tijdens de vroege stadia van NAFLD, wordt 
het vaak in een later stadium pas gediagnostiseerd, waarbij al onomkeerbare leverschade 
is ontstaan (leverfibrose, cirrhose). We weten nog weinig over de vroege, potentieel 
reversibele ziekteprocessen en hun tijdsbeloop. Daarom vestigden we onze aandacht in 
hoofdstuk 4 op de vroege stadia van NAFLD ontwikkeling, het tijdsbeloop en de progressie 
van ‘steatose’ en ‘ontsteking’ en de rol van deze processen in de overgang van NAFLD 
naar NASH. Op basis van een systemische en longitudinale analyse van leverhistologie, 
biochemische metingen en microarray data, laten we zien dat microvesiculaire, 
macrovesiculaire steatose en specifieke kenmerken van leverontsteking aan elkaar 
gerelateerd zijn. We tonen dat de twee soorten steatose een verschillend tijdsbeloop 
hebben en geassocieerd zijn met de activatie van specifieke cellulaire en moleculaire 
ontstekingsprocessen. 
    In het derde deel van het proefschrift bestudeerden we potentiële therapieën van 
NASH. In hoofdstuk 5 werden APOE*3Leiden muizen gevoed met een hoog cholesterol 
dieet met een gestandaardiseerde dosis van een anthocyaninine-rijk bosbessenextract 




gemeten aan de hand van een verbetering van de histologische resultaten (steatose, 
leverontsteking en fibrose) en een onderdrukking van levercelontsteking, wat kan worden 
verklaard door een effect van cholesterolverwerking. In hoofdstuk 6 werden 
APOE*3Leiden.CETP muizen op een hoog vet, hoog cholesterol dieet gezet dat salsalaat 
bevat, een anti-inflammatoir middel waarvan recentelijk is aangetoond dat het gunstige 
metabole effecten heeft op het glucose- en vetmetabolisme. Salsalaat voorkwam de 
progressie van NAFLD naar NASH en fibrose en - meer specifiek- verbeterde het 
vetmetabolisme door toename van β-oxidatie en afname van lipogenese. Bovendien was 
ontsteking verminderd (minder activatie van de NFκB signaleringsroute) en werd fibrose 
ontwikkeling voorkómen (minder activatie van de TGF-β signaleringsroute).  
    In het laatste gedeelte van het proefschrift werden de effecten van metabole 
overbelasting en metabole ontsteking op andere weefsels onderzocht. De effecten van 
metabole overbelasting op wit vetweefsel en lever in APOE*3Leiden muizen op hoog vet 
dieet werd bestudeerd in hoofdstuk 7. Deze muizen reageerden met een toename van wit 
vetweefsel, metabole stress, ontsteking en de ontwikkeling van NAFLD. mRNA analyse van 
wit vetweefsel toonde dat metabole overbelasting leidde tot een onmiddellijk optredend, 
stabiele respons op clusters van genen van het vetmetabolisme en later in de tijd 
ontstekingsgenen induceerde. Op het moment dat ontsteking van wit vetweefsel 
ontstond, leek de respons van de lever op hoog vet dieet op dat van wit vetweefsel. Onze 
studie impliceert dat wit vetweefsel en de lever op een samenhangende manier reageren 
op metabole overbelasting door aanpassingen in expressie van genclusters die het 
vetmetabolisme en ontstekingsprocessen reguleren. 
    Tenslotte onderzochtten we in hoofdstuk 8 1) hoe metabole stress-geïnduceerde 
ontsteking een effect heeft op de nierfunctie en 2) of farmacologische interventies die 
metabole stress-geïnduceerde ontsteking verminderen ook de nierfunctie in transgene 
muizen op een hoog vet dieet kunnen verbeteren. We toonden dat humaan C-reactief 
eiwit transgene (huCRPtg) muizen op een hoog vet dieet metabole stress-geïnduceerde 
systemische ontsteking en NASH ontwikkelden. Interventie met een PPAR-γ activator 
(rosiglitazon) verlaagde de systemische ontsteking, voorkwam insuline resistentie, leidde 
tot een toename van plasma adiponectin, verminderde nierfibrose en verbeterde de 
nierfunctie. Een statine (rosuvastatine) daarentegen, verminderde wel systemische 
ontsteking maar had geen effect op insuline resistentie of nierfunctie. 
    Samenvattend, hebben we ten eerste humaan en experimenteel NASH vergeleken om 
meer inzicht te verkrijgen in de mechanismen van de ontwikkeling van NASH. Vervolgens 
hebben we aangetoond dat activatie van AP-1 en de hiermee geassocieerde neutrofiel 
infiltratie belangrijk zijn voor NAFLD progressie naar NASH en dat dit geïnduceerd kan 
worden door ‘metabole’ stimuli voor ontsteking in het dieet. We hebben laten zien dat 
microvesiculaire/macrovesiculaire steatose en cellulaire/moleculaire ontsteking in de 
lever aan elkaar gerelateerd zijn. Daarnaast hebben we een nieuwe interventie in voeding 
en  een farmacologisch middel onderzocht als potentiële strategieën om NASH tegen te 
gaan. Tenslotte bestudeerden we de effecten van hoog vet-geïnduceerde metabole 
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